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The glutamate hypothesis of schizophrenia, which is based primarily 
on NMDA receptor dysfunction, can be expanded to include additional 
components of the glutamate synapse including the excitatory amino acid 
transporters (EAATs) which buffer and transport synaptic glutamate.  I studied 
multiple levels of expression and regulation of the EAATs in postmortem 
prefrontal cortex from patients with schizophrenia and comparison subjects.    
I used in situ hybridization, Western Blot analysis, enzymatic deglycosylation, 
and QPCR to study EAAT expression and regulation in the prefrontal cortex 
 xii 
in schizophrenia.  I found decreased EAAT1 protein expression, and found 
several factors that indicate decreased localization of EAATs at the synapse 
including decreased glycosylation of EAAT1 and EAAT2, increased 
expression of the ER retention variant EAAT2Δ9, and increased expression of 
molecules that retain EAATs in the ER, GPS1 and JWA.  These data suggest 
decreased overall EAAT expression, and abnormal localization of EAATs that 
are expressed.  Therefore, there are likely fewer EAATs expressed at the cell 
surface, and thus a decrease in the capacity for glutamate buffering and 
transport.   These data demonstrate novel sites of disruption in the glutamate 
synapse in schizophrenia.  This work could therefore provide alternative 












1.1  Schizophrenia   
Schizophrenia is a complex, debilitating mental illness that affects 
approximately 0.4 - 1% of the population worldwide1-3.  Schizophrenia has a 
high comorbidity rate with other psychiatric disorders as well as metabolic 
disorders, and mortality rate is 1.5 - 3.3 fold higher among those with 
schizophrenia than in the general population4.  Both genetic and 
environmental factors contribute to risk for developing schizophrenia, but no 
one gene has been consistently linked to the illness3. 
The symptoms of schizophrenia are broken into three clusters: positive 
symptoms, negative symptoms, and cognitive deficits1.  Positive symptoms 
include delusions, hallucinations and paranoia.  Negative symptoms include 
flattened affect, poverty of speech, social withdrawal, and anhedonia1.  
Cognitive deficits include disorganized thought processes and deficits in 
executive functioning.  Although there is no cure for schizophrenia, there are 
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treatments for the illness, but the treatments are not fully effective, can be 
expensive, and often have adverse side-effects4, 5. 
  
1.2  The glutamate hypothesis of schizophrenia 
For decades, schizophrenia research has focused on the dopamine 
hypothesis of schizophrenia, which postulates that dysregulated 
dopaminergic neurotransmission is a key feature of the pathophysiology of 
the illness.  The dopamine hypothesis is based on the observation that 
antipsychotic efficacy for reducing positive symptoms is associated with D2 
dopamine receptor blockade.  Although numerous studies point to 
dopaminergic abnormalities in schizophrenia, dopamine dysfunction does not 
completely account for all of the symptoms seen in this illness.  
Antipsychotics typically are effective only for the positive symptoms of the 
illness, while negative symptoms and cognitive deficits are relatively 
refractory to treatment 6, 7.   
Consequently, alternative neurotransmitter systems that may also be 
involved in the pathophysiology of schizophrenia have been sought, and a 
growing body of evidence now implicates glutamatergic dysfunction in this 
illness.  The strongest evidence is that phencyclidine (PCP) and similar 
compounds, which are noncompetitive antagonists of the NMDA receptor, 
can induce positive negative and cognitive symptoms in unaffected healthy 
subjects 8, 9.  Moreover, these compounds can exacerbate both positive and 
negative symptoms in schizophrenia 10.  Chronic administration of PCP-like 
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compounds reduces frontal lobe blood flow and glucose utilization, which is 
similar to the “hypofrontality” described in schizophrenia 11. More specifically, 
the most widely held hypotheses posit diminished NMDA receptor function in 
limbic brain structures, including the prefrontal cortex.  I will discuss evidence 
supporting this hypothesis, and expand the glutamate hypothesis to 
encompass other glutamatergic abnormalities beyond NMDA receptor 
dysfunction.   
 
1.2.1 Glutamate abnormalities in the prefrontal cortex  
A large number of postmortem stereological, electrophysiologic, 
neuroimaging, and gene expression studies implicate cortical dysfunction in 
schizophrenia12-15.  Two regions in particular that are implicated in this illness 
are the dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex 
(ACC).  Disturbances in executive functioning and working memory in 
schizophrenia have been linked to dysfunction of the DLPFC, and structural 
abnormalities in the DLPFC such as increased cell packing density, 
decreased somal size, and decreased neuropil are found12.  Patients with 
chronic schizophrenia show decreased NAA, glutamine, and glutamate levels 
in the DLPFC as shown through magnetic resonance spectroscopy16. The 
ACC participates in selective attention, working memory, anticipation, and 
behavioral monitoring.  Structural abnormalities such as neuronal loss in the 
ACC have been shown in schizophrenia, and deficiencies in insight and 
judgment are linked to ACC dysfunction17.  The ACC may be particularly 
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vulnerable to changes in glutamatergic signaling as administration of 
subanesthetic doses of ketamine to patients with schizophrenia results in 
increased regional cerebral blood flow to the ACC as measured by positron 
emission topography10. 
 
1.3  Glutamate neurotransmission  
 Glutamate is the major excitatory neurotransmitter in the central 
nervous system.  Glutamatergic neurons project throughout the brain, and 
deficits in glutamatergic neurotransmission can result in serious disease or 
death18-25.  Below I describe the circuitry of glutamatergic neurons in the 
prefrontal cortex and the components of the glutamate synapse. 
 
1.3.1  Prefrontal cortical glutamate circuits 
Glutamatergic projection neurons, called pyramidal neurons, comprise 
approximately two thirds of cortical neurons and exist in all layers of 
neocortex except layer I26.  Pyramidal neurons in superficial layers of cortex 
send efferents to projection neurons and interneurons in other areas of 
cortex26.  Pyramidal neurons in deep layers of cortex send their projections to 
subcortical structures26.  The prefrontal cortex in particular has dense 
reciprocal innervation with the dorsal thalamus27-30, another brain area in 




1.3.2  Components of the glutamate synapse 
The release, activity as a ligand, and reclamation of glutamate involves 
three distinct cell types: the astrocyte, presynaptic neuron and postsynaptic 
neuron 39.  In the presynaptic neuron, glutamine can be converted to 
glutamate by the enzyme glutaminase, and packaged into vesicles by a family 
of vesicular glutamate transporters (VGLUT1-3) for release into the synapse 
40, 41. Glutamate may also be synthesized by the hydrolysis of N-acetyl-alpha-
L-aspartyl-L-glutamate (NAAG) into NAA and glutamate by the enzyme 
carboxypeptidase II (GCP II) 42. Once released into the synapse, glutamate 
may occupy and activate ionotropic (NMDA, AMPA, and kainate) or 
metabotropic (mGluR1-8) glutamate receptors located on both neurons and 
astrocytes 43.  Rapid removal of glutamate from the synapse is facilitated by a 
family of plasma membrane excitatory amino acid transporters (EAATs), 
generally localized to postsynaptic neurons and astrocytes 44.  Recovered 
glutamate may enter the citric acid cycle via conversion to alpha-ketoglutarate 
by glutamate dehydrogenase, be converted to glutamine by glutamine 
synthetase and transported back into the synapse, or be released into the 
extracellular space by a cystine/glutamate antiporter 39, 45, 46.  Finally, several 
families of novel glutamate receptor and transporter associated molecules 






Figure 1.1: The Glutamate Synapse.  Glutamate is packaged into 
presynaptic vesicles by vesicular glutamate transporters (VGLUTs), and is 
released into the synaptic cleft where it can activate glutamate receptors.  
Glutamate is rapidly removed from the synapse by excitatory amino acid 




1.3.3  Vesicular glutamate transporters  
The vesicular glutamate transporters (VGLUTs), are responsible for 
the packaging of glutamate into synaptic vesicles.  Vesicular uptake of 
glutamate is an ATP–dependent process independent of sodium and 
potassium.   It has a biphasic dependence on chloride concentration, and is 
driven by an internal positive membrane potential.  The VGLUTs are highly 
selective for L-glutamate, but have a lower affinity for glutamate in 
comparison to the EAATs 51, 52.   Alterations in synaptic activity can be 
induced by the modulation of the amount of glutamate released from synaptic 
vesicles.  Therefore, VGLUT mediated transport of glutamate into vesicles for 
release into the synaptic cleft is a pivotal control point for synaptic activity 53.  
Three vesicular transporters (VGLUT1, VGLUT2, and VGLUT3) have been 
cloned and characterized 54.  
 
1.3.4  Ionotropic and Metabotropic Glutamate Receptors 
 There are four classes of functionally and pharmacologically distinct 
glutamate receptors. The ionotropic glutamate receptors, AMPA, kainate, and 
NMDA are comprised of four or five subunits that form ligand-gated ion 
channels, while the metabotropic glutamate receptors (mGluRs) are seven 
transmembrane domain G-protein coupled receptors 43, 55.  
The AMPA receptor subunits are derived from a family of four genes 
termed GluR1-GluR4 that confer heterogeneity in assembled AMPA receptors 
by alternative splicing and post-translational editing 43, 55.  Assembled AMPA 
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receptors contain discrete binding sites for glutamate, competitive antagonists 
such as CNQX, and desensitization modulators such as aniracetam.   
Kainate receptors are also ligand gated ion channels composed of 
subunits derived from genes for the low affinity GluR5-GluR7 and high affinity 
KA1-KA2 subunits 43, 55.  These subunits also undergo alternative splicing and 
post-translational editing.  Assembled kainate receptors may be composed of 
five identical subunits (homomers) or composed of low and high affinity 
subunits.  
The NMDA receptor subunits are encoded by seven genes termed 
NR1, NR2A-NR2D, and NR3A-NR3B.  NR1 is expressed as one of eight 
isoforms, due to the alternative splicing of exons 5, 21, and 22 43, 55-57.  NMDA 
receptors exhibit subunit and splice variant specific properties, and 
pharmacological regulation of this receptor depends on the unique 
combination of glutamate, glycine/D-serine, polyamine, H+, Zn2+, and Mg2+ 
binding sites 43, 55.  In addition, there is an intrachannel binding site for 
uncompetitive antagonists of the NMDA receptor, such as PCP, ketamine, 
and MK801.   
The eight metabotropic glutamate receptors (mGluRs) are divided into 
three groups (I, II, and III) based on pharmacology, sequence homology, and 
which signal transduction pathways they activate in heterologous systems 56, 
58-63. The mGluRs belong to a unique subset of G-protein coupled receptors 
with seven transmembrane domains and large extracellular amino termina. 
Group I mGluRs have been shown to stimulate phospholipase C, 
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phosphoinositide hydrolysis, and cAMP formation, while group II and III 
mGluRs inhibit forskolin-stimulated cAMP formation and adenylyl cyclase, via 
G proteins 58, 62-68. 
 
1.3.5  Glutamate receptor interacting proteins  
AMPA receptors may be mobilized to the synapse by three distinct 
mechanisms: a constitutive pool, a regulated pool, and a golgi-derived newly 
synthesized pool 69. Cycling and integration of AMPA receptors to the 
postsynaptic density by these mechanisms involve a number of molecules 
that contain AMPA receptor subunit-specific protein binding domains and are 
regulated by posttranslational modification such as phosphorylation or 
palmitoylation 69-72.  GRIP, PICK, NSF, SAP97, stargazin, JNK, Rap2, and 
ABP-L have all been implicated in AMPA receptor trafficking 69, 70, 73, 74.   
Receptor-associated molecules have also been identified for the 
NMDA receptor, including NF-L, SAP102, yotiao, PSD95, and PSD93 69, 70.  
Some of these molecules specifically bind C-terminal consensus sequences 
called PDZ domains, named for three proteins with this motif: PSD95, 
Drosophila disc-large tumor suppressor gene (Dlg-A) product, and ZO-1, a 
tight junction protein 75-77. PDZ and related binding domains link 
neurotransmitter receptors with kinases, phospholipases, and other signal 
transduction and receptor trafficking pathways. Several of the AMPA 
interacting molecules, including GRIP1 and PICK178, 79 as well as calcineurin 
80, also interact with the kainate receptors.  In addition, a family of molecules 
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that interacts with the metabotropic receptors has been identified, including 
RGS4 81-83 and Homer1-3 84-87.  
 The glutamate receptor interacting proteins modulate a variety of 
processes related to synthesis, trafficking, insertion, activation, recycling, and 
degradation of glutamate receptors. Thus, the expression and regulation of 
this family of molecules has a critical role in cortical glutamatergic synapses. 
 
1.3.6  Cortical glutamate receptor abnormalities in schizophrenia 
Glutamate receptor expression has been extensively studied in 
schizophrenia and the results of cortical studies of glutamate receptor 
expression and binding are summarized in Tables 1.1 - 1.4.  Most 
abnormalities of glutamate receptor expression in schizophrenia have been 
reported in limbic regions including the DLPFC and ACC.  With a few 
exceptions, findings of altered glutamate receptor expression in schizophrenia 
are typically region-specific and brain-collection-specific, with many studies 
yielding conflicting results.   
Alterations in NMDA receptor subunit and binding site expression are 
complex and region specific (Table 1.1). There is evidence for shifts in 
subunit stoichiometry and increased binding to at least some of the NMDA 
binding sites, primarily in cortical areas 88-93.   
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Table 1.1: NMDA receptor binding and expression in schizophrenia 
      
Level of Gene Expression Technique Probe(s)* Finding Brain Region Reference             
Receptor binding sites homogenate binding MK-801 unchanged FC 90 
      
 homogenate binding L-689,560   TC 93 
  L-689,560 unchanged MC  
  CGP 39653 unchanged TC, MC  
  ifenprodil  TC  
  ifenprodil unchanged MC  
      
 homogenate binding L-689,560  TC 94 
  L-689,560 unchanged PFC  
      
 homogenate binding glycine  cerebral cortex 95 96 
      
 autoradiography MK-801  ACC 97 
      
 autoradiography MK-801 unchanged PFC 98 
      
 autoradiography MK-801  PCC 99 
      
 autoradiography MK-801 unchanged DLPFC 100 
  CGP 39653 unchanged DLPFC              
Subunit mRNA expression ISH NR2D  PFC 92 
  NR1, NR2A-C unchanged PFC  
  NR1, NR2A-D unchanged PTC  
      
 ISH NR1 w/exon 5  FC, OCC, TC 101 
      
 ISH NR3A  PFC 102 
   unchanged ITC  
      
 Northern blot NR1  TC 91 
      
 qPCR NR1 # FC 89 
  NR1 unchanged@  FC  
      
 qPCR NR1, NR2A  PFC, OCC  88 
  NR2B unchanged PFC, OCC  
      
 Double ISH NR2A/GAD67 unchanged PFC 103             
Subunit protein expression Western blot NR1C2'  ACC 104 
  NR1C2' unchanged DLPFC  
  NR1C2 , NR2A-D unchanged ACC  
  NR1C2 , NR2A-D unchanged DLPFC              
 
*All binding studies utilized 3[H]. 
#Neuroleptic free schizophrenics vs. controls. 
@Neuroleptic treated schizophrenics vs. control. 
 
Abbreviations:  in situ hybridization (ISH), quantitative polymerase chain 
reaction (qPCR) anterior cingulated cortex (ACC), dorsolateral prefrontal 
cortex (DLPFC), prefrontal cortex (PFC), occipital cortex (OCC), visual cortex 
(VC), motor cortex (MC), frontal cortex (FC), parietal cortex (PC), temporal 
cortex (TC), inferior temporal cortex (ITC), parietotemporal cortex (PTC), 
posterior cingulate cortex (PCC), (NR1C2' ) variably spliced  NR1exon 
cassettes C2 and C2’ 
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Studies of AMPA receptor expression in schizophrenia (Table 1.2) 
result in one of the more robust and reproducible sets of findings in this field; 
many past studies have found that AMPA receptor expression is decreased in 
the hippocampus and related structures in schizophrenia, occurring at the 
levels of both transcript and subunit protein expression 105-110. With few 
exceptions, AMPA receptor expression tends to be unchanged in other 
cortical areas 89, 105, 106, 108, 111, 112.   
Unlike the AMPA receptor, findings for the kainate receptor (Table 1.3) 
are contradictory, with decreased binding reported in two studies, increased 
binding reported in three studies, and no changes reported in another study 
113-115. In addition, one study found increased GluR7 mRNA in the prefrontal 
cortex (PFC) while another found decreased GluR7 in the frontal cortex.   
Three studies have examined mGluR expression in the cortex in 
schizophrenia (Table 1.4).  Increased mGluR1a and mGluR2/3 
immunoreactivity was found in Brodmann areas 9, 11, 32, and 46 in 
schizophrenia 116, while another group found decreased expression of 
mGluR3 in DLPFC 117, and a third group found increased mGluR5 mRNA in 
the PFC in this illness 118.    
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Table 1.2: AMPA receptor binding and expression in schizophrenia 
 
      
Level of Gene Expression Technique Probe(s)* Finding Brain Region Reference 
      
      
Receptor binding sites autoradiography CNQX  PFC 98 
      
 homogenate binding AMPA unchanged FC 111 
      
 autoradiography AMPA  ACC 97 
      
 homogenate binding AMPA unchanged FC, PC, OCC, 
TC, LC 
119 
      
 autoradiography AMPA unchanged PCC 99 
      
 autoradiography AMPA unchanged DLPFC 100, 112 
      
      
Subunit mRNA expression qPCR GluR1 # FC 89 
  GluR1 unchanged@  FC  
      
 qPCR GluR1, GluR4  DLPFC 120 
  GluR2, GluR3 unchanged DLPFC  
  GluR4  OCC  
  GluR1-3 unchanged OCC  
      
 Microarray GluR2  PFC 121 
      
 ISH GluR1, GluR3 unchanged DLPFC 112 
  GluR2, GluR4    
      
      
Subunit protein expression Western blot GluR2, GluR3 unchanged cingulate cortex 105 
      
      
 
*All binding studies utilized 3[H]AMPA or 3[H]CNQX. 
#Neuroleptic free schizophrenics vs. controls.  
@Neuroleptic treated schizophrenics vs. control.  
 
Abbreviations: in situ hybridization (ISH), quantitative-polymerase chain 
reaction (qPCR) anterior cingulated cortex (ACC), dorsolateral prefrontal 
cortex (DLPFC), prefrontal cortex (PFC), frontal cortex (FC), parietal cortex 
(PC), occipital cortex (OCC), temporal cortex (TC), limbic cortex (LC), 
posterior cingulate cortex (PCC) 
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Table 1.3: Summary of Kainate receptor binding and expression data in 
schizophrenia 
 
      
Level of Gene Expression Technique Probe(s)* Finding Location Reference 
      
      
Receptor binding sites autoradiography KA  PHG 122 
      
 homogenate binding KA  PFC 113 
      
 homogenate binding KA  FC 114 
  KA unchanged TC  
      
 homogenate binding KA  PFC 115 
      
 autoradiography KA  PFC 123 
      
 autoradiography KA unchanged PCC 99 
      
 autoradiography KA  DLPFC 100 
      
 autoradiography KA unchanged ACC 97 
      
      
      
Subunit mRNA expression ISH GluR7  PFC 123 
  KA2  PFC  
  GluR5,6, KA1 unchanged PFC  
      
 RT-PCR GluR7 # FC 124 
  GluR7 unchanged@  FC  
  KA1 # FC  
  KA1 unchanged@  FC  
      
 
*All binding studies utilized 3[H]kainate. 
#Neuroleptic free schizophrenics vs. controls. 
@Neuroleptic treated schizophrenics vs. control. 
 
Abbreviations: kainate (KA), in situ hybridization (ISH), reversed transcribed-
polymerase chain reaction (RT-PCR), immunoreactive dendrites (IR) anterior 
cingulated cortex (ACC), dorsolateral prefrontal cortex (DLPFC), prefrontal 
cortex (PFC), frontal cortex (FC), occipital cortex (OCC), temporal cortex 




Table 1.4: Summary of metabotropic glutamate receptor binding and 
expression data in schizophrenia 
 
      
Level of Gene Expression Technique Probe(s) Finding Location Reference 
      
      
Subunit mRNA expression Western mGluR1a, mGluR2/3  PFC 116 
  mGluR4a, mGluR5 unchanged PFC  
      
 ISH mGluR3 unchanged PFC 118 
  mGluR5  PFC  
      
      
 




1.3.7  Cortical Glutamate Receptor interacting protein abnormalities in 
schizophrenia.   
A number of studies have moved beyond measuring receptors in the 
plasma membrane to examine the molecules which functionally link glutamate 
receptors to cellular processes. Published data on receptor interacting 
proteins revealed that cortical regions are differentially affected in 
schizophrenia (Table 1.5).  Studies of glutamate receptor interacting proteins 
suggest that glutamatergic dysfunction in schizophrenia is not simply a 
problem of too many or too few receptors, but is likely a problem of how these 
receptors are assembled, transported, and functionally linked to receptor 
signaling complexes.   
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Level of gene 
expression Technique Finding Cortical Region Reference 
       
PSD95 NMDA, AMPA, kainate mRNA ISH  DLPFC 
125 
       
  mRNA ISH  ACC 104 
    unchanged DLPFC  
       
  protein Western unchanged DLPFC 79 
       
   Western  ACC 104, 126 
    unchanged DLPFC                
PSD93 NMDA mRNA ISH  ACC 104 
    unchanged DLPFC  
  protein Western  ACC  
    unchanged DLPFC  
       
   Western unchanged DLPFC 79               
NF-L NMDA mRNA ISH unchanged ACC 104 
     DLPFC  
  protein Western unchanged ACC  
     DLPFC                
SAP-102 NMDA, AMPA mRNA ISH unchanged ACC 104 
    unchanged DLPFC  
  protein Western unchanged ACC  
    unchanged DLPFC  
       
  protein Western unchanged DLPFC 79               
NSF AMPA mRNA ISH, microarray  DLPFC 
127 
       
  mRNA ISH unchanged DLPFC 112 
       
  mRNA QPCR unchanged DLPFC 128 
       
  protein Western unchanged DLPFC, FP, PC 129 
       
  protein 2D-DIGE  DLPFC 130 
       
  protein Western unchanged DLPFC 128               
SAP97 AMPA mRNA QPCR unchanged DLPFC 78 
    unchanged OCC  
       
  protein Western  DLPFC 79               
GRIP1 AMPA, kainate, mGluR mRNA QPCR  DLPFC 
78 
     OCC  
  protein Western unchanged DLPFC 79               
PICK1 AMPA, kainate mRNA QPCR unchanged DLPFC 78 
    unchanged OCC  
       
  mRNA ISH  DLPFC 112               
ABP AMPA mRNA QPCR unchanged DLPFC 78 
     OCC                
stargazin AMPA mRNA ISH  DLPFC 112               






Level of gene 
expression Technique Finding Cortical Region Reference 
              
calcineurin kainate protein Western unchanged DLPFC 80               
RGS4 mGluR mRNA QPCR unchanged DLPFC 82 
       
  mRNA ISH  CG, SFG, IC 81 
    unchanged IFS, IFG  
       
  mRNA Microarray, ISH  DLPFC, VC, MC 
83 
       
  protein Western  FC 81 
    unchanged IC         
Homer1b mGluR1/5 mRNA ISH unchanged ACC, DLPFC 87        
Homer2 mGluR1/5 mRNA ISH  ACC, DLPFC 87 
        
 
Abbreviations: in situ hybridization (ISH), quantitative real time polymerase 
chain reaction (QPCR), two-dimensional fluorescence difference gel 
electrophoresis (2D-DIGE), anterior cingulated cortex (ACC), dorsolateral 
prefrontal cortex (DLPFC), prefrontal cortex (PFC), occipital cortex (OCC), 
visual cortex (VC), motor cortex (MC), cingulated gyrus (CG), superior frontal 
gyrus (SFG), insular cortex (IC), frontal cortex (FC), inferior frontal sulcus 




1.4  Plasma Membrane Transporters 
 Extracellular glutamate levels are maintained at very low levels by 
functionally distinct low and high affinity systems that facilitate glutamate 
reuptake. High affinity Na+-dependent synaptic reuptake of glutamate and 
aspartate is mediated by a family of excitatory amino acid transporters 
(EAAT1-EAAT5), which are localized in the plasma membrane and transport 
glutamate into neurons and glia 131, 132.  EAATs mediate glutamate transport 
by an electrogenic exchange of 3 Na+, 1 H+, and 1 glutamate molecule into 
the cell and 1 K+ ion out of the cell, with the net inward movement of one 
positive charge 133, 134. EAATs are expressed natively as homomeric trimers 
comprised of non-covalently linked subunits that have 6-10 transmembrane 
domains 51, 135, 136.  
The transporters have specific patterns of cellular localization:  EAAT1 
and EAAT2 have primarily been localized to astroglia, whereas EAAT3 and 
EAAT4 are primarily localized to neurons137-140.  EAAT5 expression is limited 
to the retina. EAAT expression may be regulated at multiple levels, including 
transcription, translation, post-translational modification, trafficking, substrate 
affinity and transport kinetics 51. Expression, intracellular localization, 
regulation and function of EAAT1-4 are discussed below. 
 
1.4.1  EAAT1 
Called GLAST in the rodent, EAAT1 is expressed on astrocytes 
throughout the CNS, with the highest levels of expression in the Bergmann 
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glia in the cerebellum and the retina 137, 141-143. Immunocytochemical studies 
suggest that GLAST/EAAT1 expression is limited to the plasma membranes 
of astrocyte cell bodies and processes, although one study suggests that 
EAAT1 is expressed in a subset of cortical neurons in subjects with 
Alzheimer’s-type pathology 142, 144. GLAST/EAAT1 expression is enriched in 
regions of the plasma membrane proximal to nerve terminals 145. Immunogold 
labeling demonstrated relatively little intracellular GLAST/EAAT1 protein 
expression, suggesting that localization of GLAST/EAAT1 to the plasma 
membrane is not regulated via mobilization of an intracellular pool of 
transporter protein 145. Cell surface expression of GLAST/EAAT1 was 
increased by insulin-like growth factor-1 via a protein kinase dependent 
mechanism, and region-specific GLAST/EAAT1 expression is increased by a 
number of peptide growth factors likely mediated by serine and tyrosine 
kinases 118, 146-149.  Recent studies have identified consensus tyrosine kinase 
phosphorylation sites targeted by specific glucocorticoid-sensitive kinase 
isoforms that facilitate increased EAAT1 activity. 
 
1.4.2  EAAT2   
Called GLT-1 in the rodent, EAAT2 is the most comprehensively 
studied of the glutamate transporters. GLT-1/EAAT2 accounts for 
approximately 90% of rodent forebrain glutamate reuptake 18, 23.  Expression 
of EAAT2 protein and mRNA has been observed throughout the human brain, 
but is highest in the forebrain 141, 150.  Astrocytes express EAAT2 transcripts 
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and protein, while EAAT2 mRNA is detectable in neurons found in the 
neocortex and thalamus 138, 139, 142, 151. EAAT2 protein is expressed in neurons 
of the retina and embryonic neuronal cultures; in one recent report, protein 
expression of an EAAT2 splice variant (GLT-1a) was detected in rodent 
hippocampal neurons, while a PDZ-domain containing variant (called 
EAAT2b) was expressed in human neurons 51, 152-154.  GLT-1/EAAT2 protein 
is enriched in the portion of the astrocytic plasma membrane facing neuropil 
145. Less than 5% of GLT-1/EAAT2 immunoreactivity is found in structures 
other than the plasma membrane, including mitochondria and the 
endoplasmic reticulum 145.  GLT-1/EAAT2 mediated glutamate uptake is 
modulated by a number of paracrine factors including arachidonic acid, 
cytokines, oxygen radicals, and peptide growth factors 147, 155-157.  
 
1.4.3  EAAT3   
Called EAAC1 in the rodent, EAAT3 is expressed on neurons in the 
neocortex, striatum, thalamus, cerebellum and other structures 158, 159. EAAT3 
protein expression has been demonstrated on glutamatergic, GABAergic and 
aminergic neurons, as well as astrocytes of the cortex and in white matter 158, 
159. In contrast to EAAT1 and EAAT2, subcellular distribution of EAAT3 
includes the cytoplasm, where it is available for rapid mobilization to 
perisynaptic regions of the plasma membrane 158-161. Dendritic trafficking of 
EAAT3 is mediated by a novel c-terminal sorting motif, but mutation of this 
motif did not impair clustering of EAAT3 on dendritic spines 162. Surface 
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expression of EAAT3 (and glutamate uptake) is rapidly increased by 
activation of PKC in C6 glioma cells constitutively expressing this transporter, 
and PKC activation increased glutamate uptake in cortical neuron cultures 163-
166. Platelet-derived growth factor (PDGF) increased surface expression of 
EAAT3 and glutamate uptake in C6 glioma cells, an effect mediated by 
activation of PI3K, and blocked by the PI3K inhibitor wortmanin 164, 167.  
Activation of the neurotensin receptor NTS1 also increased EAAC surface 
expression, an effect that did not require PKC or PI3K activity 168. The 
transcription factor RFX1 has also been shown to increase EAAT3 protein 
expression 169.  Similar to EAAT2, EAAT3 appears to be regulated by 
converging signaling pathways that utilize independent signaling substrates 
51.  
 
1.4.4  EAAT4 
In the adult CNS, human and rodent EAAT4 transcripts and protein are 
only robustly expressed in the Purkinje cells of the cerebellar molecular layer 
140, 141, 170, 171.  We have detected EAAT4 transcript expression in the human 
striatum by in situ hybridization, and low levels of EAAT4 mRNA and protein 
have been detected in rodent cortical neurons and astrocyte cultures 172-174. 
Unlike the other transporters, EAAT4 protein has an uneven subcellular 




1.5  Refining the Glutamate Hypothesis of Schizophrenia 
Although the glutamate hypothesis of schizophrenia is focused 
primarily on NMDA receptor dysfunction, recent data implicate glutamate 
transporters in schizophrenia.  Knockout mice for the glutamate transporter 
EAAT1 exhibit schizophrenia-like endophenotypes including self-neglect, 
social withdrawal, and impaired learning 20.  This hypothesis is further 
supported by a report of a subject with schizophrenia who has a partial 
deletion of the EAAT1 gene 176.  These data suggest that maintenance of 
synaptic glutamate levels may play an important role in this illness.  In fact, 
one study using an mGluR2/3 agonist, which decreases glutamate release, 
had antipsychotic properties in schizophrenia 177.   Below I discuss 
postmortem studies that have investigated EAAT expression in 
schizophrenia. 
 
1.5.1  Abnormalities in Glutamate Transporters in Schizophrenia  
Fewer studies have focused on glutamate transporters (Table 1.6) than 
glutamate receptors, and studies of glutamate transporter expression in the 
cortex have yielded conflicting results.  Of the transporters, EAAT2 has been 
the most extensively studied.  Three groups have investigated changes in 
mRNA expression of EAAT2 in the PFC in schizophrenia, all with different 
results.  Ohnuma et al. found decreased EAAT2 mRNA in the PFC using in 
situ hybridization 178, while Matute et al. found increased179 and Lauriat et al. 
found no changes in EAAT2 mRNA in the PFC using QPCR180. These 
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discrepant findings might be explained by differences in subjects studied, as 
the samples varied widely in age, postmortem interval (PMI), and neuroleptic 
treatment.  The differences could also be explained by the use of different 
methodologies, as QPCR is more sensitive than ISH for detecting mRNA 
expression. 
Another possible source of variation in these studies is the type of 
probe used to detect EAAT2.  EAAT2 is differentially spliced, and the majority 
of EAAT splice variants are either EAAT2a or EAAT2b, which differ in their 
carboxyl termini.  EAAT2a is more abundant and is generally found in 
astrocytes 142, 181, whereas EAAT2b is less abundant and generally found in 
neurons 154, 182.  These variants appear to be abnormally expressed in 
disease states such as amyotrophic lateral sclerosis 183.  Since Ohnuma et al. 
detected EAAT2 by ISH using a probe near the 3’ end of EAAT2, they likely 
detected only the EAAT2a isoforms184, while Matute et al. did not report the 
location of the EAAT2 probe used in their QPCR study179.  It is possible that 
the groups were measuring different mRNA isoforms altogether, accounting 
for their discrepant results. 
In addition to these conflicting EAAT2 data, the only other abnormality 
in glutamate transporter expression detected in the cortex in schizophrenia 
thus far is in the presynaptic vesicular glutamate transporter VGLUT1, which 
is involved in packaging of presynaptic glutamate into vesicles.  Decreased 
VGLUT1 mRNA expression was found in superficial layers of the DLPFC in 
schizophrenia 185.  This finding suggests a decrease in glutamatergic 
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neurotransmission in the DLPFC, given that VGLUT1 expression has been 
shown to directly influence quantal glutamate release 186. Such a change in 
presynaptic innervation might be consistent with deficits in cortical function in 
schizophrenia.  Given the small number of studies of EAAT expression in 
schizophrenia, this represents a rich area for exploration in this dissertation. 
 
Table 1.6: Cortical Glutamate Transporter Abnormalities in 
Schizophrenia 
 
Transporter Level of gene expression Technique Finding Cortical Region Reference 
            
EAAT1 mRNA QPCR unchanged DLPFC, PVC 180             
EAAT2 mRNA QPCR unchanged DLPFC, PVC 180 
      
 mRNA ISH  PFC 178 
      
 mRNA QPCR  PFC 179 
 protein ICC  PFC  
 glutamate transport expression in oocytes  PFC              
EAAT3 mRNA QPCR unchanged DLPFC, PVC 180             
VGLUT1 mRNA ISH unchanged STC 185 
    DLPFC  
      
      
             
 
Abbreviations: quantitative real time polymerase chain reaction (QPCR), in situ 
hybridization (ISH), immunocytochemistry (ICC), dorsolateral prefrontal cortex 
(DLPFC), primary visual cortex (PVC), prefrontal cortex (PFC), superior 
temporal cortex (STC) 
 
 
1.6  Modulation of EAAT function 
 Although a few studies have investigated EAAT expression in 
schizophrenia, other mechanisms of EAAT regulation have not been 
investigated in this illness.  EAAT function can be modulated through a 
number of mechanisms.  Several interacting partners for the EAATs have 
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been identified through yeast two hybrid screening and co-
immunoprecipitation.  Several posttranslational modifications have also been 
identified to affect EAAT function including phosphorylation, ubiquitination, 
and glycosylation.  Lastly, there exist several alternative splice forms of the 
EAATs that affect transport function.  Below we describe these mechanisms 
of EAAT regulation. 
 
1.6.1  EAAT interacting molecules 
Like the glutamate receptors, the EAATs are also regulated by a 
variety of interacting molecules that can affect transport function through 
trafficking, anchoring, phosphorylation, glycosylation, and degradation.   
Known EAAT1, EAAT2, EAAT3, and EAAT4 interacting proteins are 
discussed below. 
 
1.6.2  EAAT1 interacting proteins 
Disruption of putative c-terminal EAAT1 protein-protein interaction 
domains with a c-terminal peptide increased the affinity of EAAT1 for 
glutamate in salamander retinal glial cells, suggesting that protein-protein 
interactions modulate EAAT1 function 187. Consistent with this finding, another 
study has demonstrated that sept2, a member of the septin family of 
GTPases, negatively modulates GLAST/EAAT1 by direct binding of the 
carboxy-terminal region 188.  GLAST/EAAT1 also forms a complex with glial 
fibrillary acidic protein (GFAP), Na+/H+ exchanger regulatory factor 1 
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(NHERF1), and ezrin, which anchor it at the plasma membrane and increase 
transport function 189, 190 
 
1.6.3  EAAT2 interacting proteins  
A number of studies have found effects of the modulation of signaling 
mechanisms on GLT-1/EAAT2 expression and function, suggesting that there 
may be intermediary regulatory molecules that facilitate transporter 
localization and activation. PKC alpha, however, has been shown to directly 
interact with GLT-1/EAAT2, mediating transporter internalization 191.  Using 
the yeast-two hybrid technique, at least two additional EAAT2 interacting 
proteins have been identified. Ajuba is a cytosolic Lin11, Isl-1, and Mec-3 
(LIM) protein that translocates to the plasma membrane and colocalizes with 
GLT-1/EAAT2 49.  Ajuba interacts directly with F-actin, and may contribute to 
cell-cell junctions by bridging cadherin adhesive complexes 192.  Transcript 
expression of ajuba, however, was undetectable in the cortex by in situ 
hybridization (our unpublished observations).  Another GLT-1/EAAT2 
interacting protein, G-protein pathway suppressor 1 (GPS-1), is a subunit of 
the COP9 signalsome 50. Transfection with GPS-1 of HEK cells stably 
expressing GLT-1/EAAT2 downregulated glutamate transport activity 50. GPS-
1 also interacts with EAAT3 and EAAT4 50. Caspase 3 also interacts with 
EAAT2.  Caspase 3 can bind to and cleave EAAT2 at aspartate 505, located 
in the cytoplasmic C-terminal domain, strongly and selectively impairing 
transport activity 193.   
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1.6.4  EAAT3 interacting proteins 
Like EAAT2, EAAT3 interacts with PKC alpha 194, but unlike EAAT2, 
EAAT3 membrane expression is increased by PKC alpha activation. 
GTRAP3-18 has been identified as an EAAT3 interacting protein. GTRAP3-
18 has 95% nucleic acid homology with the human gene JWA, and 
specifically interacts with the intracellular c-terminus of EAAT3 48. Increases in 
GTRAP3-18 expression lowered EAAT3 substrate affinity, an effect mediated 
by modulation of transporter N-linked glycosylation 48, 195. GTRAP3-18 
transcripts and protein are ubiquitously expressed in the rodent, in both 
neuronal and non-neuronal cells 196.  Recently, Jena-Muenchen 4 (JM4), a 
JWA homolog sharing 62% homology with JWA and GTRAP3-18, has been 
shown to heterodimerize with JWA, and may interact with EAAT3 197.  
Interaction with the delta opiate receptor has been shown to decrease EAAT3 
function 198.  The SNARE protein Syntaxin 1A has been shown to interact with 
EAAT3 when coexpressed in oocytes, increasing membrane expression 
through trafficking, but decreasing transport activity by disrupting the structure 
of the conductance pathway 199, 200.  However, another group showed that 
syntaxin 1A is not necessary for EAAT3 membrane trafficking in C6 glioma 
cells, and that another SNARE protein SNAP-23 was involved in the 
constitutive recycling of EAAT3 201.  EAAT3 has also been shown to interact 
with the mitochondrial protein holocytochrome c synthetase (HCCS), serving 




1.6.5  EAAT4 interacting proteins 
The c-terminal end of rat EAAT4 interacts with GTRAP-41 and 
GTRAP-48, both of which increase EAAT4 mediated glutamate uptake by 
increasing and stabilizing cell surface transporter expression 47. GTRAP-41 
links EAAT4 with the cytoskeleton, while GTRAP-48 is associated with Rho-
GTPase signaling 47. Transcripts for the human isoforms of GTRAP-41 
(KIAA0302) and GTRAP-48 (ARHGEF11) are robustly expressed throughout 
the CNS, including the thalamus and neocortex (our unpublished 
observations). The mismatch in the expression of EAAT4 and these 
interacting proteins suggests they may facilitate intracellular trafficking of 
other elements of the glutamate synapse.  GPS1 is also known to interact 
with EAAT4, although its effect on function has not been demonstrated. 
 
1.6.6 Post translational modification of the EAATs 
The EAATs are also regulated at the level of post-translational 
modification.  The EAATs have been shown to be phosphorylated 146, 203-206, 
ubiquitinated 207, 208, and glycosylated 135, 139, 209-213. 
Glycosylation is a posttranslational modification that plays a role in 
molecular trafficking, protein folding, endocytosis, receptor activation, signal 
transduction, and cell adhesion 214.  Abnormalities of glycosylation can lead to 
a number of cellular storage disorders including Gaucher’s, Niemann-Pick 
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type C, Sandhoff’s, and Tay-Sach’s diseases, and congenital disorders of 
glycosylation 214.  Disruptions in glycosylation have also been implicated in 
Alzheimer’s disease, Huntington’s disease, and schizophrenia 215.  
N-linked glycosylation is the covalent linkage of oligosaccharides to 
asparagine residues of nascent proteins.   N-glycosyl residues are processed 
as proteins are trafficked through the endoplasmic reticulum (ER) and Golgi.  
There exists a small literature showing that the EAATs are n-glycosylated, 
however, glycosylation of the EAATs in human brain has not yet been 
demonstrated.  GLAST is n-glycosylated at Asn206 and Asn195 209.  GLAST 
exists in two isoforms, 70-kDa and 64-kDa, which differ only by the degree of 
N-glycosylation 212.  Non-glycosylated GLAST does not dimerize 209.   There 
is conflicting literature describing the functional effects of GLT-1 glycosylation.  
One group found that glycosylation-deficient GLT-1 resulted in decreased 
transport rate attributable to decreased expression at the plasma membrane 
216.  However, another group found no effect of N-glycosylation on the 
trafficking or transport activity of GLT-1.  In rat C-6 glioma cells, EAAC1 (the 
rodent isoforms of EAAT3) is n-glycosylated with high mannose sidechains 
and processed into complex chains, coinciding with insertion into the plasma 
membrane 213.   
 
1.6.7  Alternative splicing of the EAATs 
The EAATs may also be regulated at the level of alternative splicing 
154, 182, 183, 217-224.  Alterations in function have been demonstrated for several 
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of these variants, and it is speculated that others may also have altered 
function.  Abnormalities in EAAT splicing have been demonstrated in mood 
disorders, anxiety disorders, Alzheimer’s disease, epilepsy, hypoxia/ischemia, 
Huntington’s disease, brain injury, glaucoma, HIV-associated dementia, 
addiction, ALS, and schizophrenia 180, 183, 219, 222, 224-226.  Described below are 
the known variants of EAAT1, EAAT2, and EAAT3. 
EAAT1 contains both an exon 3 skipping 210, 224, 227 and an exon 9 
skipping variant 228.  The exon 3 skipping variant, also known as EAAT1a, is 
thought to have an opposite orientation in the cell membrane to regular 
EAAT1 and to be unglycosylated 210.  The exon 9 skipping variant, also 
known as EAAT1b is retained in the ER, is likely unglycosylated, and appears 
not only to be a non-functioning transporter, but also to exert a dominant 
negative effect on the transport of the full length transporter 229. 
Of the EAATs, the greatest number of splice variants has been 
described for EAAT2. Exon skipping variants of EAAT2 include an exon 7 
skipping variant 219, an exon 9 skipping variant 219, 221, 222 and a variant 
containing a partial deletion of exons 6 and 7 219.  Like the exon 9 skipping 
form of EAAT1, the exon 9 skipping form of EAAT2 is also retained in the ER 
230.  There are also several intron retention variants of EAAT2.  Five prime 
untranslated region retention variants of EAAT2 include HBGTII 218, 220, 
HBGTIIA 220, HBGTIIB 220, HBGTIIC 218, 220, EAAT2/3 218, and EAAT2/31 218.  
Three prime untranslated region retention variants of EAAT2 include GLT1b, 
also known as EAAT2-1 or GLT1v which retains intron 9 182, 183, 220, 221, 231, 
 31 
GLT1c which retains part of intron 10  221, 231, Intron 3’ to exon 7 which skips 
exons 8-11 219, and I7R, an intron 7 retention variant.  EAAT2b retains the 
ability to transport glutamate in vitro, but unlike EAAT2 is expressed in both 
neurons (glutamatergic and GABAergic) and glia, and is expressed 
cytoplasmically rather than at the plasma membrane 182, 183.  I7R exerts a 
dominant negative effect on normal EAAT2 functioning marking the 
transporter for decay 222. 
Like EAAT1 and EAAT2, EAAT3 can also exist as an exon 9 skipping 
variant 224.  It remains unclear, however, whether this variant is also retained 
in the ER 224. 
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1.7  Goals of dissertation research  
Only a limited number of studies have investigated prefrontal cortical 
expression of EAATs in schizophrenia.  One study found no changes in 
mRNA expression of EAAT1 or EAAT3 in prefrontal cortex while studies of 
EAAT2 expression in prefrontal cortex yield conflicting results.  The EAATs 
have yet to be studied in the prefrontal cortex in schizophrenia at the level of 
protein expression, post-translational modification, splicing, and protein-
protein interaction.  The goals of this dissertation research are to test the 
following hypotheses: 
 
1.) Expression of the EAATs and EAAT interacting proteins are altered in 
schizophrenia. 
 
2.) The EAATs are abnormally glycosylated in schizophrenia. 
 














Abnormal Expression of Glutamate Transporter and Transporter 




2.1  Abstract 
Glutamate cycling is critically important for neurotransmission, and 
may be altered in schizophrenia.  The excitatory amino acid transporters 
(EAATs) facilitate the reuptake of glutamate from the synaptic cleft and have 
a key role in glutamate cycling.  We hypothesized that expression of the 
EAATs and the EAAT regulating proteins ARHGEF11, JWA, G protein 
suppressor pathway 1 (GPS1), and KIAA0302 are altered in the brain in 
schizophrenia.  To test this, we measured expression of EAAT1, EAAT2, 
EAAT3, and EAAT interacting proteins in postmortem tissue from the DLPFC 
and ACC of patients with schizophrenia and a comparison group using in situ 
hybridization and Western blot analysis.  We found increased EAAT1 
transcripts and decreased protein expression, increased EAAT3 transcripts 
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and protein, and elevated protein expression of both GPS1 and KIAA0302 
protein.  We did not find any changes in expression of EAAT2.  These data 
indicate that proteins involved in glutamate reuptake and cycling are altered in 
the cortex in schizophrenia, and may provide potential targets for future 
treatment strategies. 
 
2.2  Introduction 
Glutamate is rapidly removed from the synapse by plasma membrane 
EAATs, primarily localized to postsynaptic neurons and astrocytes 44.  EAATs 
are critical for glutamate transmission, because it is reuptake and not 
enzymatic breakdown that is responsible for clearance of glutamate from the 
synapse 51.  Of these transporters, EAAT1-3 are expressed abundantly 
throughout the CNS, while EAAT4 is expressed primarily in the cerebellum, 
and EAAT5 is found in the retina 170, 232.  EAAT1 and EAAT2 are generally 
localized to the plasma membranes of glial cells, and are responsible for the 
majority of glutamate reuptake in the forebrain 18, 23, 142, 233.  EAAT3 is 
localized to pre- and postsynaptic neurons in the plasma membrane and 
cytoplasm, and has been implicated in the regulation of synaptic plasticity 234, 
235.    
The EAATs are regulated by a variety of mechanisms, including 
phosphorylation, glycosylation, enzymatic degradation, and protein-protein 
interactions.  A number of EAAT interacting proteins have been identified, 
including G-protein suppressor pathway 1 (GPS1), JWA, ARHGEF11, and 
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KIAA0302 (also called beta III spectrin).  GPS1 interacts with GLT-1 (the 
rodent isoform of EAAT2), EAAC1 (EAAT3), and rodent EAAT4.  GPS1 
decreases GLT-1 mediated glutamate reuptake through a direct protein-
protein interaction 50.  JWA is the human homolog of GTRAP3-18, which 
interacts with and downregulates EAAC1 mediated glutamate reuptake 48.  
GTRAP41 (the rodent isoform of ARHGEF11) and GTRAP48 (the rodent 
isoform of KIAA0302) interact with rodent EAAT4, increasing glutamate 
transport 47. 
Disruptions in cortical functioning and glutamate transmission have 
both been implicated in schizophrenia 8-10, 17, 36, 42, 54, 78, 88, 123, 132, 142, 178, 236-261.  
A genetic variant of EAAT1 has been associated with schizophrenia, and 
expression of a high-risk for schizophrenia allele of the GRM3 metabotropic 
glutamate receptor is associated with decreased EAAT2 mRNA expression in 
human prefrontal cortex 176, 262.  Because the glutamate transporters maintain 
extracellular glutamate, we hypothesized that EAAT1-3 expression is altered 
in the DLPFC and ACC in schizophrenia.   We also predicted that expression 
of molecules regulating EAAT function, including ARHGEF11, JWA, GPS1, 
and KIAA0302, are altered in schizophrenia.  To test these hypotheses, we 
investigated both the transcript and protein expression of these EAATs and 
EAAT interacting proteins in schizophrenia using in situ hybridization and 
Western blot analysis. 
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2.3  Materials and Methods 
2.3.1  Subjects 
Two groups of subjects provided separately from the Mount Sinai 
Medical Center Brain Bank were studied (Tables 2.1 and 2.2) for mRNA and 
protein expression, respectively.  11 subjects (3 control subjects and 8 
subjects with schizophrenia) were common to both groups.  
Neuropathological examination revealed no neurodegenerative disorders 
including Alzheimer’s disease in any subject.  Brain samples were prepared 
as previously described 263.  ACC was dissected at the level of the genu of 
the corpus callosum. Tissue blocks were dissected from the dorsal surface of 
the corpus callosum extending 12–15 mm dorsally and extending 12–15 mm 
laterally from the midline.  DLPFC was dissected as described by Rajkowska 
and Goldman-Rakic 264.   
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 Table 2.1: Subject Characteristics for In Situ Hybridizations 
 
Age (Years) Sex 
PMI 
(hours) pH Cause of Death    
        
Comparison Group        
79* F 3.0 6.3 CPF    
96* F 3.3 6.7 CPF    
90* F 2.3 6.0 CPF    
69 M 4.3 6.3 Unknown    
64 F 19.1 6.1 Pulmonary edema    
93 M 19.0 6.4 Congestive heart failure    
102 F 7.1 6.5 Acute Myocardial Infarction    
73 F 3.4 6.3 Acute Myocardial Infarction    
79 F 7.7 6.5 Acute Myocardial Infarction    
84 F 18.5 6.2 Unknown    
101 M 4.7 6.8 Coronary artery disease    
mean ± SD: 85 ± 13 3M/8F 8.6 ± 6.8 6.4 ±0.2     
        





84 F 15.6 6.2 Unknown par thi/chl 115 
61* M 3.5 6.5 CPF undif per/hal/ser 1 
69* M 4.5 6.4 
Cardiac infarction, renal 
failure par hal/flu/tri/chl 6 
63* M 6.2 5.9 CPF undif hal 0 
69* F 13.9 6.2 CPF undif thi/tri 4 
87* M 11.2 6.5 CPF undif thi/tri 11 
68* M 5.6 6.8 CPF par pro 2 
85 M 5.3 6.3 CPF undiff flu/chl 0 
73 M 7.9 6.5 CPF disorg hal 0 
66 M 12.1 6.5 Acute cardiac failure undif unknown unknown 
76 F 21.2 6.1 Cardiogenic shock par flu/tri/chl 0 
97 M 9.3 6.5 CPF undif hal 0 
66 M 8.4 6.7 CPF sa hal 0 
82 F 18.8 6.6 CPF res ris 124 
79 F 9.9 6.8 Cardiac Arrest undif thx 364 
68 M 17.3 6.6 CPF cat flu 0 
86 F 6.9 5.8 
Respiratory insufficiency, 
renal failure cat thx/chl 36 
65* F 5.8 5.9 CPF undif unknown unknown 
79* F 20.4 7.1 CPF, cancer of pancreas undif thi/thx 9 
84* M 6.2 6.5 CPF undif hal/per/thi/chl 106 
mean ± SD: 75 ± 10 12M/8F 10.5 ± 5.6 6.5 ±0.3     
Abbreviations: post-mortem interval (PMI), standard deviation (SD), female 
(F), male (M), cardiopulmonary failure (CPF), paranoid (par), undifferentiated 
(undif), disorganized (disorg), schizoaffective (sa), residual (res), catatonic 
(cat), antipsychotic medication (Rx), Thioridazine (thi), Chlorpromazine (chl), 
Perphenazine (per), Haloperidol (hal), Trifluoperazine (tri), Prochlorperazine 
(pro), Fluphenazine (flu), Thiothixene (thx), Risperidone (ris).  Asterisks 






Table 2.2: Subject Characteristics for Western Blot Analyses 
 
Age (Years) Sex 
PMI 
(hours) pH Cause of Death    
        
Comparison Group        
88 M 4.8 5.9 Cardiac    
86 F 4.7 6.5 Unknown    
55 M 10.0 5.7 Cancer    
79* F 3.0 6.3 CPF    
96* F 3.3 6.7 CPF    
90* F 4.2 6.0 CPF    
74 F 2.3 6.0 CPF    
70 M 8.0 6.0     
mean ± SD: 74 ± 13 3M / 5F 5.1 ± 2.6  6.1 ± 0.3      
        
Schizophrenia     Subtype Rx 
Weeks Rx 
free 
54 M 8.2 6.0 Acute myelocytic leukemia disorg unknown unknown 
61* M 3.5 6.5 CPF undif per/hal/ser 1 
84* M 6.2 6.5 CPF undif hal/per/thi/chl 106 
69* M 4.5 6.4 
Cardiac infarction, renal 
failure par hal/flu/tri/chl 6 
76 F 8.5 6.1 CPF, breast cancer par thi 0 
87* M 11.2 6.5 CPF undif thi/tri 11 
68* M 5.6 6.8 CPF par pro 2 
86 F 5.5 6.2 Cardiac, pneumonia undif unknown unknown 
72 M 20.6 6.6 CPF undif neuroleptic 12 
65* F 5.8 5.9 CPF undif unknown unknown 
79* F 20.4 7.1 CPF, pancreatic cancer undif thi/thx 9 
63* M 6.2 5.9 CPF undif hal 0 
69* F 13.7 6.2 CPF undif thi/tri 4 
mean ± SD: 72 ± 13  8M / 5F 9.2 ± 5.7  6.4 ± 0.4      
Abbreviations: post-mortem interval (PMI), standard deviation (SD), female 
(F), male (M), cardiopulmonary failure (CPF), paranoid (par), undifferentiated 
(undif), disorganized (disorg), antipsychotic medication (Rx), Thioridazine 
(thi), Chlorpromazine (chl), Perphenazine (per), Haloperidol (hal), 
Fluphenazine (flu), Trifluoperazine (tri), Prochlorperazine (pro), Thiothixene 
(thx).  Asterisks indicate subject is present in both in situ hybridization and 





2.3.2  In Situ Hybridization  
mRNA expression was measured using in situ hybridization for the 
following subclones: GPS-1 (Genebank accession no. BC064503; nucleotide 
coding region 1396-1602), ARHGEF11 (NM_014784; 1935-2309), JWA 
(NM_006407; 181-520), KIAA0302 (AB008567; 5958-6345), EAAT1 
(U03504; 526-825), EAAT2 (NM004171; 601-1026), and EAAT3 (NM004170; 
156-979), GLAST (rat EAAT1, X63744 S49018; 569–1001) as previously 
described 34, 173.  We have previously shown specificity of the probes for 
EAAT1, EAAT2, and EAAT3 using sense and antisense probes 173.  




Figure 2.1: Probe specificity of KIAA0302 and GPS1.  In situ hybridization 
analysis of KIAA0302 and GPS1 mRNA expression using sense and 




2.3.3  Western Blot Analysis 
Western Blot analysis was performed as described previously 263.  For 
each assay, protein was transferred to membranes from multiple gels 
together in the same apparatus, and subsequent treatments were performed 
in parallel under identical conditions to minimize interblot variability.  
Membranes were incubated in blocking solution (5% milk powder in Tris 
buffered saline with 0.1% Tween (milk/TBST) for GPS1 and KIAA0302, 5% 
milk powder in phosphate buffered saline with 0.1% Tween (milk/PBST) for 
EAAT1 and EAAT2, and 3% milk/TBST for EAAT3) for 1 hour at room 
temperature.  Membranes were incubated in primary antibody diluted 1:1000 
for GPS1 (Abcam, ab4535), EAAT1 (Santa Cruz, sc-7758), and EAAT2 
(Chemicon, AB1783), 1:200 for KIAA0302 (Santa Cruz, sc-28273) 1:250 for 
EAAT3 (Alpha Diagnostics, EAAC11-A), and 1:10,000 for beta-tubulin 
(Upstate, 05-661) in blocking solution overnight at 4oC.  The GLT-1 antibody 
was raised to a peptide sharing 100% sequence homology with human 
EAAT2, and cross-reacts with human EAAT2 265.  The EAAC1 and spectrin β 
III antibodies were raised to peptides sharing 100% sequence homology with 
human EAAT3 and KIAA0302.  Membranes were washed in TBST or PBST, 
then incubated for 1 hour with horseradish peroxidase (HRP) coupled 
secondary antibody diluted 1:5000 in blocking solution for EAAT1, GPS1, 
KIAA0302, and beta-tubulin, 1:4000 for EAAT2, and 1:400 for EAAT3.  
Membranes were washed in TBST or PBST followed by high purity water.  
Prior to examining protein expression, we tested our EAAT1, EAAT2, EAAT3, 
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GPS1, KIAA0302, and beta-tubulin Western blot assays using varying 
concentrations of total protein of human cortical tissue homogenate.  These 
control studies demonstrated that our assay was linear for the protein 
concentrations used in our studies. 
 
2.3.4  Statistical Analysis 
Values from two sections (for in situ hybridizations) or bands (for 
Western blots) per subject for each region were averaged and converted to 
optical density.  For in situ hybridizations, background from white matter 
(EAAT1, EAAT2, EAAT3, ARHGEF11, KIAA0302, and JWA) or slide 
background (GPS1) was subtracted from cortical expression grayscale values 
before conversion to optical density.  For Western blots, optical density was 
divided by optical density of beta-tubulin from the same lane as a loading 
control and analyzed as a ratio.  Outliers, defined as values more than 2 
standard deviations from the mean, were excluded.  Because tissue pH is a 
predictor of RNA integrity, correlation analysis was performed to investigate 
possible associations between transcript expression and tissue pH 266.  
Protein integrity is generally not affected by pH 266.  Diagnostic groups were 
matched for age, pH, and PMI, and t-tests revealed no statistically significant 
differences between groups for any of these variables.  When significant 
associations between transcript expression and pH were found, analysis of 
covariance (ANCOVA) was utilized; otherwise analysis of variance (ANOVA) 
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was utilized with diagnosis as the independent variable and optical density or 
optical density ratio as the dependent variable.  For all tests α = 0.05. 
  
2.4  Results 
2.4.1 Transcript Studies 
Using in situ hybridization, transcript expression of EAAT1-3, 
ARHGEF11, GPS1, JWA, and KIAA0302 were measured.  There were no 
associations between EAAT1, EAAT2, ARHGEF11, or KIAA0302 transcript 
expression and pH in either the ACC or the DLPFC.  Correlation analysis 
revealed an association between EAAT3 transcript expression and pH in ACC 
(R= 0.49, p < 0.05) but not DLPFC.  Correlation analysis revealed an 
association between JWA transcript expression and pH in ACC (R = 0.45, p < 
0.05) but not DLPFC.   
EAAT1 transcript expression was increased in schizophrenia in ACC 
(F(1,21) = 4.54, p < 0.05), but not DLPFC (Figure 2.2).  EAAT3 transcript 
expression was increased in schizophrenia in ACC (F(1, 19) = 18.07, p <  
0.05), but not DLPFC (Figure 2.2).  JWA transcript expression was increased 
in schizophrenia in ACC (F(1,24) = 5.73, p < 0.05).  KIAA0302 transcript 
expression was increased in schizophrenia in ACC (F(1,24) = 8.59, p< 0.05), 
but not DLPFC.  There were no significant differences between groups for 
EAAT2, ARHGEF11, or GPS1 (Figures 2.2 and 2.3). Sense controls 
confirmed the specificity of our antisense probes for KIAA0302 and GPS1 
(Figure 2.1).  Emulsion dipping in the vicinity of layer V of the ACC confirmed 
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the specificity of EAAT2 expression to small cells, consistent with astrocytic 




Figure 2.2: EAAT transcript expression.  In situ hybridization analysis of 
EAAT1-3 mRNA expression in the anterior cingulate cortex and dorsolateral 
prefrontal cortex from control and schizophrenia subjects.  Nissl stained 
sections are shown for comparison.  Roman numerals indicate cortical layers.  
Data expressed as means +/- standard error of the mean.  Asterisks indicate 
a significant difference between control and schizophrenia (p < 0.05).  
Abbreviations:  Optical density (OD), control (C), schizophrenia (S), anterior 
cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), excitatory 






Figure 2.3: EAAT interacting partner transcript expression.  In situ 
hybridization analysis of ARHGEF11, GPS1, JWA, and KIAA0302 mRNA 
expression in the anterior cingulate cortex and dorsolateral prefrontal cortex 
from control and schizophrenia subjects.  Data expressed as means +/- 
standard error of the mean.  Abbreviations:  Optical density (OD), control (C), 
schizophrenia (S), anterior cingulate cortex (ACC), dorsolateral prefrontal 
cortex (DLPFC), ARHGEF11 (ARH), G-protein suppressor pathway 1 






Figure 2.4:  Cellular expression pattern of EAAT2.  Emulsion dipped in situ 
hybridization of EAAT2 mRNA in nissl stained tissue from the vicinity of layer 
V of anterior cingulate cortex.  Large circle indicates large cell, small circles 
indicate small cells. 
 
 
2.4.2  Protein Studies 
Using Western blot analysis, protein expression of EAAT1-3, GPS1, 
and KIAA0302 were measured.  For EAAT1-3, protein bands were present for 
both monomeric and multimeric forms (Figure 2.5).  Each of these bands was 
analyzed separately and in sum.  Decreased total EAAT1 expression was 
found in the DLPFC (F(1,14) = 6.25, p < 0.05),  associated with decreased 
expression of the monomer (F(1, 15) = 7.31, p < 0.05), but not the multimer 
(Figure 2.6).  There were no changes in EAAT1 protein expression in the 
ACC. There were no changes in EAAT2 protein expression in the DLPFC or 
ACC (Figure 6).  Increased expression of the EAAT3 multimer was found in 
the ACC (F(1, 16) = 4.92, p < 0.05) but not the DLPFC in schizophrenia 
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(Figure 2.6). There were no changes in expression of the monomer or the 
total amount of EAAT3 protein. 
GPS1 protein expression was increased in the ACC in schizophrenia 
(F(1, 17) = 6.41, p < 0.05) (Figure 3),  but unaltered in the DLPFC.  KIAA0302 
protein expression was increased in the DLPFC (F(1, 16) = 10.56 ; p < 0.05), 




Figure 2.5:  Protein expression profiles.  Western blot analysis of all 
proteins studied.  Numbers on left indicate molecular weight in kDa.  




Figure 2.6: EAAT and EAAT interacting partner protein expression.  
Western blot analysis in the anterior cingulate cortex and dorsolateral 
prefrontal cortex from control and schizophrenia subjects for EAAT1-3, GPS1, 
and KIAA0302.  Values are normalized to tubulin.  Asterisks indicate a 
significant difference between control and schizophrenia (p < 0.05).  Data 
expressed as means +/- standard error of the mean.  Abbreviations:  Optical 
density (OD), control (CTL), schizophrenia (SCZ), anterior cingulate cortex 
(ACC), dorsolateral prefrontal cortex (DLPFC), excitatory amino acid 




2.4.3  Sex Effects 
There was a sex imbalance between diagnostic groups, so the 
dependent variables that differed by diagnosis were tested for sex effects. 
There were generally no sex effects for these variables with the exception of 
EAAT3 transcripts.  EAAT3 transcript expression was increased in male 
subjects compared to female subjects in the ACC (F(1,20) = 11.07, p < 0.05).  
When split by sex, EAAT3 transcript expression was increased in males 
(F(1,8) = 15.04, p < 0.05) and females (F(1,10) = 5.04, p < 0.05) with 
schizophrenia compared to same sex controls. 
 
2.4.4  Antipsychotic Effects 
A number of patients with schizophrenia were medication-free for at 
least 6 weeks prior to death.  No differences in transcript expression were 
detected between medicated and unmedicated patients for most of the 
transcripts found altered with the exception of JWA.  An increase in JWA 
expression in the ACC was found in medicated versus unmedicated patients 
(F(1,4) = 13.13, p < 0.05).  No changes in transcript expression detected 
between control subjects and unmedicated patients with schizophrenia for 
any of the transcripts found altered in schizophrenia.  No differences in 
protein expression were detected between medicated and unmedicated 
patients with schizophrenia for any of the proteins found altered in 
schizophrenia.  No changes in protein expression were detected between 
control subjects and unmedicated patients with schizophrenia for EAAT1, 
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GPS1, or KIAA0302.  EAAT3 protein expression was increased in the ACC in 
unmedicated patients with schizophrenia compared to controls (F(1, 9) = 
7.07, p < 0.05). 
 
2.5  Discussion 
 We found alterations in expression of molecules involved in glutamate 
transport in schizophrenia, suggesting abnormal glutamate reuptake is 
involved in the pathophysiology of this illness.  Of particular interest are the 
changes in protein expression of the glial transporter EAAT1, the neuronal 
transporter EAAT3, and the negative modulator of EAAT2 mediated 
glutamate reuptake, GPS1.  These results suggest that neuronal glutamate 
reuptake may be increased in schizophrenia, while glial glutamate reuptake 
may be diminished.   
We detected a decrease in total EAAT1 protein expression in the 
DLPFC, most likely attributable to decreased expression of the monomer.  
While the EAATs function natively as homomultimers 136, this result suggests 
that there may be a decrease in monomeric pools of EAAT1.  Decreased 
EAAT1 protein expression may reflect decreased glutamate reuptake into 
glial cells or a decrease in the total number of EAAT1 expressing glia.  In 
addition to decreased protein expression in the DLPFC, we detected 
increased EAAT1 transcript, but not protein, expression in the ACC.  
Unchanged protein expression with increased mRNA expression may be due 
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to a number of factors including abnormal translation and folding, abnormal 
post-translational modifications, or increased protein turnover.   
We did not detect changes in transcript or protein expression of 
EAAT2, the transporter responsible for approximately 90% of glutamate 
reuptake in the forebrain 267.  Previous studies of EAAT2 expression have 
yielded discrepant results.  Two studies found increased EAAT2 transcript 
expression in the PFC, while another found no changes 178-180.  While we did 
not find changes in EAAT2, it is possible that EAAT2 mediated glutamate 
reuptake is regulated by processes other than simply increasing or 
decreasing gene expression.  Phosphorylation of specific serine residues and 
degradation pathways are known to influence EAAT2 function 193, 203. 
 EAAT2 mediated glutamate reuptake may also be regulated by GPS1 
which interacts with the C-terminus of GLT-1 (the rat homolog of EAAT2), 
regulating surface trafficking through a leucine zipper-like motif 50.  
Coexpression of GPS-1 with GLT-1 downregulates glutamate reuptake in 
HEK cells 268.  We found increased GPS1 protein, but not mRNA, in the ACC, 
suggesting decreased EAAT2 mediated glutamate reuptake.  GPS1 protein 
levels have not previously been examined in schizophrenia, but in a different 
study 34, we found no changes in GPS1 mRNA expression in the thalamus, 
suggesting that changes in GPS1 may be region specific.  
 GPS1 may have other functions besides regulating GLT-1/EAAT2.  
GPS1 also associated with EAAC1 and rodent EAAT4 in an in vitro binding 
assay, and it might regulate these transporters in a manner similar to GLT-1 
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50.  It has also been suggested that GPS1 functions in humans as a 
suppressor of G-protein pathway signaling 269.  Thus, it is possible that GPS1 
could also have effects on G-protein linked receptors, including the mGluRs.  
mGluRs play a role in glutamate cycling because activation of group I 
mGluRs or group II-III mGluRs enhances and inhibits glutamate release, 
respectively 270. 
While it appears that EAAT2 is not regulated simply by changes in 
gene expression, EAAT3 expression was increased at both transcript and 
protein levels.  Animal and cell culture experiments have shown that the 
EAATs exist natively as homomultimers 136.  EAAT trimers are formed 
immediately after biosynthesis, and are the only functioning forms of EAAT3 
in native systems 135.  It is unclear whether the multimer bands we measured 
are dimers or trimers, given that undissociated proteins do not migrate with a 
uniform surface area to charge ratio 271.  Our data suggest increased EAAT3 
mediated glutamate reuptake in the ACC in schizophrenia, since we found an 
increase in multimer protein expression. 
We propose that the changes in EAAT3 expression are secondary to 
changes in EAAT1 and GPS1 expression.  Decreased EAAT1 and increased 
GPS1 expression may cause decreased glutamate reuptake in glial cells, 
leading to increased basal synaptic glutamate levels and synaptic spillover.  
EAAT3 is largely localized in perisynaptic regions and contributes to 
clearance of glutamate spillover 272, 273.   Thus, EAAT3 expression may be 
increased in neurons to compensate for these changes.  Consistent with this 
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notion, EAAT3 protein is localized to regulatable cytosolic pools that may be 
rapidly mobilized to the plasma membrane, suggesting a biological process 
that is highly responsive to changes in glutamate levels 164.   It is also 
possible that increased EAAT3 expression is an effect of direct interaction 
with GPS1, or another EAAT regulating molecule.  However, it is not known 
what effect, if any, GPS1 has on EAAT3 mediated glutamate reuptake. 
 In addition to the changes in GPS1, EAAT1, and EAAT3, we detected 
increased KIAA0302 protein expression in the DLPFC.  This increase is 
difficult to interpret as it relates to glutamate transport because KIAA0302 is 
reported to interact only with EAAT4 47.  Although both transcript and protein 
levels of KIAA0302 are highly expressed in the cortex, EAAT4 is expressed at 
very low levels, and is predominantly expressed in the cerebellum 171, 274.  
This anatomical mismatch suggests that KIAA0302 has other functions.  
KIAA0302 is a structural molecule involved in Golgi and vesicular membrane 
skeletons, binds to dynein and dynactin, and it has been implicated in 
vesicular trafficking along microtubules 47, 275, 276.   Given the scarcity of 
EAAT4, it is likely that KIAA0302 serves structural, trafficking, or other roles in 
the prefrontal cortex. 
We did not detect changes in transcript expression for any of the EAAT 
interacting proteins that we studied.  This suggests that these molecules are 
not altered in schizophrenia at the mRNA level.  We were unable to measure 
protein expression of JWA or ARHGEF11 with commercially available 
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antibodies.  It is therefore possible that, similar to GPS1 and KIAA0302, they 
are altered in schizophrenia at the level of protein, but not mRNA, expression. 
Another point of interest from these data is that all significant changes were 
detected in the ACC but not the DLPFC.  Although the DLPFC has been a 
major focus of studies involving altered gene expression in schizophrenia, 
many other regions have also been implicated in this disease, and may have 
more robust changes.  In a microarray study of multiple brain regions in 
schizophrenia, the ACC had ~20 fold more altered genes than the 
dorsolateral prefrontal cortex 277.  Thus, our findings are consistent with the 
hypothesis that the ACC may be a particularly vulnerable site in the 
pathophysiology of schizophrenia. 
There are several potential limitations of this study.  One concern is the 
advanced age of the subjects.  Disorder-specific alterations in gene 
expression could be masked by age effects on those genes.  However, we 
have previously detected robust changes in glutamate receptor transcripts, 
proteins, and binding sites in a similar sample from the same brain bank, 
demonstrating significant changes in gene expression in older subjects 32-34, 
36, 38.  Sex effects may also be a confounding factor.  In our entire sample, we 
found an increase in EAAT3 transcript expression in males compared to 
females in the ACC.  However, EAAT3 expression was increased in 
schizophrenia compared to controls in both males and females when 
analyzed separately, suggesting that our diagnosis-related results are likely 
not attributable to sex differences. 
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Another limitation of this study is the potential effects of treatment with 
antipsychotic medications 278, 279.  We generally did not detect any differences 
in expression between medicated and unmedicated patients for any 
transcripts or proteins we found increased in schizophrenia with one 
exception.   We detected increased JWA transcript expression in the ACC in 
medicated versus unmedicated subjects.  These analyses, however, are 
underpowered.  The increased JWA transcript expression in schizophrenia 
may therefore be due to either disease specific or medication specific effects.  
However, we did find increased EAAT3 protein expression in the ACC in 
unmedicated patients with schizophrenia, compared to control subjects, 
suggesting that our EAAT3 findings are not due to a medication effect. 
Our results shed light on several aspects of glutamate cycling in 
schizophrenia.  Increased GPS1 protein and decreased EAAT1 protein 
suggest decreased glutamate reuptake capacity in glia, leading to increased 
synaptic glutamate levels and synaptic spillover.  The increase in EAAT3 
expression might be compensatory to decreased glutamate reuptake by glia.  
This scenario suggests a state of increased basal synaptic glutamate levels in 
the prefrontal cortex in schizophrenia.  It remains unclear how KIAA0302 fits 
into this model, as the transporter subtype it regulates is expressed at very 
low levels in the cortex.  These findings have important implications for 
neuronal plasticity in schizophrenia, and provide new targets for the 








Abnormal Glycosylation of EAAT1 and EAAT2 in Prefrontal Cortex of 
Elderly Patients with Schizophrenia 
 
 
3.1  Abstract  
EAATs may be regulated by N-glycosylation, a posttranslational 
modification that is critical for many cellular functions including localization in 
the plasma membrane.  We hypothesized that glycosylation of the EAATs is 
abnormal in schizophrenia.  To test this hypothesis, we treated postmortem 
tissue from the DLPFC and ACC of patients with schizophrenia and 
comparison subjects with deglycosylating enzymes.  We then measured the 
resulting shifts in molecular weight of the EAATs using Western blot analysis 
to determine the mass of glycans cleaved from the transporter.  We found 
evidence for less glycosylation of both EAAT1 and EAAT2 in schizophrenia.  
We did not detect N-linked glycosylation of EAAT3 in either schizophrenia or 
the comparison subjects in these regions.  Our data suggest an abnormality 
of posttranslational modification of glutamate transporters in schizophrenia 
that suggests a decreased capacity for glutamate reuptake.  
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3.2  Introduction 
Glycosylation of proteins is a posttranslational modification that plays a 
role in molecular trafficking, protein folding, endocytosis, receptor activation, 
signal transduction, and cell adhesion 214.  Abnormalities of glycosylation can 
lead to a number of cellular storage disorders including Gaucher’s, Niemann-
Pick type C, Sandhoff’s, and Tay-Sach’s diseases, as well as other congenital 
disorders of glycosylation 214.  Disruptions in glycosylation have also been 
implicated in Alzheimer’s disease 280, Huntington’s disease 281, and 
schizophrenia 215.  
Two common forms of protein glycosylation include N-linked 
glycosylation and O-linked glycosylation.  N-linked glycosylation is the 
covalent linkage of oligosaccharides to asparagine residues of proteins.   N-
glycosyl residues are processed as proteins are trafficked through the ER and 
Golgi.  The EAATs are N-glycosylated proteins that transport extracellular 
glutamate out of the synapse and thus are critical for glutamatergic signaling.  
However, glycosylation of the EAATs in human brain has not been evaluated. 
EAAT1 is variably expressed throughout the cortex in astroglia 138, 142, 
143, 181, 233, 282, 283.  GLAST, the rodent form of EAAT1, exists as two isoforms, 
70-kDa and 64-kDa, which differ only by the degree of N-glycosylation at 
Asn206 and Asn195 209, 212.  Glycosylation of this transporter may serve an 
important functional role because nonglycosylated GLAST does not form 
homomultimers, which are the native conformation of GLAST in vivo 209.  In 
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addition, glycosylation of GLAST has been correlated with trafficking of 
GLAST to plasma membrane and increased glutamate uptake 284. 
EAAT2 is an astrocytic transporter responsible for the majority of 
glutamate uptake in the cortex.  Deglycosylation of the rodent isoforms of 
EAAT2 (GLT-1) resulted in a ~10-15 kDa shift in molecular weight of the 
monomer band 230. There is a conflicting literature describing the functional 
effects of EAAT2 glycosylation.  One group found that glycosylation-deficient 
GLT-1 had a decreased rate of glutamate transport due to decreased 
expression in the plasma membrane 216.  This may be attributed to retention 
of GLT-1 in the ER, because mutant GLT-1 expressing an altered 
extracellular leucine-based motif is immaturely glycosylated and retained in 
the ER 230.  However, another group found no effect of N-glycosylation on the 
trafficking or transport activity of GLT-1 in transfected BHK cells, but 
increased stability at the plasma membrane, which may be critical for 
transporter localization in vivo 211.  
EAAT3 is a neuronal glutamate transporter expressed in the cortex.  In 
rat C-6 glioma cells, EAAC1 (the rodent form of EAAT3) is N-glycosylated 
with high mannose-containing sidechains and processed into complex chains, 
coinciding with insertion into the plasma membrane 213.  A shift of 
approximately 5 kDa was detected when EAAT3 immunoprecipitated from 
human brain synaptosomes were treated with Endoglycosidase F 285.   
We previously reported alterations in EAAT1 and EAAT3 protein in 
prefrontal cortex in schizophrenia, suggesting diminished EAAT-mediated 
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glutamate reuptake as a part of the pathophysiology of this illness 286.  
However, localization of the transporters may be as important as overall 
protein levels.  Altered EAAT localization may lead to glutamate spillover into 
the extrasynaptic space and adjacent synapses, causing loss of input 
specificity 287-289.  Since glycosylation is important for targeting of the EAATs 
to the plasma membrane, abnormal glycosylation of these proteins may play 
a role in schizophrenia.   
 Glycobiology is a growing field with an increasing number of tools.  The 
enzyme peptide-N4-(N-acetyl-beta-glucosaminyl) asparagine amidase F 
(PNGase F) cleaves N-linked sugars off of proteins attached at asparagine 
residues.  Endoglycosidase H (Endo H) cleaves hybrid and high mannose 
containing residues from glycoproteins, and is therefore specific to immaturely 
glycosylated proteins that have not been processed beyond the ER.  The 
removal of glycans is often substantial enough to detect a change in 
molecular weight of proteins when measured by Western blot analysis.  In this 
study, we assessed glycosylation of EAAT1, EAAT2, and EAAT3 through 
enzymatic deglycosylation in schizophrenia and a comparison group. 
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3.3  Materials and Methods 
 
3.3.1  Subjects 
Subjects from the Mount Sinai Medical Center Schizophrenia Brain 
Bank were studied (Table 3.1), including 35 individuals diagnosed with 
schizophrenia and 33 comparison subjects.  Subjects were diagnosed with 
schizophrenia if the presence of schizophrenic symptoms was documented 
before age 40, the medical records contained evidence of psychotic 
symptoms and at least 10 years of psychiatric hospitalization with diagnosis 
of schizophrenia, and a DSM-III-R diagnosis of schizophrenia was agreed 
upon by two experienced clinicians.  Diagnostic groups did not significantly 
differ for age, sex, postmortem interval, and tissue pH.  Upon 
neuropathological examination, no evidence of Alzheimer’s or other 
neurodegenerative disease was found.  The brain banking procedures were 
approved by the Mount Sinai School of Medicine Institutional Review Board. 
 
Table 3.1: Subject Characteristics for Deglycosylation Studies 
 
 Comparison Group Schizophrenia  
Region ACC DLPFC ACC DLPFC 
N 34 32 34 33 
Sex 14 m / 20 f 12 m / 20 f 24 m / 10 f 23 m / 10 f 
Tissue pH 6.4 ± 0.2 6.5 ± 0.2 6.4 ± 0.3 6.4 ± 0.3 
PMI (hours) 8.3 ± 6.7 8.2 ± 6.8 13.4 ± 8.1 12.5 ± 6.7 
Age (years) 78 ± 14 78 ± 14 74 ± 12 74 ± 12 
On / Off Rx 0 / 34 0 / 32 23 / 11 22 / 11 
Values presented as mean ± standard deviation 
Abbreviations: anterior cingulate cortex (ACC), dorsolateral prefrontal cortex 
(DLPFC), male (m), female (f), antipsychotic medication (Rx), postmortem 
interval (PMI). 
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3.3.2  Tissue preparation 
Brains were obtained after autopsy and one hemisphere was cut 
coronally into ~0.8 - 1 cm3 slabs and flash frozen.  Gray matter was dissected 
from ACC (n = 68) and DLPFC (n = 66).  ACC was dissected at the level of 
the genu of the corpus callosum. Tissue blocks were dissected from the 
dorsal surface of the corpus callosum extending 12–15 mm dorsally and 
extending 12–15 mm laterally from the midline.  DLPFC was dissected 
corresponding to Brodmann area 46 and measuring ≈ 1.5 cm along the 
cortical surface as described by Rajkowska and Goldman-Rakic 264. 
Approximately 1 cm3 of frozen tissue was pulverized in liquid nitrogen, then 
homogenized (10% wt/vol) in 5 mM Tris-HCl (pH 7.4) with 320 mM sucrose 
and 1 protease inhibitor tablet (Complete mini, Roche Diagnostics, Manheim, 
Germany) per 10 mL for 30 sec with a polytron homogenizer (Fisher 
Scientific, Pittsburgh, Pennsylvania) and stored at -80oC in 0.5 mL aliquots.  
To determine protein concentrations, assay by the Bradford method  290 was 
performed on these homogenates.  
 
3.3.3  Deglycosylation 
16 µg of protein for each sample was added to 6.7 µl 5X reaction 
buffer (QA Bio), 1.7 µl denaturation solution (2% SDS/ 1M β 
mercaptoethanol) (QA Bio), and adjusted to volume with deionized water.   
Samples were then incubated at 70oC for 10 min.  Samples were cooled to 
room temperature and incubated with 1.3 µl Endoglycosidase H or 1.3 µl 
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PNGase F and 1.7 µl  15% triton X-100 (QA Bio) at 37oC for 12 hours. Non-
enzyme-treated samples were prepared identically to the enzyme-treated 
samples with the same buffers except that they were incubated with water 
instead of the deglycosylating enzymes. 
 
3.3.4  Electrophoresis 
NuPAGE sample reducing agent (Invitrogen), and NuPAGE LDS 
sample buffer (Invitrogen) were added to the samples, which were then 
incubated at 70oC for 10 minutes.  The Novex Mini Cell NuPAGE system 
(Invitrogen) with 4-12% Bis-Tris gradient polyacrylamide gels (Invitrogen) was 
used and 8µg of protein was added per lane.  A molecular mass standard 
was run on each gel (Kaleidescope prestained standards, BioRad).  Gels 
were suspended in a bath of NuPAGE MES SDS running buffer (Invitrogen) 
with 500µl NuPAGE antioxidant (Invitrogen) during electrophoresis.  
 
3.3.5  Western blot analysis 
Following electrophoresis, proteins were transferred onto Immobilon-
FL PVDF membranes (Millipore) using a semi-dry transfer apparatus (Bio-
Rad).  After electroblot transfer, membranes were washed twice and 
incubated with Li-Cor Blocking Buffer (Li-Cor Biosciences) for 1 hour at room 
temperature with rocking to block nonspecific antibody binding.  Membranes 
were incubated with either a rabbit polyclonal antibody to EAAT1 (Santa Cruz 
sc-15316) diluted 1:1,000, rabbit polyclonal antibody to EAAT2 (Santa Cruz 
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sc-15317) diluted 1:1000, mouse moloclonal antibody to EAAT3 (Chemicon 
MAB1578) diluted 1:1000, rabbit polyclonal antibody to EAAT3 (Santa Cruz 
sc-25658) diluted 1:500, or rabbit polyclonal antibody to EAAT3 (Alpha 
Diagnostics #EAAC11-A) diluted 1:500 in blocking buffer with 0.1% Tween 
overnight at 4oC with rocking.  Next, the membranes were washed three times 
for ten minutes in tris-buffered saline with 0.1% Tween (TBST), then rocked 
for 15 minutes at room temperature with anti-rabbit or anti-mouse IR-Dye 
800CW secondary antibody (Li-Cor Biosciences) diluted 1:10,000 in blocking 
buffer with 0.1% Tween.  Membranes were washed three times for 10 
minutes in TBST then washed 5 times in deionized water and allowed to dry 
for 3-5 minutes before scanning (infrared imaging system; Li-Cor 
Biosciences).   
 
3.3.6  Data Analysis 
Membranes probed with infrared-labeled secondary antibodies were 
scanned using a Li-Cor Odyssey scanner, and the migration distance for each 
protein band was measured in pixels using the Odyssey 2.1 software 
package.  Migration distance was converted to molecular mass by plotting the 
relative migration of the molecular mass standards against the log of their 
molecular masses, and fitting the relative migration of the bands of interest to 
that standard curve 291 (Figure 3.1).  Band shift was measured as molecular 
mass of the control band minus the molecular mass of the enzyme treated 
band in the adjacent lane, as described previously 292-294 (Figure 3.1).  EAAT1 
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and EAAT2 migrate as both monomers and multimers 286, and the molecular 
mass shifts of monomers and multimers were analyzed separately. 
 
Figure 3.1:  Schematic of a gel with control and deglycosylation treatments.  
Molecular mass was calculated by plotting the relative migration of the 
molecular mass standards against the log of their molecular masses, and 
fitting the relative migration of the bands of interest to that standard curve.  
Molecular mass shift was calculated by subtracting the molecular mass of the 
adjacent control band from the band of interest.  Abbreviations: relative 
migration (Rf), endoglycosidase H (endo H), peptide-N4-(N-acetyl-beta-
glucosaminyl) asparagine amidase F (PNGase F).  
 
 
3.3.7  Statistical Analysis 
All statistical analyses were performed using Statistica (StatSoft, Tulsa, 
Oklahoma).  Outliers more than 6 standard deviations from the mean were 

















































































between the dependent variable, molecular mass shift and age, PMI, and pH.  
We analyzed deglycosylation induced changes in molecular mass using 
analysis of variance (ANOVA), or analysis of covariance (ANCOVA) when 
significant correlations were detected.  To test for possible medication effects, 
patients with schizophrenia off antipsychotic medication for at least 6 weeks 
prior to death were compared to patients on antipsychotic medication within 6 
weeks of death.   
 
3.4  Results  
When samples were treated with EndoH, none of the transporters 
exhibited shifts in molecular mass of either monomeric or multimeric forms 
(Figure 3.2).  When samples were treated with PNGase F, EAAT1 and 
EAAT2 exhibited detectable shifts in molecular mass for both monomeric and 
multimeric forms (Figure 3.2).  However, EAAT3 did not shift when treated 
with PNGase F (Figure 3.2).  Because we were concerned that the lack of 
shift could be due to a loss of an epitope following enzymatic digestion, we 
performed Western blots with two additional EAAT3 antibodies raised against 






Figure 3.2: Western blots of deglycosylated EAATs.   Western blot analysis of 
EAAT1, EAAT2, and EAAT3 deglycosylated with the enzymes 
Endoglycosidase H and PNGase F.  EndoH and PNGase F lanes indicate 
enzyme treated samples.  EndoH control and PNGase F control lanes were 
treated identically to the corresponding enzyme treated samples except the 
enzymes were omitted. Molecular masses of EAAT1 and EAAT2 monomers 
and multimers were shifted in the PNGase F treated lanes.  No shift was 
detected for EAAT3.  Abbreviations:  kDa (kilodaltons), excitatory amino acid 
transporter (EAAT), endoglycosidase H (EndoH), peptide-N4-(N-acetyl-beta-




We examined the effects of PNGase treatment on monomer and 
multimer forms of EAAT1 and EAAT2 in schizophrenia and comparison 
subjects.  There were generally no correlations detected between age, PMI 
(which differs between diagnosis groups (F(1, 66)=7.3766, p=.00843)), or pH 
and our dependent measures with the exception of shift of EAAT1 monomer 
in the DLPFC: (R= 0.28, p < 0.05).  We found less of a molecular mass shift 
for the EAAT1 monomer in schizophrenia in the ACC (F(1, 61) = 6.40; p < 
0.05) (Figure 3.3).  We found less of a mass shift for the EAAT2 multimer in 
schizophrenia in the DLPFC (F(1,52) = 9.41; p < 0.05) (Figure 3.2). There 
was no effect of medication status in the subjects with schizophrenia on either 
of these dependent measures (EAAT1 monomer in ACC (F(1, 29) = 0.06, p = 




Figure 3.3: Molecular mass shifts of EAAT1 and EAAT2 in schizophrenia and 
a comparison group following enzymatic deglycosylation with PNGase F.  
Data expressed as means +/- standard error of the mean.  Asterisks indicate 
a significant difference between schizophrenia and comparison subjects (p < 
0.05).  Abbreviations:  kDa (kilodaltons), anterior cingulate cortex (ACC), 
dorsolateral prefrontal cortex (DLPFC), excitatory amino acid transporter 
(EAAT), endoglycosidase H (EndoH), peptide-N4-(N-acetyl-beta-





Figure 3.4: Molecular mass shifts of EAAT1 and EAAT2 following enzymatic 
deglycosylation with PNGase F in patients with schizophrenia off or on 
medication 6 weeks prior to death.  Data expressed as means +/- standard 
error of the mean.  Abbreviations:  kDa (kilodaltons), anterior cingulate cortex 





3.5  Discussion  
Previous work has demonstrated altered glycosylation of several 
proteins in schizophrenia.  Increases in the plasma activity of the 
glycosylating enzyme alpha 2,6 sialyltransferase and in serum levels of alpha 
2 and beta globulins have been found in schizophrenia 295, 296.  In addition, a 
decrease in the number of cells expressing polysialated neural cell adhesion 
molecule (NCAM) was detected in the hilus of the hippocampus without an 
overall change in NCAM expression 297.    We detected two additional 
proteins that have altered glycosylation in schizophrenia, suggesting that 
deficits in glycosylation may have a role in the pathophysiology of this illness. 
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We found that EAAT1 and EAAT2, but not EAAT3, are N-glycosylated 
in the human brain.  Given that we found changes in the glial (EAAT1 and 
EAAT2) but not neuronal (EAAT3) transporters, it is possible that the 
mechanisms for glycosylation deficits in schizophrenia are glia-specific.  Our 
EAAT3 finding is surprising, given that in the rodent EAAT3 (EAAC1) is 
glycosylated 213, and that another study demonstrated deglycosylation of 
EAAT3 in an immunoprecipitated fraction from human brain synaptosomes 
285.  These divergent findings might be due to the type of deglycosylating 
enzyme used, or that immunoprecipitating EAAT3 from synaptosomes 
significantly enriched EAAT3, allowing detection of subtle changes that might 
not be apparent in tissue homogenate.  It may be that a small subset of 
EAAT3 is glycosylated in human brain, while the majority of EAAT3 is 
unglycosylated, and thus not detectable with our approach.  Alternatively, the 
absence of a molecular mass shift in EAAT3 could be due to a loss of 
epitopes associated with glycosylation for the EAAT3 antibodies following 
enzymatic digestion 234, 298.  For example, an antibody might bind to bind to a 
glycosylated residue of EAAT3 and lose antigenicity if that glycan is cleaved.  
However, we feel this is unlikely because we did not detect a shift using any 
of the three EAAT3 antibodies raised to different epitopes and one of these 
epitopes does not contain any putative N-glycosylation sites.  
We found that EAAT1 has fewer sugar residues added by N-
glycosylation in schizophrenia.  The change in molecular mass shift of EAAT1 
was relatively small (~5%) between schizophrenia and the comparison group.  
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It is difficult to determine if such a small change in glycosylation is of 
physiological significance.  It is possible that because the change is small, it 
may be a type I statistical error due to a high coefficient of variation.  
However, if this change is real, preclinical data suggests that a small change 
in glycosylation can have a strong effect on glutamate uptake.  For example, 
activation of astrocytes with ciliary neurotrophic factor (CNTF) results in a 
small increase in glycosylation of GLAST (~8% shift), with increased 
localization of GLAST to lipid rafts at the cell surface and increased glutamate 
reuptake, resulting in a 67% decrease in extracellular glutamate levels upon 
quinolinate evoked glutamate release 284.  This suggests that the decrease in 
glycosylation of EAAT1 that we detected may significantly impact glutamate 
reuptake.    
We also found evidence for less glycosylation of the other astrocytic 
transporter, EAAT2, in schizophrenia.  The difference in molecular mass shift 
between groups was larger for EAAT2 (~13%) than for EAAT1, although the 
functional effect of this larger shift is not known.  Less glycosylation of EAAT2 
might reflect decreased glutamate reuptake, since altered glycosylation of 
EAAT2 is associated with ER retention and decreased plasma membrane 
expression, and trafficking of EAAT2 to the plasma membrane is necessary 
for EAAT2 mediated glutamate reuptake 216, 230.  
One potential mechanism for the decreases in glycosylation could be 
altered splice variant expression.  EAAT1 and EAAT2 can both be 
alternatively spliced to skip exon 9, which contains an ER exit motif.  These 
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splice variants are retained in the ER, and cause ER retention of any full 
length variants with which they dimerize 230.  The transporters that are 
retained in the ER are less glycosylated than transporters that are not 
retained 230.  Thus, it is possible that the decreases in glycosylation that we 
found are due to increased expression of these exon skipping variants.  In 
fact, we found increases in the exon 9 skipping variant of EAAT2, which could 
explain the decrease we found in EAAT2 glycosylation (Chapter 4). 
It is also possible that the changes in glycosylation we found are due to 
changes in the levels or activity of the glycosyl transferases that attach 
glycans to the proteins.  Few studies have investigated glycosyl transferases 
in schizophrenia.  An increase has been detected in the plasma activity of the 
glycosylating enzyme alpha 2,6 sialyltransferase 295.  An increase in activity of 
a glycosyl transferase is unlikely to explain a decrease in glycosylation, but it 
is possible that other glycosyl transferases are decreased in schizophrenia.   
Since most of the patients with schizophrenia were treated with antipsychotic 
medications, the reductions we found in glycosylation could be due to a 
medication effect.  However, we did not find any effects of medication on 
molecular mass shift when comparing patients on medication 6 weeks prior to 
death to patients off medication at least 6 weeks prior to death. 
The reductions in EAAT1 and EAAT2 glycosylation suggest decreased 
plasma membrane expression of these transporters.  Altered localization of 
EAAT1 and EAAT2, combined with the decreased EAAT1 protein expression 
we previously described 286, suggest that there is decreased perisynaptic 
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glutamate reuptake into astrocytes in schizophrenia.  The glutamate 
transporters are important for maintaining low synaptic glutamate levels by 
buffering and transporting synaptic glutamate 299, 300.  Diminished perisynaptic 
reuptake and buffering may lead to glutamate spillover and loss of input 
specificity 287, 288.  Our data suggesting decreased glutamate reuptake support 
a hypothesis of increased synaptic glutamate levels and/or glutamate 
spillover in schizophrenia.  Consistent with this hypothesis, EAAT1 deficient 
mice exhibit endophenotypes including self-neglect, social withdrawal, and 
impaired learning, suggesting that schizophrenia-associated rodent 
endophenotypes can be modeled by disruption of EAAT1-mediated glutamate 
reuptake 20.  This hypothesis is further supported by a report of a subject with 
schizophrenia who has a partial deletion of the EAAT1 gene 176.  Finally, our 
data suggest that reducing synaptic glutamate could be a useful strategy in 
the treatment of schizophrenia.  One study using an mGluR2/3 agonist, which 
decreases glutamate release, had antipsychotic effects in schizophrenia 177.   
Taken together, these data support a role for diminished glutamate reuptake 















4.1  Abstract  
Alternative splicing of the EAATs provides one mechanism by which 
EAAT function can be regulated.  Given that abnormal EAAT expression and 
evidence for dysregulation of glutamatergic neurotransmission have been 
found in schizophrenia, we hypothesized that expression of EAAT splice 
variants may be abnormal in schizophrenia.  To test this hypothesis, we 
measured transcript expression of five EAAT isoforms: EAAT1, EAAT1Δ9, 
EAAT2, EAAT2B and EAAT2Δ9 by QPCR in postmortem tissue from the 
prefrontal cortex of patients with schizophrenia and comparison subjects.   
We found increased expression of EAAT2Δ9 in schizophrenia.  Our data 
suggest abnormal glutamate transporter splicing in schizophrenia, consistent 
with decreased capacity for glutamate reuptake.  
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4.2  Introduction 
The EAATs are known to be alternatively spliced, which is associated 
with their functional regulation 183, 218-224.  EAAT1 can be alternatively spliced 
as an exon 3 skipping 210, 224, 227 or an exon 9 skipping variant 228.  The exon 3 
skipping variant, also known as EAAT1a, is thought to have an opposite 
orientation in the cell membrane to regular EAAT1 and to be unglycosylated 
210.  The exon 9 skipping variant, also known as EAAT1Δ9 or EAAT1b is 
retained in the ER, is likely unglycosylated, and appears to be a non-
functioning transporter exerting a dominant negative effect on the native 
transporter 229. 
Several splice variants have also been described for EAAT2. Exon 
skipping variants of EAAT2 include an exon 7 skipping variant 219, an exon 9 
skipping variant 219, 221, 222 and a variant containing a partial deletion of exons 
6 and 7 219.  Like the exon 9 skipping form of EAAT1, the exon 9 skipping 
form of EAAT2 (EAAT2Δ9) is also retained in the ER 230.  There are also 
several intron retention variants of EAAT2.  For example, EAAT2b is an intron 
10-11 retention variant that retains the ability to transport glutamate in vitro, 
but unlike EAAT2, is expressed in neurons and glia, and is expressed in the 
cytoplasm rather than the plasma membrane 182, 183.   
EAAT function must be tightly regulated in order to ensure proper 
glutamatergic neurotransmission.  We previously demonstrated abnormalities 
in EAAT expression in schizophrenia286.  Alterations in splicing could also 
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cause disturbances in EAAT function. Abnormalities in EAAT splicing have 
been demonstrated in mood disorders, anxiety disorders, Alzheimer’s 
disease, epilepsy, hypoxia/ischemia, Huntington’s disease, brain injury, 
glaucoma, HIV-associated dementia, addiction, ALS, and schizophrenia225.  
Additionally, changes in splicing of several other glutamatergic molecules 
including AMPA and NMDA receptor subunits have previously been shown in 
schizophrenia33, 104, 107.  In this study, we measured expression of EAAT1 and 
EAAT2 splice variants in postmortem brain from patients with schizophrenia 
and a comparison group.  We hypothesized that there is abnormal splice 
variant expression of EAAT1 and EAAT2 in schizophrenia. 
 
4.3  Methods 
4.3.1  Subjects 
Subjects from the Mount Sinai Medical Center Schizophrenia Brain 
Bank were studied (Table 4.1), including 25 individuals diagnosed with 
schizophrenia and 25 comparison subjects.  Subjects were diagnosed with 
schizophrenia if the presence of symptoms was documented before age 40, 
the medical records contained evidence of psychotic symptoms and at least 
10 years of psychiatric hospitalization with diagnosis of schizophrenia, and a 
DSM-III-R diagnosis of schizophrenia was agreed upon by two experienced 
clinicians.  Diagnostic groups did not significantly differ for age, sex, 
postmortem interval, and tissue pH.  Upon neuropathological examination, no 
evidence of Alzheimer’s or other neurodegenerative disease was found.  The 
 77 
brain banking procedures were approved by the Mount Sinai School of 
Medicine Institutional Review Board. 
 
Table 4.1: Subject Characteristics for Splice Variant Studies 
 
 Comparison Group Schizophrenia 
   N 25 25 
Sex 12 m / 13 f 16 m / 9 f 
Tissue pH 6.6 ± 0.3 6.5 ± 0.2 
PMI (hours) 8.6 ± 7.0 17.1 ± 10.0 
Age (years) 76 ± 11 75 ± 13 
On / Off Rx 0 / 25 18 / 7 
Values presented as mean ± standard deviation 
Abbreviations: male (m), female (f), antipsychotic medication (Rx), 
postmortem interval (PMI). 
 
 
4.3.2  RNA preparation 
Brains were obtained after autopsy and one hemisphere was cut 
coronally into ~0.8 - 1 cm3 slabs and flash frozen.  Gray matter was dissected 
from ACC (n = 68) and DLPFC (n = 66).  ACC was dissected at the level of 
the genu of the corpus callosum, from the dorsal surface of the corpus 
callosum extending 12–15 mm dorsally and extending 12–15 mm laterally 
from the midline.  DLPFC was dissected corresponding to Brodmann area 46 
measuring approximately 1.5 cm along the cortical surface.  Approximately 1 
cm3 of frozen tissue was pulverized in liquid nitrogen.  The tissue was then 
homogenized in Buffer RLT Plus (AllPrep DNA/RNA Mini Kit (Qiagen)) by 
passing it 10 times through a 20-guage needle and RNA was extracted with 
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the AllPrep DNA/RNA Mini Kit (Qiagen).  RNA concentration was determined 
using UV spectrophotometry at 260nm. 
 
4.3.2  Reverse Transcription 
Equivalent amounts of RNA (1 g) were treated with DNase I at 37°C 
for 30 minutes (1 unit DNase per g RNA; Promega, Madison, WI), DNase 
was inactivated at 65°C for 15 minutes, and RNA was reverse-transcribed 
using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, 
CA). 
 
4.3.3  Primers 
The following primers were used for QPCR:  
β-actin forward: AGTACTCCGTGTGGATCGGC,  
β-actin reverse: GCTGATCCACATCTGCTGGA,  
18S forward: CGCCGCTAGAGGTGAAATTC,  
18S reverse: TTGGCAAATGCTTTCGCTC,  
cyclophilin forward: CTCCTTTGAGCTGTTTGCAG,  
cyclophilin reverse: CACCACATGCTTGCCATCC,  
EAAT2 forward:  GGGCACCGCTTCCAGTG, 
EAAT2 reverse:  ATACTGGCCGCGCCG, 
EAAT2Δ9 forward: GGGCACCGCTTCCAGTG,  
EAAT2Δ9 reverse: GACTGAAGTTCTCATCCTGTCCCTT,  
EAAT2b forward: GGACAGGATGAGAACTTCAGTCAA,  
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EAAT2b reverse: ACAAGTCTCGATATCCATGAATGG,  
EAAT1 forward: CGAAGCCATCATGAGACTGGTA,  
EAAT1 reverse: TCCCAGCAATCAGGAAGAGAA,  
EAAT1Δ9 forward: TGCCCTCTATGAGGCTTTGG,  
EAAT1Δ9 reverse: GTCCGGAGGCGATCCCT. 
 
4.3.4  QPCR 
All amplification reactions were performed in duplicate using 96-well 
optical reaction plates (Stratagene) on a Stratagene detection system.  For 
each reaction, 3 ul of cDNA (1:3 diluted) was placed in a 20 ul reaction 
containing 10 ul of SYBR Green PCR Master Mix (Applied Biosystems) and 
10 pmol of each primer (Invitrogen).  Reactions were performed with an initial 
ramp time of 3 minutes at 95°C, and 50-60 subsequent cycles of 15 seconds 
at 95°C and 1minute at the annealing temperature.  The annealing 
temperature was 63oC for EAAT2Δ9 and was 59oC for all other primer sets.  
60 cycles were used for EAAT2B and EAAT2Δ9, and 50 cycles were used for 
all other primer sets.  For negative controls for the QPCR reactions, cDNA 
was omitted. Relative concentrations of the transcripts of interest were 
calculated with comparison to a standard curve made with dilutions of cDNA 
from a pooled sampling of all the subjects. Values for the transcripts of 
interest were normalized to the geometric mean of 18s, actin, and cyclophilin 
values for the same samples.  
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4.3.5  Statistical Analysis 
All statistical analyses were performed using Statistica (StatSoft, Tulsa, 
Oklahoma).  Outliers more than 6 standard deviations from the mean were 
excluded.  Correlation analysis was performed to determine associations 
between transcript expression and age, PMI, and pH.  We analyzed transcript 
expression using analysis of variance (ANOVA) or analysis of covariance 
(ANCOVA) as appropriate.  To test for possible medication effects, patients 
with schizophrenia off antipsychotic medication for at least 6 weeks prior to 
death were compared to patients on antipsychotic medication within 6 weeks 
of death in a post hoc analysis. 
 
4.4  Results  
Using QPCR, transcript expression of EAAT1, EAAT2, EAAT1Δ9, 
EAAT2Δ9 and EAAT2B was measured.  There were no associations between 
EAAT1, EAAT2, EAAT1Δ9, or EAAT2B transcript expression and age, pH, or 
PMI in the ACC or DLPFC.  Correlation analysis revealed an association 
between EAAT2Δ9 transcript expression and age in ACC (R= 0.31, p < 0.05) 
but not DLPFC.   
EAAT2Δ9 transcript expression was increased in schizophrenia in 
ACC (F(1,42) = 6.03, p < 0.05), and DLPFC (F(1, 43) =4.65, p < 0.05) (Figure 
4.1).   There was no effect of medication status in the subjects with 
schizophrenia on EAAT2Δ9 expression.  There were no significant 
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differences between groups for EAAT1, EAAT2, EAAT1Δ9, or EAAT2B 






Figure 4.1: EAAT splice variant transcript expression. QPCR analysis of 
EAAT1, EAAT1Δ9, EAAT2, EAAT2Δ9, and EAAT2B splice variant mRNA 
expression in the anterior cingulate cortex and dorsolateral prefrontal cortex 
from subjects with schizophrenia (n = 25) and a comparison group (n = 25).  
Expression is normalized to the geometric mean of 18s, actin, and cyclophilin.  
Data expressed as fold change of control +/- standard error of the mean.  
Asterisks indicate a significant difference between control and schizophrenia 
(p < 0.05).  Abbreviations:  anterior cingulate cortex (ACC), dorsolateral 
prefrontal cortex (DLPFC), excitatory amino acid transporter (EAAT), EAAT1 




4.5  Discussion 
In this study, we found increases in EAAT2Δ9 mRNA expression, but 
no changes in expression of EAAT1, EAAT1Δ9, EAAT2, or EAAT2B in 
schizophrenia brain.  We previously studied expression of transcripts for 
EAATs in the ACC and DLPFC using in situ hybridization in a different set of 
subjects from the same brain bank286.   We found no changes in EAAT2 
transcript expression in this smaller set286.  Another study using subjects from 
the same brain bank also found no changes in EAAT2 transcript expression 
using QPCR180.  Other studies of EAAT2 expression in prefrontal cortex in 
schizophrenia have found a decreased ratio of EAAT2 to mGluR using in situ 
hybridization178, while another group found increased EAAT2 expression 
using QPCR179.  The balance of these data suggests that native EAAT2 
transcripts are unchanged in schizophrenia. 
In our previous study, we also measured transcript expression of 
EAAT1 by in situ hybridization286.  While we found no changes in EAAT1 in 
the present study using QPCR, with situ hybridization we found an increase in 
EAAT1 transcript expression in ACC 286.   The difference in EAAT1 findings 
may be due to differences in the set of subjects used, or because the ACC 
samples used in the current work were dissected from a portion of the 
cingulate that is located more caudally than the samples from our previous 
study286.  EAAT1 transcript expression in the DLPFC of subjects from the 
same brain bank was also measured by QPCR, and no difference between 
diagnostic groups was found180. 
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Previously, only one other study has examined EAAT2 splice variants 
in schizophrenia180.  EAAT2B, an intron retaining form of EAAT2, was found 
to be unchanged180.  We did not find changes in EAAT2B, suggesting that the 
expression of this splice variant is not affected in schizophrenia. 
EAAT2 is responsible for the majority of glutamate reuptake in the forebrain, 
and is tightly regulated to prevent perturbations in glutamate transmission51.  
EAAT2Δ9 exerts a dominant negative effect on EAAT2 function by 
heterodimerizing with full length EAAT2 and preventing it from exiting the ER.  
Thus, increased EAAT2Δ9 expression may lead to decreased glutamate 
buffering and reuptake, resulting in increased synaptic glutamate levels.  
Decreases in perisynaptic EAAT expression could also lead to glutamate 
spillover into adjacent synapses and loss of input specificity287, 288.  The 
increase we detected in EAAT2Δ9 is consistent with decreases in EAAT2 
glycosylation we previously detected because disruption of exon 9 results in 
immaturely glycosylated EAAT2230. 
Abnormal expression of splice variants affecting ER trafficking have 
previously been demonstrated in schizophrenia.  One group found an 
increase in the ratio of the flip : flop isoforms of the GluR2 AMPA subunit in 
hippocampus in schizophrenia107.  Because the flop variant contains an ER 
retention sequence and the flip variant does not, these data suggest AMPA 
receptors may be forward trafficked too quickly in schizophrenia.  Another 
study found increased expression of the alternatively spliced NR1 NMDA 
receptor subunit NR1C2’ in ACC in schizophrenia104.  This variant confers 
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accelerated trafficking of the NMDA receptor through the ER.  Decreased 
expression of exon 22 containing splice variants of the NR1 NMDA receptor 
subunit was found in the thalamus in schizophrenia33.  This finding also points 
to forward trafficking of the NMDA receptor because the long C-terminal tails 
of these variants block release from the ER.  Taken together with the current 
study, these data suggest alterations in splice variants involved in ER 
retention and trafficking may play an important role in the pathophysiology of 
schizophrenia. 
Since most of the patients with schizophrenia were treated with 
antipsychotic medications, the increases we found in EAAT2Δ9 expression 
could be due to a medication effect.  However, we did not find any effects of 
medication on EAAT2Δ9 expression when comparing patients on medication 
6 weeks prior to death to patients off medication at least 6 weeks prior to 
death. 
 Expression of the exon 9 skipping variant of EAAT2, EAAT2Δ9, is 
increased in the ACC and DLPFC of elderly patients with schizophrenia.  We 
suggest that this increase in a dominant negative splice variant could lead to 
decreased glutamate buffering and reuptake and increased synaptic 










5.1  Summary of findings  
The objective of this dissertation was to determine how the EAATs are 
expressed and potentially dysregulated in schizophrenia.  EAATs may be 
regulated at the level of transcript expression, alternative splicing, protein 
expression, post-translational modification, and protein-protein interactions.  
We attempted to determine whether there were changes in EAAT expression 
or regulation at each of these levels.  First, we measured transcript 
expression of the EAATs and four EAAT interacting proteins using in situ 
hybridization.  We found increased expression of transcripts for EAAT1, 
EAAT3, the EAAT4 interacting molecule KIAA0302, and the EAAT1-EAAT4 
interacting molecule JWA.  Then, we measured protein expression of the 
EAATs and two EAAT interacting proteins through Western blot analysis.  We 
found increased protein expression of EAAT3, the EAAT2-EAAT4 interacting 
protein GPS1, and KIAA0302, and decreased protein expression of EAAT1.  
Next, we studied glycosylation of the EAATs using enzymatic deglycosylation.  
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We found decreased glycosylation of EAAT1 and EAAT2.  Finally, we 
examined splice variant expression of the EAATs using QPCR.  We found 
increased transcript expression of the dominant negative splice variant of 
EAAT2 EAAT2Δ9.  Below is a summary of all changes we found in 
schizophrenia compared to comparison groups (Table 5.1). 
 
 
Technique Molecule Region 
  ACC DLPFC 
ISH EAAT1   
 EAAT3   
 KIAA   
 JWA   
Westerns EAAT1   
 EAAT3   
 GPS1   
 KIAA   
Glycosylation EAAT1   
 EAAT2   
QPCR EAAT2Δ9   
 
Table 5.1: Summary of changes EAAT expression and regulation in 
schizophrenia.  Arrows indicate changes in schizophrenia relative to 
comparison groups.  Abbreviations: in situ hybridization (ISH), quantitative 
polymerase chain reaction (QPCR), anterior cingulate cortex (ACC), 
dorsolateral prefrontal cortex (DLPFC), excitatory amino acid transporter 
(EAAT), KIAA0302 (KIAA), g-protein pathway suppressor 1 (GPS1), 
excitatory amino acid transporter 2 exon 9 skipping (EAAT2Δ9). 
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5.1.1  EAAT protein expression 
 Using Western blot analysis, we measured protein expression of 
EAAT1, EAAT2, and EAAT3 in prefrontal cortex.  We found decreased 
protein levels of EAAT1, no changes in EAAT2, and increased protein levels 
of EAAT3.  These data are consistent with decreased glutamate uptake into 
glia, which comprises the major component of synaptic glutamate buffering 
and reuptake, and increased uptake into neurons which comprise a smaller 
component of glutamate buffering and reuptake. 
 
5.1.2  Alternative splicing of EAATs 
Using QPCR, we found increased transcript expression of EAAT2Δ9 in 
two regions of cortex.  This exon 9 skipping variant is retained in the ER and 
also causes retention of full length EAAT2 by heterodimerization230.  Removal 
of exon 9 also results in decreased glycosylation of EAAT2230.  These data 
suggest that EAAT2 exit from the ER may be decreased in schizophrenia.  
Based on these data, we would also predict less glycosylation of EAAT2 in 
schizophrenia. 
 
5.1.3  EAAT Glycosylation 
Using enzymatic deglycosylation, we found less N-linked glycosylation 
of EAAT1 and EAAT2 in schizophrenia.  Because proper glycosylation is 




5.1.4  EAAT Interacting Proteins 
Using in situ hybridization, we found increased transcript expression of 
JWA.  JWA downregulates EAAT1, EAAT2, EAAT3, and EAAT4 function by 
interacting with the exon 9 ER exit motif shared by these transporters301.  
Using Western blot analysis, we found increased expression of GPS1.  GPS1 
downregulates EAAT2 function by interacting with the exon 9 ER exit motif of 
EAAT250, and likely downregulates the function of EAAT3 and EAAT4 through 
the same mechanism50.   These data also suggest that EAAT exit from the 
ER may be decreased in schizophrenia. 
 
5.2  Schizophrenia as a disorder of ER retention 
We have shown in schizophrenia decreased EAAT protein levels, 
increased expression of splice variants associated with ER retention, 
decreased levels of glycosylation, and increased levels of molecules that 
promote ER retention.  Put together, these data demonstrate several levels of 
support for a hypothesis that the astrocytic EAATs are expressed in lower 
levels in the plasma membrane due to relative retention in the ER.  This is 
illustrated in Figure 5.1.  
Previous studies in this and other labs point to abnormalities in ER 
trafficking of glutamatergic molecules.  For example, abnormal expression of 
splice variants affecting ER trafficking have previously been demonstrated in 
schizophrenia.  One group found an increase in the ratio of the flip: flop 
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isoforms of the GluR2 AMPA subunit in hippocampus in schizophrenia107.  
Because the flop variant contains an ER retention sequence and the flip 
variant does not, these data suggest AMPA receptors may be processed too 
quickly in schizophrenia.  Another study found increased expression of the 
alternatively spliced NR1 NMDA receptor subunit NR1C2’ in ACC in 
schizophrenia104.  This variant confers accelerated trafficking of the NMDA 
receptor through the ER.  Decreased expression of exon 22 containing splice 
variants of the NR1 NMDA receptor subunit was found in the thalamus in 
schizophrenia33.  This finding also points to accelerated forward trafficking of 
the NMDA receptor because the long C-terminal tails of these variants block 
release from the ER.  In addition to these splice variant studies, our group has 
detected a decrease in the ratio of Endo H sensitive to Endo H insensitive 
GluR2 in DLPFC302.  This finding suggests that GluR2 is processed more 
quickly in schizophrenia because glycoproteins become Endo H insensitive 
once they have been trafficked through the ER.  Taken together, these ER 
trafficking implications point to faster forward trafficking of receptors and 
slower trafficking of transporters.  This would lead to increased synaptic 
glutamate accompanied by increased number of receptors to which glutamate 
may bind.   
This idea that regulation of protein trafficking through the ER may be 
disrupted in schizophrenia is consistent with the notion that oxidative stress 
may play a role in the pathophysiology of schizophrenia.  Oxidative stress has 
long been implicated in schizophrenia303.  Dysregulation of protein processing 
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in the ER could be primary or secondary to increased oxidative stress.  On 
the one hand, the oxidative environment in the ER must be tightly regulated in 
order to allow for disulfide bond formation and ensure proper protein folding.  
Increased presence of free radicals in the ER could offset this balance and 
put additional stress on the machinery required to ensure proper protein 
folding and modification.  On the other hand, disulfide bond formation in the 
ER leads to the formation of reactive oxygen species304.  Thus, problems with 
ER functioning could lead to creation of more reactive oxygen species and 



































5.3  Potential effects of glutamate transporter abnormalities on 
neurotransmission 
 I found decreased EAAT1 expression, and I found several factors that 
indicate decreased localization of EAATs at the synapse including decreased 
glycosylation, increased expression of an ER retention variant, and increased 
expression of molecules that retain EAATs in the ER.  These data suggest 
that there are fewer EAATs expressed at the cell surface, and thus a 
decrease in the capacity for glutamate buffering and transport.  This 
decreased capacity would likely lead to increased synaptic glutamate levels. 
Increased synaptic glutamate can have a number of effects.  First, it 
could lead to increased activation of receptors at postsynaptic sites.  Second, 
glutamate that is not removed from the synapse could also spillover into 
perisynaptic regions and activate perisynaptic receptors.  Finally, 
extrasynaptic glutamate may also spillover into adjacent synapses and 
activate receptors in those synapses, leading to a loss of input specificity299.  
LTP is associated with a translocation of the EAAT3 from the cytosol to the 
plasma membrane234, and inhibition of glutamate transporters is sufficient to 
reduce input specificity of LTP287. 
 
5.3.1  Literature support for this hypothesis   
Based on my data suggesting decreased glutamate reuptake, I 
propose a hypothesis of increased synaptic glutamate levels and/or glutamate 
spillover in schizophrenia.  This hypothesis is supported by the fact that a 
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subject with schizophrenia has a partial deletion of the EAAT1 gene 176.  Also 
consistent with this hypothesis, EAAT1 deficient mice exhibit schizophrenia-
like endophenotypes including self-neglect, social withdrawal, and impaired 
learning20.  In addition, increased prefrontal cortical glutamate levels in with 
schizophrenia has been shown through spectroscopy305, 306.  Further, 
glutaminase deficient mice, which cannot efficiently convert glutamine into 
glutamate, are resistant to pharmacological models of schizophrenia22.   A 
recent study has indicated that a member of the family of phosphatidylinositol-
phosphate kinases phosphatidylinositol-4-phosphate 5-kinase II alpha 
(PIP5K2A), results in increased EAAT3 mediated glutamate reuptake when 
coexpressed in oocytes, whereas a mutant version that has been associated 
with schizophrenia, N251SPIP5K2A, downregulates EAAT3 mediated glutamate 
uptake307.  Additionally, GFAP, a protein that helps increase EAAT1 function 
by anchoring it at the plasma membrane308 is decreased in ACC in 
schizophrenia189.   
Finally, our data suggest that reducing synaptic glutamate could be a 
useful strategy in the treatment of schizophrenia.  Cognitive and behavioral 
abnormalities caused by NMDA antagonist administration in rodents can be 
rescued by glutamate release inhibitors such as lamotrigine309 and mGluR 2 
agonists310.  One study using an mGluR2/3 agonist, which decreases 
glutamate release, had antipsychotic effects in schizophrenia 177.   Taken 
together, these data support a role for diminished glutamate reuptake in the 
pathophysiology of schizophrenia. 
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5.4  Primary vs. compensatory changes  
I propose that any number of changes that lead to increased synaptic 
glutamate contribute to the pathophysiology of schizophrenia.  This is 
supported by the fact that a patient with schizophrenia was identified with a 
genetic disruption of the EAAT1 gene SLC1A3176.  It is unlikely that there is 
any one primary deficit that causes schizophrenia, as evidenced by the fact 
that many genes have been identified as risk factors, each contributing a very 
small percentage of risk.  However, many factors can lead to increased 
synaptic glutamate levels.   
Perhaps the reason why NMDA receptor blockade models many 
aspects of schizophrenia is because it can result in increased synaptic 
glutamate release311.  Administration of PCP also results in increased EAAT 
expression312 which may be compensatory to the increase in glutamate 
release.  Therefore, if changes in EAAT expression were secondary to 
changes in synaptic glutamate levels, one might expect to find increased 
EAAT expression.  However, I found decreased EAAT1 expression, 
increased EAAT3 expression, and other changes that may lead to decreased 
surface expression of the astrocytic EAATs.  
This hypothesis is further supported by the fact that the drug 
memantine, which is an uncompetitive NMDA receptor antagonist used to 
treat Alzheimer’s disease, does not appear to affect schizophrenia 
symptoms313.  If schizophrenia symptoms were induced purely through NMDA 
receptor signaling and not through increased glutamate release, one would 
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expect memantine to induce these symptoms as well.  This suggests that the 
noncompetitive NMDA receptor antagonists might exert their psychomimetic 
effects through increased glutamate release. 
Alternatively, the changes I found could be secondary to alterations in 
dopamanergic signaling.  The original hypothesis behind the pathogenesis of 
schizophrenia is that it is a disorder of too much dopamine.  Monoaminergic 
signaling cascades can converge to affect NMDA and AMPA receptor 
functioning314.  Dopaminergic neurons act to modulate glutamatergic function 
by terminating on presynaptic glutamate terminals and inhibiting presynaptic 
release315, 316.  Thus, increased dopaminergic tone could act to cause 
decreased glutamatergic signalling.  Therefore, glutamate reuptake may be 
downregulated in schizophrenia to compensate for decreased gluatamate 
release. 
We hypothesize that the changes in EAAT3 expression are secondary 
to decreases in plasma membrane activity of EAAT1 and EAAT2.  Decreased 
plasma membrane expression of EAAT1 and EAAT2 may cause decreased 
glutamate reuptake in glial cells, leading to increased basal synaptic 
glutamate levels and synaptic spillover.  EAAT3 is largely localized in 
perisynaptic regions and contributes to clearance of glutamate spillover 272, 
273.  Thus, EAAT3 expression may be increased in neurons to compensate for 
these changes.  Consistent with this notion, EAAT3 protein is localized to 
regulatable cytosolic pools that may be rapidly mobilized to the plasma 
membrane, suggesting a biological process that is highly responsive to 
 96 
changes in glutamate levels 164.   It is also possible that EAAT3 expression is 
compensatory to increased glutamatergic signaling through a different 
mechanism.  Perhaps the increased EAAT3 expression is localized to 
presynaptic GABA terminals.  This would supply more glutamate to 
GABAergic neurons for GABA synthesis, allowing those cells to inhibit 
overactive pyramidal neurons. 
Alternatively, the changes in EAAT3 expression may have more to do 
with its ability to transport cysteine than its ability to transport glutamate.  In 
animal models, knockdown of EAAC1 does not result in changes in 
extracellular glutamate, but it does lead to 20-40% decreases in cysteine and 
glutathione, as well as increased oxidant levels and increased vulnerability to 
oxidative stress317.  Transport of cysteine by EAAT3 is the rate-limiting step of 
glutathione synthesis in neurons317.  Glutathione is the major free-radical 
scavenger present in neurons and plays an important role in maintaining 
oxidative balance.  Many posit schizophrenia to be a disorder of increased 
oxidative stress303.  Increases in EAAT3 expression may be compensatory in 
order to increase the amount of cysteine available in neurons to synthesize 
glutathione and combat increases in oxidative stress. 
 
5.5  Region specific changes  
It is important to note that the changes we have described are region 
specific.  With the exception of increased transcript of EAAT2Δ9, all changes 
were detected in either DLPFC or ACC, but not both.  Even within one of 
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these areas, there can be considerable heterogeneity.  For example, we 
found differences in EAAT1 transcript expression in the ACC between the in 
situ hybridization and QPCR studies.  This may be attributable to the fact that 
the ACC samples used in the QPCR study were dissected from a portion of 
the cingulate that is located more caudally than the samples from the in situ 
hybridization study.  Therefore, it is important to consider the areas being 
examined when comparing different studies, and to understand the capacity 
for heterogeneity even within a defined area such as prefrontal cortex 
In this dissertation, we described abnormalities in EAAT expression 
and regulation in ACC and DLPFC, but there are many brain areas that are 
also affected in schizophrenia.  Abnormal mRNA expression of the EAATs 
and EAAT interacting proteins has also been described in other regions of the 
brain in schizophrenia.  EAAT3 transcript was decreased in striatum in 
schizophrenia, using brain samples from another brain collection173.  Using 
samples from the same brain collection used in this dissertation, several 
changes in EAAT and EAAT interacting molecules have also been found.  
EAAT1 and EAAT2 transcript expression was increased in thalamus36, and 
JWA and KIAA transcripts were increased in thalamus34.  A decrease in 
EAAT2 mRNA was described in the parahippocampal gyrus184.  Thus, it 




5.6  Cell specific changes  
 The cellular expression profiles of the EAATs have been well 
described in the literature.  For example, EAAT1 and EAAT2 are generally 
localized to astrocytes and EAAT3 is generally localized to neurons137-140.  
However, several exceptions to these expression profiles have been 
demonstrated.  For example, EAAT1 expression has been demonstrated in 
other types of glia including oligodendrocytes and microglia283.  EAAT2 
mRNA has been detected in Bergmann glia and some neurons318.  Some 
expression of EAAT3 has been identified in astrocytes158.   
Splice variants of the EAATs are often expressed in different cell types 
than their full-length counterparts154, 182, 183. Therefore, changes in splice 
variant expression can result in altered localization of the EAATs to different 
cell types.  Increased expression of EAAT2b, and decreased expression of 
full length EAAT2, resulting in reduced astrocytic expression and increased 
neuronal expression has been demonstrated in ALS183.  One group 
hypothesizes that mRNA for the “glial” EAATs is constitutively expressed in 
neurons, but that they are not translated into protein unless the cells are 
stressed224.  EAAT1 was strongly expressed in cortical pyramidal neurons, 
co-localizing with tau in patients with Alzheimer’s dementia144.  It is unknown 




5.7  Transcript vs. protein  
One phenomenon that we observed is that changes in transcript 
expression do not necessarily correspond to similar changes in protein 
expression.  For example, we found increased EAAT1 mRNA expression in 
ACC cortex with no changes in protein expression, and decreased EAAT1 
protein expression in DLPFC with no changes in mRNA expression.  No 
change in protein expression with increased mRNA expression may be due to 
a number of inter-related causes including improper translation and folding, 
abnormal post-translational modifications, or increased protein turnover.   
In some cases, differences in transcript and protein expression can be 
attributable to cell type.  For example, a protein that is expressed 
postsynaptically may exist in a projection that is in another region of the brain 
from the cell body where the transcripts are expressed.  Therefore, a change 
in protein expression in the DLPFC could be the result of a change in mRNA 
expression in the thalamus.  This however is an unlikely explanation for 
proteins that are generally expressed in astrocytes such as EAAT1 and 
EAAT2. 
Another phenomenon is that the differences in direction of change can 
be observed across regions.  The most striking example of this is EAAT1, 
which is increased at the transcript level in the ACC and decreased at the 
protein level in the DLPFC.  This could be attributed to two possible factors: 
methodology or pathophysiology.   
 100 
Methodologically, the reason why we do not detect consistency 
between the two regions could simply be due to the fact that these studies are 
underpowered.  In general, we find that changes seem to occur in the same 
direction across regions, but that only one region reaches statistical 
significance.  Given a larger number of subjects, it is possible we would 
detect more changes that are consistent across both regions.  Another 
methodological explanation is that there is limited overlap in the subjects used 
for transcript and protein studies.  If a subset of subjects is responsible for a 
given finding, they may not be present for both types of studies.  However, 
because we don’t have the same set of subjects for all studies, it would be 
difficult to mine for differences in subgroups. 
Another explanation is that there are complex pathophysiological 
differences between these regions that could account for the seeming 
anatomical mismatches.  Many studies show opposite changes between ACC 
and DLPFC, whereas studies examining closely related areas of DLPFC 
(Brodmann areas 9 and 46) are relatively consistent319.  For example, 
decreases in neuropil and number of synapses as well as decreases in 
astrocytic processes have been demonstrated in DLPFC, whereas the ACC 
appears to be relatively spared319, 320.  Thus, EAAT1, which is expressed on 
astrocytic processes may be decreased at the protein level in DLPFC due to 
changes in astrocyte morphology, even though transcripts that may be 
present closer to the nucleus may be spared.  Changes in cell density, 
neuropil, astrocytic processes, or synapse number have not been 
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demonstrated in the ACC, although metabolic changes have been 
demonstrated319.  Perhaps the ACC is challenged in schizophrenia similarly to 
the DLPFC, but is able to quickly repair sick parts of cells through active 
mechanisms that require energy.  Thus, it is possible that in the ACC, EAAT1 
is degraded more quickly in schizophrenia compared to healthy individuals, 
but that by increased synthesis (requiring increased EAAT1 transcription), 
cells are able to maintain a steady level of EAAT1 protein. 
Given that this phenomenon is observed in many postmortem studies 
of schizophrenia brain319, it appears more likely that these patterns do exist 
as part of the pathology and not just as artifacts.  Careful examination of 
these patterns across multiple studies could yield important information about 
what kinds of cells and circuits are most vulnerable in this illness. 
Given that protein and transcript studies can yield opposite results, one 
might question the usefulness of transcript studies, since protein studies 
provide a more direct measure of what is occurring in the cell.  One 
advantage of in situ hybridization is that it yields quantitative anatomical 
information.  For example, we were able to examine layer specific expression 
of the EAAT interacting proteins using in situ hybridization, whereas we could 
only measure regional changes using Western blot analysis.  On a practical 
level, sometimes there are proteins for which specific antibodies have not 
been designed.  For example, there are currently no commercially available 
antibodies for the alternative splice forms of the EAATs.  Also, much less 
material is required to perform transcript studies, so protein studies may not 
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be feasible when studying small quantities of material such as laser capture 
microdissected cells.   
 
5.8  Antipsychotic effects 
A limitation of these studies is the potential effects of treatment with 
antipsychotic medications 278, 279.  We generally did not detect any differences 
between medicated and unmedicated patients with a few exceptions.  These 
analyses, however, are relatively underpowered given that the vast majority of 
patients with schizophrenia received treatment up until the time of death.   It 
should also be noted that the unmedicated group was defined as individuals 
not on medication within the 6 weeks prior to death.  Therefore, medications 
taken prior to this period could still have potentially affected our dependent 
variables.   
We also measured transcripts of the EAATs and EAAT interacting 
molecules in rats treated with haloperidol, clozapine, or vehicle.  In general, 
there were few changes in these molecules in the haloperidol group.  There 
tended to be more changes with clozapine.  However, most of the patients in 
these studies were treated with typical antipsychotics, so the haloperidol 
treatment group is better for comparison to the patients with schizophrenia 
that were studied in this dissertation work.  It should be noted that the 
treatment study in rats was acute, whereas patient antipsychotic treatment 
was chronic.  It would therefore be useful to treat rats with antipsychotic 
medications chronically in order to better determine the effects of long-term 
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antipsychotic treatment on our dependent variables.  It would also be useful 
to study the effects of antipsychotic treatment on protein expression, 
glycosylation, and splice variant expression, as these studies have not yet 
been done.  It is also important to interpret these findings with the 
understanding that the effects of antipsychotic treatment in rats may be 
different than in patients with schizophrenia, due to differences both in 
species and the fact that they may act differently in healthy brain versus 
schizophrenia brain. 
Another consideration is that the patients used in these studies were 
elderly.  This means that not only could their brains have adjusted to a lifetime 
of protein alterations due to illness, but that they could also have adjusted to 
long-term antipsychotic drug treatment.  In fact, schizophrenia studies 
involving younger patients have often found different results than studies 
involving older patients104.  Despite these confounds, there are also 
advantages to studying an elderly cohort.  For example, the patients are 
generally well cared for, don’t have access to drugs of abuse or alcohol, and 
tend to die of natural causes, whereas younger cohorts have high 
comorbidities with drug abuse and suicide.  Given these confounds, it is 
important to interpret our findings with the understanding that the changes 
found may be due to long term antipsychotic exposure and/or adjustment to 
lifelong changes in brain function/composition.  However, even if the changes 
we found are purely attributable to these confounds, that does not render 
them unimportant.  This would merely reflect that the data must be interpreted 
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as changes secondary to age and medication related factors rather than 
primary to the onset of illness itself. 
 
5.9  Future directions 
 The current work has yielded many testable hypotheses.  The following 
future directions attempt to address questions that arise from this dissertation 
work.  First, we describe how we might attempt to address subcellular 
localization of the EAATs.  Second, we describe other transcript and protein 
studies that might more completely describe the abnormalities in EAAT and 
EAAT interacting protein expression in schizophrenia.  Third, we propose 
additional studies of EAAT posttranslational modifications that could shed 
additional light on how the EAATs may be abnormally regulated in 
schizophrenia.  Finally, we describe animal studies that investigate the 
mechanisms of EAAT dysregulation in this illness. 
 
5.9.1  Subcellular localization 
 We hypothesize that there is a decrease in EAAT mediated buffering 
and transport attributable to increased ER retention and decreased plasma 
membrane expression of the EAATs.  It would therefore be important to 
directly test this hypothesis by examining the subcellular localization of the 
EAATs.  This could be accomplished through subcellular fractionation or by 
using electron microscopy.  Additionally, surface activity could be measured 
using reuptake assays in synaptosomal preparations.  These studies would 
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yield a more complete picture of how EAAT mediated buffering and reuptake 
are altered in schizophrenia. 
 
5.9.1.a  Subcellular fractions 
Given that we suspect changes in ER retention and plasma membrane 
expression of the EAATs, it would be useful to examine EAAT expression in 
individual subcellular compartments.  Traditional methods of subcellular 
fractionation involve high speed centrifugation through a sucrose gradient.  
However, while these methods are excellent for separating organelles in 
freshly prepared tissue, they do not generally produce good results in 
postmortem tissue, likely due to rupture of cell membranes upon freezing of 
the tissue.  However, immunoisolation has been used in our lab to 
successfully isolate subcellular compartments.  Using sepharose beads 
attached to antibodies against the ER specific protein calnexin, we could 
isolate ER fractions from patients with schizophrenia and comparison 
subjects and probe for differences in EAAT expression using Western blot 
analysis.  Specificity of this immunoisolation technique could be confirmed 
through electron microscopy of the beads and any attached organelles, as 
well as probing our Western blots for markers of other subcellular 
compartments from postmortem human brain.  In addition to isolation of the 
ER, we could study other subcellular compartments such as plasma 
membranes, Golgi bodies, and endosomes.  Antibodies directed against 
Na+/K+ ATPase or cadherin could be used to immunoisolate the plasma 
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membrane, antibodies directed against golgin-97 could be used to 
immunoisolate the Golgi, antibodies directed against EEA1, or rab5 could be 
used to immunoisolate early endosomes, antibodies directed against rab7 
could be used to immunoisolate late endosomes, and antibodies directed 
against rab11 could be used to immunoisolate recycling endosomes. 
 
5.9.1b  Electron microscopy 
Another way to measure subcellular localization of the EAATs is 
through electron microscopy.  We could immunogold label EAAT1, EAAT2, 
and EAAT3 in the prefrontal cortex of patients with schizophrenia and 
comparison subjects.  We could then examine expression of the EAATs at 
perisynaptic locations on the plasma membrane as well as expression in the 
ER.  Immunogold labeling coupled to electron microscopy is a technically 
challenging technique, but it has been done in human postmortem brain321-325. 
 
5.9.1c  Uptake assays 
The functional endpoint of EAAT trafficking is glutamate reuptake.  
Measuring glutamate uptake in tissue from patients and comparison subjects 
provides a more direct measure of EAAT function than measuring expression 
alone.  Although technically challenging, a few groups have measured 
reuptake of glutamate and other neurotransmitters in synaptosomes prepared 
from postmortem tissue326-329.  Although synaptosomes are thought to be 
comprised of the terminals of neurons, knockdown of GLT-1 results in 
 107 
dramatic reductions in synaptosomal glutamate uptake18, 23.  Therefore, it 
appears as though synaptosomes are a good model system for uptake 
mediated by both neuronal and astrocytic EAATs.  We could prepare 
synaptosomes from prefrontal cortical tissue of patients with schizophrenia 
and comparison subjects, and measure uptake of radioactive glutamate to 
test the hypothesis that glutamate reuptake is diminished in schizophrenia.  
 
5.9.2  Expanded protein and transcript studies 
There are several EAAT interacting molecules that we did not examine 
in this dissertation due to the fact they had not yet been identified or 
antibodies were not yet available at the time that those studies were 
performed.  Sept2 is a molecule that interacts with EAAT1 and downregulates 
its function188.  JM4 is a homologue to JWA that downregulates function of 
EAAT1, EAAT2, EAAT3, and EAAT4 by interacting with exon9 and preventing 
ER exit197, 301.  CNTF is a molecule that increases expression of EAAT1 at the 
plasma membrane284.  Analysis of these molecules would give a more 
complete picture of the abnormalities in EAAT regulation in schizophrenia.  
We could perform in situ hybridization to measure transcript expression of 
sept2, JM4, and CNTF.  We could perform Western blot analysis to measure 
protein expression of CNTF, sept2, JWA, JM4, and ARHGEF11. 
 There are also several EAAT splice variants that we did not measure in 
this dissertation because either they were too low in abundance to detect with 
our methods, the functional effect on transport was unknown, or there were 
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technical problems with the assays.  There exists an exon 3 skipping variant 
of EAAT1 that is unglycosylated and likely has an opposite orientation in the 
cell membrane210, 224, 227.  Several additional splice variants exist for EAAT2.  
About 5-15% of EAAT2 can exist as an exon 7 skipping 219. There also exists 
an exon skipping variant of EAAT2 that contains a partial deletion of exons 6 
and 7219.  5’UTR intron retention variants of EAAT2 include HBGTII 218, 220, 
HBGTIIA 220, HBGTIIB 220, HBGTIIC 218, 220, EAAT2/3218, and EAAT2/31218.  
3’UTR variants of EAAT2 include GLT1 c which retains part of intron 10 and 
exists at very low levels in brain221, 231, I7R which retains intron 7 and is 
marked for decay222, and a variant that retains an intron from the 3’ end to 
exon 7 and skips exons 8-11219.  EAAT3 also can exist as an exon 9 skipping 
variant which is likely retained in the ER224.  These splice variants could be 
measured through QPCR. 
Given that we found increases in EAAT2Δ9 in schizophrenia, it would 
be interesting to see if this change in transcript results in a change in protein.  
This could be done by western blot with splice variant specific antibodies.  An 
antibody against this variant exists and has been used for 
immunocytochemical localization of EAAT2Δ9, although it is not yet 
commercially available223.  If we could obtain this antibody from the lab that 
has produced the antibody, we could glean important information on the 
functional effects of increased EAAT2Δ9 transcript expression.  Additionally, 
we could perform western blot analysis for any additional variants for which 
we find changes in transcript expression. 
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Given the regional increases in transcript expression of these 
molecules, we are also interested in determining which cells express these 
changes.  Cell level studies will allow us to determine if EAATs are being 
abnormally expressed in a different cell type and if there is a particular cell 
type that is more affected by the disease.  Using laser capture microscopy 
and quantitative real-time PCR, we could measure cell-level transcript 
expression of the EAATs, EAAT splice variants, and EAAT interacting 
proteins. Specifically, we could analyze pyramidal neurons in layers II, III, and 
V, parvalbumin-containing GABAergic interneurons in layers II, III, and V, and 
astrocytes in all 6 layers of the DLPFC and ACC. Multiple subtypes of 
GABAergic interneurons exist in each cortical layer, and thus we have chosen 
a subset of these neurons that have been previously implicated in the 
pathology of schizophrenia330-332. These include chandelier cells, small 
GABAergic interneurons present in cortical layers II-VI with axo-axonic 
projections to nearby pyramidal cells within the same layer, and basket cells, 
large GABAergic interneurons present in cortical layers III-VI with projections 
to the soma and proximal dendrites of pyramidal cells within the same 
layer333.   While this type of study is difficult to perform, the techniques have 
already been established in the lab. 
 
5.9.3  Expanded post-translational regulation studies 
Because EAAT activity is regulated through protein-protein interactions 
with specific proteins, it is important not only to probe for abnormalities in 
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expression, but also to detect any changes in the interactions between these 
proteins.  We could use co-immunoprecipitation to probe for abnormalities in 
interactions between transporters and EAAT interacting proteins.  Specifically, 
we could immunoprecipitate EAAT1, EAAT2, and EAAT3, and then probe 
immunologically for the proteins associated with each. For EAAT1, we would 
like to probe for interactions with mGluR2/3, CNTF, GFAP, Sept2, JWA, and  
JM4. For EAAT2, we would like to probe for interactions with GPS1, JWA, 
JM4, NR1, and PSD-95.  We have developed a successful protocol for 
immunoprecipitation of EAAT1, which could be further developed and 
expanded to the other EAATs.  However, this technique is very tissue 
intensive, so it is important to probe each immunoprecipitation for as many 
interacting partners as possible in a thoughtful manner to minimize tissue use.   
Following gene expression of transporters and transporter interacting 
proteins, glutamate reuptake can also be modulated through transporter post-
translational modification.  The EAATs are known to be regulated by 
phosphorylation, ubiquitination, and glycosylation.  We could develop 
phosphospecific antibodies to measure changes in EAAT phosphorylation.  
With an immunoisolation protocol, one can study additional posttranslational 
modifications of the EAATs.  Ubiquitination can be studied by pulling down an 
EAAT and probing with an anti-ubiquitin antibody.  Preliminary data from our 
lab suggests that ubiquitination of PSD95 is detectable in this tissue.  One 
potential problem, however, is that we may not be able to detect changes in 
ubiquitination in our samples, because ubiquitinated transporters may be 
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degraded too quickly to be detected.  
Lectins are proteins that recognize and bind to specific glycosyl 
residues.  Biotinylated lectins, coupled with IR labeled streptavidin, can be 
used to detect specific sugar groups from an immunoprecipitated protein.  
Wheat germ agglutinin (WGA) recognizes n-acetylglucosamine, and is a 
marker for maturely glycosylated protiens.  Lens culinaris agglutinin (LCA) 
binds to mannose and glucose and is a marker for immaturely glycosylated 
proteins.  There also exist many other lectins that can be used to detect 
subtle differences in the branching patterns of glycosyl residues.  We could 
determine what glycosyl residues are responsible for the changes in EAAT1 
and EAAT2 glycosylation through lectin blot analysis of immunoprecipitated 
EAATs.  We have performed preliminary experiments using this technique 
and it appears to be a viable approach to study glycosylation in human brain. 
 
5.9.4  Animal models 
Animal models provide a mechanistic way to study the changes we 
have described in postmortem tissue.  We could mimic the expression of the 
transporters and their interacting partners in rodents using a viral expression 
vector or RNAi to overexpress or underexpress proteins of interest.  For 
example, we could decrease EAAT1 expression or increase GPS1 or 
EAAT2Δ9 expression in rats.  We could then perform behavioral tests to 
determine the effects of this manipulation on tasks implicated in 
schizophrenia such as working memory and prepulse inhibition.  We could 
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also dissect the brains of these animals and determine the 
electrophysiological and neurochemical effects of altering these molecules. 
 
5.10  Conclusions 
In this dissertation work, I used in situ hybridization, Western Blot 
analysis, enzymatic deglycosylation, and QPCR to study EAAT expression 
and regulation in the prefrontal cortex in schizophrenia.  I found decreased 
EAAT1 protein expression, and we found several factors that indicate 
decreased localization of EAATs at the synapse including decreased 
glycosylation, increased expression of an ER retention variant, and increased 
expression of molecules that retain EAATs in the ER.  These data suggest 
decreased overall EAAT expression, and abnormal localization of EAATs that 
are expressed.  Therefore, there are likely fewer EAATs expressed at the cell 
surface, and thus a decrease in the capacity for glutamate buffering and 
transport.   I have found several levels of abnormal EAAT expression, thus 
demonstrating novel sites of disruption in the glutamate synapse in 
schizophrenia.  This work could therefore provide alternative targets for 




























A.1  Abstract 
 
We compared protein expression by Western blot analysis in four 
areas of postmortem brain from patients with schizophrenia and control 
subjects for several proteins that are often used as controls for Western blot 
studies: β-tubulin, actin, glyceraldehyde-3-phosphate dehydrogenase, and 
valosin containing protein.  We did not detect any differences in expression 
between subjects with schizophrenia and a comparison group.  These results 
suggest that all four proteins are suitable loading controls for postmortem 
studies of schizophrenia. 
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A.2  Introduction 
Western blotting is a common technique used to measure protein 
levels.  To ensure even loading, blotting, and processing between samples, 
an internal control is utilized.  These loading controls are usually so-called 
housekeeping proteins measured in the same lane of the gel for each sample, 
and are assumed to have constant between-sample expression relative to the 
amount of sample loaded.  Commonly used loading controls include the 
cytoskeletal structural molecules β-tubulin and actin, and the glycolytic 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH).   
Valosin containing protein (VCP) is a 97kDa protein used as a loading 
control in one postmortem schizophrenia study 266.  VCP is an ATPase 
involved in the ubiquitin-proteasome degradation pathway, membrane fusion, 
transcription activation, cell cycle control, apoptosis, and molecular 
chaperoning 334.  Although it is not predicted to be affected in this disease, it 
has not been determined whether VCP is abnormally regulated in 
schizophrenia.  In this study, we examined expression of VCP, β-tubulin, 
actin, and GAPDH in patients with schizophrenia and control subjects. 
 
A.3  Materials and Methods 
A.3.1  Subjects 
Subjects from the Mount Sinai Medical Center Department of 
Psychiatry Schizophrenia Brain Bank were studied (Table 1), including 39 
individuals diagnosed with schizophrenia and 41 comparison subjects.  
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Subjects were diagnosed with schizophrenia if the presence of schizophrenic 
symptoms were documented before age 40, the medical records contained 
evidence of psychotic symptoms and at least 10 years of psychiatric 
hospitalization with diagnosis of schizophrenia, and a DSM-III-R diagnosis of 
schizophrenia was agreed upon by two experienced clinicians.  Diagnostic 
groups were matched for age, postmortem interval, and tissue pH.  Upon 
neuropathological examination, no evidence of Alzheimer or other 
neurodegenerative disease was found.  The brain banking procedures were 
approved by the Mount Sinai School of Medicine Institutional Review Board. 
 
Table A.1:  Subject Characteristics for Housekeeping Protein Study 
 
 Comparison Group Schizophrenia    
N 41 39 
Sex 18 m / 23 f 27 m / 12 f 
Tissue pH 6.4 ± 0.3 6.4 ± 0.3 
PMI (hours) 8.1 ± 6.3 13.7 ± 7.8 
Age (years) 78 ± 14 74 ± 12 
On / Off Rx 0 / 41 28 / 11 
Values presented as mean ± standard deviation 
Abbreviations:  male (m), female (f), antipsychotic medication (Rx), 





A.3.2  Tissue preparation   
Brains were obtained after autopsy and one hemisphere was cut 
coronally into ~0.8 - 1 cm3 slabs and flash frozen.  Tissue was dissected from 
anterior cingulate cortex (ACC) (n = 68), dorsolateral prefrontal cortex 
(DLPFC) (n = 66), hippocampus (n = 49), and primary visual cortex (PVC) (n 
= 46).  Approximately 1 cm3 of frozen tissue was first pulverized, then 
homogenized (10% wt/vol) in 5 mM Tris-HCl (pH 7.4) with 320 mM sucrose 
and 1 protease inhibitor tablet per 10 mL (Complete mini, Roche Diagnostics, 
Manheim, Germany) for 30 sec with a polytron homogenizer (Fisher 
Scientific, Pittsburgh, Pennsylvania) and stored at -80oC in 0.5 mL aliquots. 
For our loading control, tissue from the frontal cortex was dissected from a 
9.8 year old female pig-tail macaque (Macaca nemestrina) provided by the 
University of Washington Regional Primate Research Center.  The animal 
was sacrificed as part of a protocol (which did not require brain tissue) 
unrelated to the present study.   Protocols involving this animal were reviewed 
by the Washington Primate Research Center Research Review Committee 
and the University of Washington IACUC.  Frozen macaque cortex was 
thawed on ice, cut into pieces of approximately 1 cm3, and homogenized as 
described above and stored at -80oC in 1.2 mL aliquots.  To determine protein 




A.3.3  Western blot analysis 
 For gel electrophoresis, tissue samples were adjusted to a 
concentration of 0.8 µg/ul with sterile water, reducing buffer (Invitrogen), and 
denaturing buffer (Invitrogen).  Samples were then incubated at 70oC for 10 
minutes.   
The Novex Mini Cell NuPAGE system (Invitrogen) with 4-12% Bis-Tris 
gradient polyacrylamide gels (Invitrogen) was used.  8 µg of denatured 
protein homogenate was run in each lane.  Samples were loaded in duplicate 
in adjacent lanes, and a molecular weight standard was run on each gel.  A 
lane containing 8µg of homogenized macaque cortex was also loaded onto 
each gel to control for interblot variability.  Gels were suspended in a bath of 
NuPAGE MES SDS running buffer (Invitrogen) with 500µl NuPAGE 
antioxidant (Invitrogen) during electrophoresis.  
Following electrophoresis, proteins were transferred onto Immobilon-
FL PVDF membranes (Millipore) using a semi-dry transfer apparatus (Bio-
Rad).  After electroblot transfer of the protein, membranes were washed twice 
and incubated with Odyssey Blocking Buffer (Li-Cor Biosciences) for 1 hour at 
room temperature with rocking to block nonspecific antibody binding.  
Membranes were exposed to the primary polyclonal antibody diluted 1:10,000 
for actin (Chemicon MAB150R), VCP (Abcam ab11433), and β-tubulin 
(Upstate 05-661), and 1:20,000 for GAPDH (Sigma G9545) in blocking buffer 
with 0.1% tween overnight at 4oC with rocking.  Next, the membranes were 
washed three times for ten minutes in tris-buffered saline with 0.1% tween 
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(TBST), then rocked for 1 hour with anti-mouse IR-Dye 680 or 800CW 
secondary antibody (Li-Cor Biosciences) diluted 1:10,000 in blocking buffer 
with 0.1% tween.  Membranes were washed three times for 10 minutes in 
TBST then washed 5 times in high purity water and allowed to dry for 3-5 
minutes before scanning (infrared imaging system; Li-Cor Biosciences).  We 
pre-tested the β-tubulin, actin, GAPDH, and VCP Western blot assays using 
varying concentrations of protein from a human cortical tissue homogenate 
sample.  These experiments demonstrated that each assay was linear with 
protein concentrations found in this study (VCP: R = 0.99, p < 0.01; β-tubulin: 
R = 0.99, p < 0.01; actin: R = 0.95, p = 0.01; GAPDH: R = 0.98, p < 0.01). 
 
A.3.4  Data Analysis 
Membranes were scanned using a Li-Cor Odyssey scanner, and the 
intensity value for each protein band was measured using the Odyssey 2.1 
software package. Specific protein values were corrected for lane background 
and divided by intensity values for the macaque cortex homogenate lane 
used as an internal loading control. Because all of the proteins studied are 
typically used as loading controls, we did not divide these values by another 
within-lane control value.  Finally, adjusted intensity values from duplicate 
lanes were averaged for each subject. 
 
A.3.5  Statistical Analysis 
All statistical analyses were performed using Statistica (StatSoft, Tulsa, 
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Oklahoma).  Outliers more than 6 standard deviations from the mean were 
excluded.  Correlation analysis was performed to analyze associations 
between protein expression and age, postmortem interval, and pH.  We 
analyzed protein expression using analysis of variance (ANOVA) or with 
analysis of covariance (ANCOVA) when significant correlations were 
detected. 
 
A.4  Results 
We detected bands for all four proteins at the predicted molecular 
masses of 97 kDa (VCP), 55 kDa (β-tubulin), 42 kDa (actin), and 36 kDa 
(GAPDH) (Figure A.1).  After exclusion of outliers, the following numbers of 
subjects remained for analysis (VCP in ACC: 33 control / 33 schizophrenia; β-
tubulin in ACC: 34 control / 33 schizophrenia; actin and GAPDH in ACC: 33 
control / 32 schizophrenia; VCP, β-tubulin, and actin in hippocampus: 26 
control / 22 schizophrenia; GAPDH in hippocampus: 27 control / 22 
schizophrenia; VCP, β-tubulin, and GAPDH in PVC: 24 control / 22 
schizophrenia; actin in PVC: 23 control / 22 schizophrenia; VCP in DLPFC: 31 
control / 33 schizophrenia; β-tubulin in DLPFC: 30 control / 30 schizophrenia; 
actin in DLPFC: 31 control / 30 schizophrenia; GAPDH in DLPFC: 30 control / 
32 schizophrenia).  Regression analysis revealed a correlation between 
tissue pH and actin expression in PVC (r = 0.33, p < 0.05).  No other 
correlations were detected between age (VCP in ACC: r = 0.10, p = 0.43; 
VCP in hippocampus: r = 0.03, p = 0.29; VCP in PVC: r = 0.04, p = 0.78; VCP 
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in DLPFC: r = 0.08, p = 0.52; β-tubulin in ACC: r = 0.14, p = 0.24; β-tubulin in 
hippocampus: r = 0.10, p = 0.51; β-tubulin in PVC: r = 0.13, p = 0.40; β-
tubulin in DLPFC: r = 0.09, p = 0.50; actin in ACC: r = 0.07, p = 0.58; actin in 
hippocampus: r = 0.01, p = 0.95; actin in PVC: r = 0.09, p = 0.54; actin in 
DLPFC: r = 0.09, p = 0.48; GAPDH in ACC: r = 0.17, p = 0.18; GAPDH in 
hippocampus: r = 0.03, p = 0.86; GAPDH in PVC: r = 0.07, p = 0.63; GAPDH 
in DLPFC: r = 0.05, p = 0.69) or pH (VCP in ACC: r = 0.08, p = 0.52; VCP in 
hippocampus: r = 0.24, p = 0.10; VCP in PVC: r = 0.15, p = 0.32; VCP in 
DLPFC: r = 0.04, p = 0.77; β-tubulin in ACC: r = 0.06, p = 0.64; β-tubulin in 
hippocampus: r = 0.11, p = 0.44; β-tubulin in PVC: r = 0.02, p = 0.87; β-
tubulin in DLPFC: r = 0.01, p = 0.93; actin in ACC: r = 0.09, p = 0.45; actin in 
hippocampus: r = 0.27, p = 0.06; actin in DLPFC: r = 0.01, p = 0.94; GAPDH 
in ACC: r = 0.14, p = 0.27; GAPDH in hippocampus: r = 0.15, p = 0.31; 
GAPDH in PVC: r = 0.15, p = 0.32; GAPDH in DLPFC: r = 0.20, p = 0.11)  for 
any of the proteins studied.  Because sex is a non-continuous variable, we 
performed ANOVA with sex as the independent variable, and protein 
expression as the dependent variable to test for effects of sex on protein 
expression.  There was an increase in GAPDH expression in PVC in males 
compared to females (F = 7.35, p = 0.01), but this effect was not robust 
enough to withstand a correction for multiple comparisons.  No other 
associations between sex and protein expression were detected (VCP in 
ACC: F = 0.21, p = 0.65; VCP in hippocampus: F = 0.00, p = 0.99; VCP in 
PVC: F = 2.37, p = 0.13; VCP in DLPFC: F = 3.03, p = 0.09; β-tubulin in ACC: 
 121 
F = 0.10, p = 0.75; β-tubulin in hippocampus: F = 0.09, p = 0.77; β-tubulin in 
PVC: F = 2.22, p = 0.14; β-tubulin in DLPFC: F = 0.32, p = 0.57; actin in ACC: 
F = 0.16, p = 0.67; actin in hippocampus: F = 0.18, p = 0.68; actin in PVC: F = 
1038, p = 0.25; actin in DLPFC: F = 0.02, p = 0.90; GAPDH in ACC: F = 0.91, 
p = 0.34; GAPDH in hippocampus: F = 0.02, p = 0.89; GAPDH in DLPFC: F = 
2064, p = 0.11).  We did not detect any differences in expression for any of 
the proteins studied between subjects with schizophrenia and the comparison 
group in any of the four regions studied (Figure A.1). 
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Figure A.1:  Housekeeping protein expression in multiple brain regions. 
Data are expressed as ratio of signal intensity for subjects with schizophrenia 
divided by signal intensity for comparison subjects.  None of these proteins 
differed between diagnostic groups in any region studied.  On the right are 
representative Western blots for the 4 proteins studied.    Abbreviations: 
anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), 
hippocampus (HPC), primary visual cortex (PVC), comparison subject (C), 
schizophrenia (S), valosin-containing protein (VCP), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), kilodaltons (kDa). 
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A.5  Discussion 
Several studies have shown variations in expression of housekeeping 
proteins in experimental or disease conditions.  GAPDH protein levels in 
cultured human keratinocytes increased with 2,3,7,8-Tetrachlorodibenzo-p-
dioxin treatment 335, spinal cord injury increased actin expression in rats 336, 
and actin, β-tubulin and GAPDH were expressed at higher levels in renal 
tumors compared to normal kidney tissue 337.  Sex differences were found in 
GAPDH expression in the developing rat brain 338.  These findings highlight 
the importance of confirming that the loading controls used for Western blot 
analyses are not affected by the condition being studied.  We did not find 
differences in the expression of the proteins studied in this cohort in 
schizophrenia.  It unlikely that the mismatch in sex distribution between 
groups influenced our results given that we did not find any significant 
influence of sex on protein expression.  Because all of the proteins studied 
are putative loading controls, we did not normalize to a within-lane 
comparison protein. However, we normalized to a constant amount of protein 
loaded on each gel as a control for interblot variability.  Our results are 
consistent with one other study that also found no changes in actin 
expression in schizophrenia 339.   
While actin, β-tubulin, and GAPDH have traditionally been used as 
loading controls, VCP has a higher molecular weight (97 kDa) which makes it 
useful on blots probed for smaller proteins.  In summary, we found no 
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changes in four different brain regions of expression of 3 housekeeping 
proteins that are commonly used to normalize protein data, and a fourth 
protein, VCP, that has not previously been characterized in schizophrenia.   
Based on these findings, VCP appears to be an acceptable loading control to 
use for low molecular weight proteins in postmortem protein studies of 






1. Association AP. Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revision. Fourth Edition ed. Washington, D.C.: 
American Psychiatric Association; 2000. 
2. Bhugra D. The global prevalence of schizophrenia. PLoS Med May 
2005;2(5):e151; quiz e175. 
3. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts" 
what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 
Jul 2008;102(1-3):1-18. 
4. Sharif Z. Side effects as influencers of treatment outcome. J Clin 
Psychiatry 2008;69 Suppl 3:38-43. 
5. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "Just the 
Facts": what we know in 2008 part 1: overview. Schizophr Res Mar 
2008;100(1-3):4-19. 
6. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased 
dopamine transmission in schizophrenia: relationship to illness phases. 
Biol Psychiatry Jul 1 1999;46(1):56-72. 
7. Joyce JN, Meador-Woodruff JH. Linking the family of D2 receptors to 
neuronal circuits in human brain: insights into schizophrenia. 
Neuropsychopharmacology Jun 1997;16(6):375-384. 
8. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of 
schizophrenia. Am J Psychiatry 1991;148(10):1301-1308. 
9. Tamminga C. Glutamatergic aspects of schizophrenia. Br J Psychiatry 
Suppl 1999(37):12-15. 
10. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates 
psychosis and alters limbic blood flow in schizophrenia. Neuroreport 
1995;6(6):869-872. 
11. Hertzmann M, Reba RC, Kotlyarov EV. Single photon emission 
computed tomography in phencyclidine and related drug abuse. Am J 
Psychiatry Feb 1990;147(2):255-256. 
12. Jones LB. Recent cytoarchitechtonic changes in the prefrontal cortex 
of schizophrenics. Front Biosci Nov 1 2001;6:E148-153. 
 126 
13. Lewis DA, Glantz LA, Pierri JN, Sweet RA. Altered cortical glutamate 
neurotransmission in schizophrenia: evidence from morphological 
studies of pyramidal neurons. Ann N Y Acad Sci Nov 2003;1003:102-
112. 
14. McCullumsmith RE, Clinton SM, Meador-Woodruff JH. Schizophrenia 
as a disorder of neuroplasticity. Int Rev Neurobiol 2004;59:19-45. 
15. Meador-Woodruff JH, Hogg AJ, Smith RE. Striatal ionotropic glutamate 
receptor expression in schizophrenia, bipolar disorder, and major 
depressive disorder. Brain Res Bull 2001;55(5):631-640. 
16. Ohrmann P, Siegmund A, Suslow T, Spitzberg K, Kersting A, Arolt V, 
Heindel W, Pfleiderer B. Evidence for glutamatergic neuronal 
dysfunction in the prefrontal cortex in chronic but not in first-episode 
patients with schizophrenia: a proton magnetic resonance 
spectroscopy study. Schizophr Res Mar 1 2005;73(2-3):153-157. 
17. Quintana J, Wong T, Ortiz-Portillo E, Marder SR, Mazziotta JC. 
Anterior cingulate dysfunction during choice anticipation in 
schizophrenia. Psychiatry Res Dec 15 2004;132(2):117-130. 
18. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of 
glutamate transporters reveals a major role for astroglial transport in 
excitotoxicity and clearance of glutamate. Neuron 1996;16(3):675-686. 
19. Karlsson RM, Tanaka K, Heilig M, Holmes A. Loss of glial glutamate 
and aspartate transporter (excitatory amino acid transporter 1) causes 
locomotor hyperactivity and exaggerated responses to 
psychotomimetics: rescue by haloperidol and metabotropic glutamate 
2/3 agonist. Biol Psychiatry Nov 1 2008;64(9):810-814. 
20. Karlsson RM, Tanaka K, Saksida LM, Bussey TJ, Heilig M, Holmes A. 
Assessment of glutamate transporter GLAST (EAAT1)-deficient mice 
for phenotypes relevant to the negative and executive/cognitive 
symptoms of schizophrenia. Neuropsychopharmacology May 
2009;34(6):1578-1589. 
21. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced 
NMDA receptor expression display behaviors related to schizophrenia. 
Cell 1999;98(4):427-436. 
22. Gaisler-Salomon I, Miller GM, Chuhma N, et al. Glutaminase-Deficient 
Mice Display Hippocampal Hypoactivity, Insensitivity To Pro-Psychotic 
Drugs And Potentiated Latent Inhibition: Relevance To Schizophrenia. 
Neuropsychopharmacology Jun 10 2009. 
 127 
23. Tanaka K, Watase K, Manabe T, et al. Epilepsy and exacerbation of 
brain injury in mice lacking the glutamate transporter GLT-1. Science 
1997;276(5319):1699-1702. 
24. Watase K, Hashimoto K, Kano M, et al. Motor discoordination and 
increased susceptibility to cerebellar injury in GLAST mutant mice. Eur 
J Neurosci 1998;10(3):976-988. 
25. Chen L, Chetkovich DM, Petralia RS, Sweeney NT, Kawasaki Y, 
Wenthold RJ, Bredt DS, Nicoll RA. Stargazin regulates synaptic 
targeting of AMPA receptors by two distinct mechanisms. Nature Dec 
21-28 2000;408(6815):936-943. 
26. Douglas R, Martin KAC. Neocortex. Third edition ed. New York: Oxford 
University Press; 1990. 
27. Siwek DF, Pandya DN. Prefrontal projections to the mediodorsal 
nucleus of the thalamus in the rhesus monkey. J Comp Neurol Oct 22 
1991;312(4):509-524. 
28. Ray JP, Price JL. The organization of projections from the mediodorsal 
nucleus of the thalamus to orbital and medial prefrontal cortex in 
macaque monkeys. J Comp Neurol Nov 1 1993;337(1):1-31. 
29. Goldman-Rakic PS, Porrino LJ. The primate mediodorsal (MD) nucleus 
and its projection to the frontal lobe. J Comp Neurol Dec 22 
1985;242(4):535-560. 
30. Vogt BA, Pandya DN, Rosene DL. Cingulate cortex of the rhesus 
monkey: I. Cytoarchitecture and thalamic afferents. J Comp Neurol 
Aug 8 1987;262(2):256-270. 
31. Auer DP, Wilke M, Grabner A, Heidenreich JO, Bronisch T, Wetter TC. 
Reduced NAA in the thalamus and altered membrane and glial 
metabolism in schizophrenic patients detected by 1H-MRS and tissue 
segmentation. Schizophr Res Oct 1 2001;52(1-2):87-99. 
32. Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-
Woodruff JH. Increased expression of glutaminase and glutamine 
synthetase mRNA in the thalamus in schizophrenia. Schizophr Res 
Jun 1 2005;75(1):27-34. 
33. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH. Altered 
Transcript Expression of NMDA Receptor-Associated Postsynaptic 
Proteins in the Thalamus of Subjects With Schizophrenia. Am J 
Psychiatry Jun 2003;160(6):1100-1109. 
 128 
34. Huerta I, McCullumsmith RE, Haroutunian V, Gimenez-Amaya JM, 
Meador-Woodruff JH. Expression of excitatory amino acid transporter 
interacting protein transcripts in the thalamus in schizophrenia. 
Synapse Jun 1 2006;59(7):394-402. 
35. Meador-Woodruff JH, Clinton SM, Beneyto M, McCullumsmith RE. 
Molecular abnormalities of the glutamate synapse in the thalamus in 
schizophrenia. Ann N Y Acad Sci Nov 2003;1003:75-93. 
36. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression 
of excitatory amino acid transporter transcripts in the thalamus of 
subjects with schizophrenia. Am J Psychiatry 2001;158(9):1393-1399. 
37. Davidkova G, McCullumsmith RE, Meador-Woodruff JH. Expression of 
ARHGEF11 mRNA in schizophrenic thalamus. Ann N Y Acad Sci Nov 
2003;1003:375-377. 
38. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Vesicular 
glutamate transporter transcript expression in the thalamus in 
schizophrenia. Neuroreport 2001;12(13):2885-2887. 
39. Salt TE, Eaton SA. Functions of ionotropic and metabotropic glutamate 
receptors in sensory transmission in the mammalian thalamus. Prog 
Neurobiol Jan 1996;48(1):55-72. 
40. Bellocchio EE, Reimer RJ, Fremeau RT, Jr., Edwards RH. Uptake of 
glutamate into synaptic vesicles by an inorganic phosphate transporter. 
Science 2000;289(5481):957-960. 
41. Takamori S, Rhee JS, Rosenmund C, Jahn R. Identification of a 
vesicular glutamate transporter that defines a glutamatergic phenotype 
in neurons. Nature 2000;407(6801):189-194. 
42. Ghose S, Weickert CS, Colvin SM, Coyle JT, Herman MM, Hyde TM, 
Kleinman JE. Glutamate carboxypeptidase II gene expression in the 
human frontal and temporal lobe in schizophrenia. 
Neuropsychopharmacology Jan 2004;29(1):117-125. 
43. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev 
Neurosci 1994;17:31-108. 
44. Masson J, Sagne C, Hamon M, El Mestikawy S. Neurotransmitter 
transporters in the central nervous system. Pharmacol Rev 
1999;51(3):439-464. 
45. Bassi MT, Gasol E, Manzoni M, et al. Identification and 
characterisation of human xCT that co-expresses, with 4F2 heavy 
 129 
chain, the amino acid transport activity system xc. Pflugers Arch 
2001;442(2):286-296. 
46. Kim JY, Kanai Y, Chairoungdua A, et al. Human cystine/glutamate 
transporter: cDNA cloning and upregulation by oxidative stress in 
glioma cells. Biochim Biophys Acta 2001;1512(2):335-344. 
47. Jackson M, Song W, Liu MY, et al. Modulation of the neuronal 
glutamate transporter EAAT4 by two interacting proteins. Nature Mar 1 
2001;410(6824):89-93. 
48. Lin CI, Orlov I, Ruggiero AM, Dykes-Hoberg M, Lee A, Jackson M, 
Rothstein JD. Modulation of the neuronal glutamate transporter EAAC1 
by the interacting protein GTRAP3-18. Nature Mar 1 
2001;410(6824):84-88. 
49. Marie H, Billups D, Bedford FK, Dumoulin A, Goyal RK, Longmore GD, 
Moss SJ, Attwell D. The amino terminus of the glial glutamate 
transporter GLT-1 interacts with the LIM protein Ajuba. Mol Cell 
Neurosci 2002;19(2):152-164. 
50. Watanabe M, Robinson MB, Kalandadze A, Rothstein JD. GPS1, 
interacting protein with GLT-1. Program No 37216 2003 SFN Abstract 
2003. 
51. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001;65(1):1-105. 
52. Danbolt NC, Chaudhry FA, Dehnes Y, Lehre KP, Levy LM, Ullensvang 
K, Storm-Mathisen J. Properties and localization of glutamate 
transporters. Prog Brain Res 1998;116:23-43. 
53. Wilson NR, Kang J, Hueske EV, Leung T, Varoqui H, Murnick JG, 
Erickson JD, Liu G. Presynaptic regulation of quantal size by the 
vesicular glutamate transporter VGLUT1. Journal of Neuroscience 
2005;25(26):6221-6234, 2005 Jun 6229. 
54. Hisano S. Vesicular glutamate transporters in the brain. Anat Sci Int 
Dec 2003;78(4):191-204. 
55. Wheal HV, Thomson AM. Excitatory Amino Acids and Synaptic 
Transmission (2nd ed.). Academis Press, New York 1995. 
56. Nakanishi S. Molecular diversity of glutamate receptors and 
implications for brain function. Science Oct 23 1992;258(5082):597-
603. 
57. Durand GM, Bennett MV, Zukin RS. Splice variants of the N-methyl-D-
aspartate receptor NR1 identify domains involved in regulation by 
 130 
polyamines and protein kinase C. Proc Natl Acad Sci U S A Jul 15 
1993;90(14):6731-6735. 
58. Corti C, Cavanni P, Caveggion E, Ferraguti F, Corsi M, Trist DG. 
Different levels of receptor expression as a new procedure to estimate 
agonist affinity constant. Application to the metabotropic receptors. 
Ann N Y Acad Sci May 30 1997;812:231-233. 
59. Corti C, Restituito S, Rimland JM, Brabet I, Corsi M, Pin JP, Ferraguti 
F. Cloning and characterization of alternative mRNA forms for the rat 
metabotropic glutamate receptors mGluR7 and mGluR8. Eur J 
Neurosci Dec 1998;10(12):3629-3641. 
60. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure 
and functions. Neuropharmacology Jan 1995;34(1):1-26. 
61. Prezeau L, Carrette J, Helpap B, Curry K, Pin JP, Bockaert J. 
Pharmacological characterization of metabotropic glutamate receptors 
in several types of brain cells in primary cultures. Mol Pharmacol Apr 
1994;45(4):570-577. 
62. Saugstad JA, Kinzie JM, Shinohara MM, Segerson TP, Westbrook GL. 
Cloning and expression of rat metabotropic glutamate receptor 8 
reveals a distinct pharmacological profile. Mol Pharmacol Jan 
1997;51(1):119-125. 
63. Schoepp DD. Novel functions for subtypes of metabotropic glutamate 
receptors. Neurochem Int May 1994;24(5):439-449. 
64. Pin JP, Waeber C, Prezeau L, Bockaert J, Heinemann SF. Alternative 
splicing generates metabotropic glutamate receptors inducing different 
patterns of calcium release in Xenopus oocytes. Proc Natl Acad Sci U 
S A Nov 1 1992;89(21):10331-10335. 
65. Pickering DS, Thomsen C, Suzdak PD, et al. A comparison of two 
alternatively spliced forms of a metabotropic glutamate receptor 
coupled to phosphoinositide turnover. J Neurochem Jul 1993;61(1):85-
92. 
66. McCool BA, Pin JP, Brust PF, Harpold MM, Lovinger DM. Functional 
coupling of rat group II metabotropic glutamate receptors to an omega-
conotoxin GVIA-sensitive calcium channel in human embryonic kidney 
293 cells. Mol Pharmacol Oct 1996;50(4):912-922. 
67. Joly C, Gomeza J, Brabet I, Curry K, Bockaert J, Pin JP. Molecular, 
functional, and pharmacological characterization of the metabotropic 
glutamate receptor type 5 splice variants: comparison with mGluR1. J 
Neurosci May 1995;15(5 Pt 2):3970-3981. 
 131 
68. Aramori I, Nakanishi S. Signal transduction and pharmacological 
characteristics of a metabotropic glutamate receptor, mGluR1, in 
transfected CHO cells. Neuron Apr 1992;8(4):757-765. 
69. Contractor A, Heinemann SF. Glutamate receptor trafficking in 
synaptic plasticity. Sci STKE Oct 29 2002;2002(156):RE14. 
70. McGee AW, Bredt DS. Assembly and plasticity of the glutamatergic 
postsynaptic specialization. Curr Opin Neurobiol Feb 2003;13(1):111-
118. 
71. Lin DT, Makino Y, Sharma K, Hayashi T, Neve R, Takamiya K, 
Huganir RL. Regulation of AMPA receptor extrasynaptic insertion by 
4.1N, phosphorylation and palmitoylation. Nat Neurosci Jul 
2009;12(7):879-887. 
72. Hayashi T, Rumbaugh G, Huganir RL. Differential regulation of AMPA 
receptor subunit trafficking by palmitoylation of two distinct sites. 
Neuron Sep 1 2005;47(5):709-723. 
73. Thomas GM, Lin DT, Nuriya M, Huganir RL. Rapid and bi-directional 
regulation of AMPA receptor phosphorylation and trafficking by JNK. 
Embo J Jan 23 2008;27(2):361-372. 
74. Zhu Y, Pak D, Qin Y, et al. Rap2-JNK removes synaptic AMPA 
receptors during depotentiation. Neuron Jun 16 2005;46(6):905-916. 
75. Sheng M, Pak DT. Ligand-gated ion channel interactions with 
cytoskeletal and signaling proteins. Annu Rev Physiol 2000;62:755-
778. 
76. Lin JW, Wyszynski M, Madhavan R, Sealock R, Kim JU, Sheng M. 
Yotiao, a novel protein of neuromuscular junction and brain that 
interacts with specific splice variants of NMDA receptor subunit NR1. J 
Neurosci Mar 15 1998;18(6):2017-2027. 
77. Ehlers MD, Fung ET, O'Brien RJ, Huganir RL. Splice variant-specific 
interaction of the NMDA receptor subunit NR1 with neuronal 
intermediate filaments. J Neurosci Jan 15 1998;18(2):720-730. 
78. Dracheva S, McGurk SR, Haroutunian V. mRNA expression of AMPA 
receptors and AMPA receptor binding proteins in the cerebral cortex of 
elderly schizophrenics. J Neurosci Res Mar 15 2005;79(6):868-878. 
79. Toyooka K, Iritani S, Makifuchi T, et al. Selective reduction of a PDZ 
protein, SAP-97, in the prefrontal cortex of patients with chronic 
schizophrenia. J Neurochem Nov 2002;83(4):797-806. 
 132 
80. Kozlovsky N, Scarr E, Dean B, Agam G. Postmortem brain calcineurin 
protein levels in schizophrenia patients are not different from controls. 
Schizophr Res Apr 2006;83(2-3):173-177. 
81. Erdely HA, Tamminga CA, Roberts RC, Vogel MW. Regional 
alterations in RGS4 protein in schizophrenia. Synapse Jun 15 
2006;59(8):472-479. 
82. Lipska BK, Mitkus S, Caruso M, et al. RGS4 mRNA Expression in 
Postmortem Human Cortex Is Associated with COMT Val158Met 
Genotype and COMT Enzyme Activity. Hum Mol Genet Aug 11 2006. 
83. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-
specific changes in regulator of G-protein signaling 4 (RGS4) 
expression in schizophrenia. Mol Psychiatry May 2001;6(3):293-301. 
84. Xiao B, Tu JC, Petralia RS, et al. Homer regulates the association of 
group 1 metabotropic glutamate receptors with multivalent complexes 
of homer-related, synaptic proteins. Neuron Oct 1998;21(4):707-716. 
85. Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, Linden DJ, 
Worley PF. Homer binds a novel proline-rich motif and links group 1 
metabotropic glutamate receptors with IP3 receptors. Neuron Oct 
1998;21(4):717-726. 
86. Kammermeier PJ, Xiao B, Tu JC, Worley PF, Ikeda SR. Homer 
proteins regulate coupling of group I metabotropic glutamate receptors 
to N-type calcium and M-type potassium channels. J Neurosci Oct 1 
2000;20(19):7238-7245. 
87. Meador-Woodruff JH, Reyes, E., Haroutunian, V., and Kristiansen, L. 
V. Abnormal Expression of Transcripts for GKAP and Shank Suggest 
Alterations of Interactions Between Metabotropic and Ionotropic 
Glutamate Receptors in Schizophrenic Brain. Paper presented at: 
ACNP 44th Annual Meeting; December 11-15, 2005, 2005; Waikoloa, 
Hawaii. 
88. Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, 
Haroutunian V. N-methyl-D-aspartic acid receptor expression in the 
dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am 
J Psychiatry Sep 2001;158(9):1400-1410. 
89. Sokolov BP. Expression of NMDAR1, GluR1, GluR7, and KA1 
glutamate receptor mRNAs is decreased in frontal cortex of 
"neuroleptic-free" schizophrenics: evidence on reversible up-regulation 
by typical neuroleptics. J Neurochem 1998;71(6):2454-2464. 
 133 
90. Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds 
GP, Andrews HB, Beckmann H. [3H]MK-801 binding sites in 
postmortem brain regions of schizophrenic patients. J Neural Transm 
1989;77(2-3):231-236. 
91. Humphries C, Mortimer A, Hirsch S, de Belleroche J. NMDA receptor 
mRNA correlation with antemortem cognitive impairment in 
schizophrenia. Neuroreport 1996;7(12):2051-2055. 
92. Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene 
expression for NMDA receptor subunits in prefrontal cortex of 
schizophrenics. J Neurosci 1996;16(1):19-30. 
93. Grimwood S, Slater P, Deakin JF, Hutson PH. NR2B-containing NMDA 
receptors are up-regulated in temporal cortex in schizophrenia. 
Neuroreport 1999;10(3):461-465. 
94. Nudmamud S, Reynolds GP. Increased density of glutamate/N-methyl-
D-aspartate receptors in superior temporal cortex in schizophrenia. 
Neurosci Lett May 18 2001;304(1-2):9-12. 
95. Ishimaru M, Kurumaji A, Toru M. Increases in strychnine-insensitive 
glycine binding sites in cerebral cortex of chronic schizophrenics: 
evidence for glutamate hypothesis. Biol Psychiatry Jan 15 
1994;35(2):84-95. 
96. Ishimaru M, Kurumaji A, Toru M. NMDA-associated glycine binding site 
increases in schizophrenic brains. Biol Psychiatry Aug 15 
1992;32(4):379-381. 
97. Zavitsanou K, Ward PB, Huang XF. Selective alterations in ionotropic 
glutamate receptors in the anterior cingulate cortex in schizophrenia. 
Neuropsychopharmacology Nov 2002;27(5):826-833. 
98. Noga JT, Hyde TM, Bachus SE, Herman MM, Kleinman JE. AMPA 
receptor binding in the dorsolateral prefrontal cortex of schizophrenics 
and controls. Schizophr Res Mar 30 2001;48(2-3):361-363. 
99. Newell KA, Zavitsanou K, Huang XF. Ionotropic glutamate receptor 
binding in the posterior cingulate cortex in schizophrenia patients. 
Neuroreport Aug 22 2005;16(12):1363-1367. 
100. Scarr E, Beneyto M, Meador-Woodruff JH, Deans B. Cortical 
glutamatergic markers in schizophrenia. Neuropsychopharmacology 
Aug 2005;30(8):1521-1531. 
 134 
101. Le Corre S, Harper CG, Lopez P, Ward P, Catts S. Increased levels of 
expression of an NMDARI splice variant in the superior temporal gyrus 
in schizophrenia. Neuroreport Apr 7 2000;11(5):983-986. 
102. Mueller HT, Meador-Woodruff JH. NR3A NMDA receptor subunit 
mRNA expression in schizophrenia, depression and bipolar disorder. 
Schizophr Res Dec 1 2004;71(2-3):361-370. 
103. Woo TU, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 
67 messenger RNA-containing neurons that express the N-methyl-D-
aspartate receptor subunit NR2A in the anterior cingulate cortex in 
schizophrenia and bipolar disorder. Arch Gen Psychiatry Jul 
2004;61(7):649-657. 
104. Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH. 
Changes in NMDA receptor subunits and interacting PSD proteins in 
dorsolateral prefrontal and anterior cingulate cortex indicate abnormal 
regional expression in schizophrenia. Mol Psychiatry Aug 
2006;11(8):737-747, 705. 
105. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype 
expression in human postmortem brain tissue from schizophrenics and 
alcohol abusers. Brain Res 1995;674(1):82-90. 
106. Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, 
Harrison PJ. Decreased expression of mRNAs encoding non-NMDA 
glutamate receptors GluR1 and GluR2 in medial temporal lobe 
neurons in schizophrenia. Brain Res Mol Brain Res 1995;29(2):211-
223. 
107. Eastwood SL, Burnet PW, Harrison PJ. GluR2 glutamate receptor 
subunit flip and flop isoforms are decreased in the hippocampal 
formation in schizophrenia: a reverse transcriptase- polymerase chain 
reaction (RT-PCR) study. Brain Res Mol Brain Res 1997;44(1):92-98. 
108. Eastwood SL, Kerwin RW, Harrison PJ. Immunoautoradiographic 
evidence for a loss of alpha-amino-3-hydroxy-5- methyl-4-isoxazole 
propionate-preferring non-N-methyl-D-aspartate glutamate receptors 
within the medial temporal lobe in schizophrenia. Biol Psychiatry 
1997;41(6):636-643. 
109. Harrison PJ, McLaughlin D, Kerwin RW. Decreased hippocampal 
expression of a glutamate receptor gene in schizophrenia. Lancet 
1991;337(8739):450-452. 
110. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis 
of glutamate binding sites in the hippocampal formation in normal and 
schizophrenic brain post mortem. Neuroscience 1990;39(1):25-32. 
 135 
111. Freed WJ, Dillon-Carter O, Kleinman JE. Properties of [3H]AMPA 
binding in postmortem human brain from psychotic subjects and 
controls: increases in caudate nucleus associated with suicide. Exp 
Neurol 1993;121(1):48-56. 
112. Beneyto M, Meador-Woodruff JH. Lamina-Specific abnormalities of 
AMPA receptor trafficking and signaling molecule transcripts in the 
prefrontal cortex in schizophrenia. Synapse 2006:In press. 
113. Takamori S, Malherbe P, Broger C, Jahn R. Molecular cloning and 
functional characterization of human vesicular glutamate transporter 3. 
EMBO Rep Aug 2002;3(8):798-803. 
114. Theberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine 
measured with 4.0 T proton MRS in never-treated patients with 
schizophrenia and healthy volunteers. Am J Psychiatry Nov 
2002;159(11):1944-1946. 
115. Rutter AR, Freeman FM, Stephenson FA. Further characterization of 
the molecular interaction between PSD-95 and NMDA receptors: the 
effect of the NR1 splice variant and evidence for modulation of channel 
gating. J Neurochem Jun 2002;81(6):1298-1307. 
116. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, 
Meador-Woodruff JH. Metabotropic glutamate receptor protein 
expression in the prefrontal cortex and striatum in schizophrenia. 
Synapse Sep 1 2005;57(3):123-131. 
117. Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA. 
Differential expression of metabotropic glutamate receptors 2 and 3 in 
schizophrenia: a mechanism for antipsychotic drug action? Am J 
Psychiatry Jul 2009;166(7):812-820. 
118. Schluter K, Figiel M, Rozyczka J, Engele J. CNS region-specific 
regulation of glial glutamate transporter expression. Eur J Neurosci 
Sep 2002;16(5):836-842. 
119. Kurumaji A, Ishimaru M, Toru M. Alpha-[3H]amino-3-hydroxy-5-
methylisoxazole-4-propionic acid binding to human cerebral cortical 
membranes: minimal changes in postmortem brains of chronic 
schizophrenics. J Neurochem Sep 1992;59(3):829-837. 
120. Dracheva S, McGurk SR, Haroutunian V. mRNA expression of AMPA 
receptors and AMPA receptor binding proteins in the cerebral cortex of 
elderly schizophrenics. J Neurosci Res Feb 4 2005;79(6):868-878. 
121. Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, 
Becker KG, Freed WJ. Microarray analysis of gene expression in the 
 136 
prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res 
Nov 1 2002;58(1):11-20. 
122. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression 
of glutaminase transcripts 
in the thalamus in schizophrenia. Biological Psychiatry 2002;51:25. 
123. Meador-Woodruff JH, Davis KL, Haroutunian V. Abnormal kainate 
receptor expression in prefrontal cortex in schizophrenia. 
Neuropsychopharmacology May 2001;24(5):545-552. 
124. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on 
extrapyramidal function. CNS Drugs 2002;16(1):23-45. 
125. Ohnuma T, Kato H, Arai H, Faull RL, McKenna PJ, Emson PC. Gene 
expression of PSD95 in prefrontal cortex and hippocampus in 
schizophrenia. Neuroreport Sep 28 2000;11(14):3133-3137. 
126. Funk AJ, Rumbaugh G, Harotunian V, McCullumsmith RE, Meador-
Woodruff JH. Decreased expression of NMDA receptor-associated 
proteins in frontal cortex of elderly patients with schizophrenia. 
Neuroreport Jul 15 2009;20(11):1019-1022. 
127. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular 
characterization of schizophrenia viewed by microarray analysis of 
gene expression in prefrontal cortex. Neuron Oct 2000;28(1):53-67. 
128. Imai C, Sugai T, Iritani S, et al. A quantitative study on the expression 
of synapsin II and N-ethylmaleimide-sensitive fusion protein in 
schizophrenic patients. Neurosci Lett Jun 15 2001;305(3):185-188. 
129. Gray L, Scarr E, Dean B. N-Ethylmaleimide sensitive factor in the 
cortex of subjects with schizophrenia and bipolar I disorder. Neurosci 
Lett Jan 2 2006;391(3):112-115. 
130. Prabakaran S, Swatton JE, Ryan MM, et al. Mitochondrial dysfunction 
in schizophrenia: evidence for compromised brain metabolism and 
oxidative stress. Mol Psychiatry Jul 2004;9(7):684-697, 643. 
131. Arriza JL, Kavanaugh MP, Fairman WA, Wu YN, Murdoch GH, North 
RA, Amara SG. Cloning and expression of a human neutral amino acid 
transporter with structural similarity to the glutamate transporter gene 
family. J Biol Chem 1993;268(21):15329-15332. 
132. Utsunomiya-Tate N, Endou H, Kanai Y. Cloning and functional 
characterization of a system ASC-like Na+- dependent neutral amino 
acid transporter. J Biol Chem 1996;271(25):14883-14890. 
 137 
133. Zerangue N, Kavanaugh MP. ASCT-1 is a neutral amino acid 
exchanger with chloride channel activity. J Biol Chem Nov 8 
1996;271(45):27991-27994. 
134. Levy LM, Warr O, Attwell D. Stoichiometry of the glial glutamate 
transporter GLT-1 expressed inducibly in a Chinese hamster ovary cell 
line selected for low endogenous Na+-dependent glutamate uptake. J 
Neurosci Dec 1 1998;18(23):9620-9628. 
135. Gendreau S, Voswinkel S, Torres-Salazar D, et al. A trimeric 
quaternary structure is conserved in bacterial and human glutamate 
transporters. J Biol Chem Sep 17 2004;279(38):39505-39512. 
136. Haugeto O, Ullensvang K, Levy LM, Chaudhry FA, Honore T, Nielsen 
M, Lehre KP, Danbolt NC. Brain glutamate transporter proteins form 
homomultimers. J Biol Chem Nov 1 1996;271(44):27715-27722. 
137. Banner SJ, Fray AE, Ince PG, Steward M, Cookson MR, Shaw PJ. The 
expression of the glutamate re-uptake transporter excitatory amino 
acid transporter 1 (EAAT1) in the normal human CNS and in motor 
neurone disease: an immunohistochemical study. Neuroscience 
2002;109(1):27-44. 
138. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash 
N, Kuncl RW. Localization of neuronal and glial glutamate transporters. 
Neuron 1994;13(3):713-725. 
139. Furuta A, Rothstein JD, Martin LJ. Glutamate transporter protein 
subtypes are expressed differentially during rat CNS development. J 
Neurosci 1997;17(21):8363-8375. 
140. Furuta A, Martin LJ, Lin CL, Dykes-Hoberg M, Rothstein JD. Cellular 
and synaptic localization of the neuronal glutamate transporters 
excitatory amino acid transporter 3 and 4. Neuroscience 
1997;81(4):1031-1042. 
141. Bar-Peled O, Ben-Hur H, Biegon A, Groner Y, Dewhurst S, Furuta A, 
Rothstein JD. Distribution of glutamate transporter subtypes during 
human brain development. J Neurochem 1997;69(6):2571-2580. 
142. Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC. 
Differential expression of two glial glutamate transporters in the rat 
brain: quantitative and immunocytochemical observations. J Neurosci 
Mar 1995;15(3 Pt 1):1835-1853. 
143. Schmitt A, Asan E, Puschel B, Kugler P. Cellular and regional 
distribution of the glutamate transporter GLAST in the CNS of rats: 
 138 
nonradioactive in situ hybridization and comparative 
immunocytochemistry. J Neurosci 1997;17(1):1-10. 
144. Scott HL, Pow DV, Tannenberg AE, Dodd PR. Aberrant expression of 
the glutamate transporter excitatory amino acid transporter 1 (EAAT1) 
in Alzheimer's disease. J Neurosci Feb 1 2002;22(3):RC206. 
145. Chaudhry FA, Lehre KP, van Lookeren Campagne M, Ottersen OP, 
Danbolt NC, Storm-Mathisen J. Glutamate transporters in glial plasma 
membranes: highly differentiated localizations revealed by quantitative 
ultrastructural immunocytochemistry. Neuron 1995;15(3):711-720. 
146. Conradt M, Stoffel W. Inhibition of the high-affinity brain glutamate 
transporter GLAST-1 via direct phosphorylation. J Neurochem Mar 
1997;68(3):1244-1251. 
147. Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J. Regulation of 
glial glutamate transporter expression by growth factors. Exp Neurol 
Sep 2003;183(1):124-135. 
148. Figiel M, Engele J. Pituitary adenylate cyclase-activating polypeptide 
(PACAP), a neuron-derived peptide regulating glial glutamate transport 
and metabolism. J Neurosci May 15 2000;20(10):3596-3605. 
149. Gamboa C, Ortega A. Insulin-like growth factor-1 increases activity and 
surface levels of the GLAST subtype of glutamate transporter. 
Neurochem Int Apr 2002;40(5):397-403. 
150. Milton ID, Banner SJ, Ince PG, Piggott NH, Fray AE, Thatcher N, 
Horne CH, Shaw PJ. Expression of the glial glutamate transporter 
EAAT2 in the human CNS: an immunohistochemical study. Brain Res 
Mol Brain Res 1997;52(1):17-31. 
151. Berger UV, Hediger MA. Comparative analysis of glutamate 
transporter expression in rat brain using differential double in situ 
hybridization. Anat Embryol (Berl) Jul 1998;198(1):13-30. 
152. Rauen T, Kanner BI. Localization of the glutamate transporter GLT-1 in 
rat and macaque monkey retinae. Neurosci Lett Mar 14 1994;169(1-
2):137-140. 
153. Chen W, Mahadomrongkul V, Berger UV, et al. The glutamate 
transporter GLT1a is expressed in excitatory axon terminals of mature 
hippocampal neurons. J Neurosci Feb 4 2004;24(5):1136-1148. 
154. Schmitt A, Asan E, Lesch KP, Kugler P. A splice variant of glutamate 
transporter GLT1/EAAT2 expressed in neurons: cloning and 
localization in rat nervous system. Neuroscience 2002;109(1):45-61. 
 139 
155. Volterra A, Trotti D, Racagni G. Glutamate uptake is inhibited by 
arachidonic acid and oxygen radicals via two distinct and additive 
mechanisms. Mol Pharmacol 1994;46(5):986-992. 
156. Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC. Cytokine effects 
on glutamate uptake by human astrocytes. Neuroimmunomodulation 
2000;7(3):153-159. 
157. Dunlop J, Lou Z, Zhang Y, McIlvain HB. Inducible expression and 
pharmacology of the human excitatory amino acid transporter 2 
subtype of L-glutamate transporter. Br J Pharmacol 1999;128(7):1485-
1490. 
158. Conti F, DeBiasi S, Minelli A, Rothstein JD, Melone M. EAAC1, a high-
affinity glutamate tranporter, is localized to astrocytes and gabaergic 
neurons besides pyramidal cells in the rat cerebral cortex. Cereb 
Cortex Mar 1998;8(2):108-116. 
159. Kugler P, Schmitt A. Glutamate transporter EAAC1 is expressed in 
neurons and glial cells in the rat nervous system. Glia 1999;27(2):129-
142. 
160. He Y, Hof PR, Janssen WG, Rothstein JD, Morrison JH. Differential 
synaptic localization of GluR2 and EAAC1 in the macaque monkey 
entorhinal cortex: a postembedding immunogold study. Neurosci Lett 
Oct 5 2001;311(3):161-164. 
161. He Y, Janssen WG, Rothstein JD, Morrison JH. Differential synaptic 
localization of the glutamate transporter EAAC1 and glutamate 
receptor subunit GluR2 in the rat hippocampus. J Comp Neurol Mar 13 
2000;418(3):255-269. 
162. Cheng C, Glover G, Banker G, Amara SG. A novel sorting motif in the 
glutamate transporter excitatory amino acid transporter 3 directs its 
targeting in Madin-Darby canine kidney cells and hippocampal 
neurons. J Neurosci Dec 15 2002;22(24):10643-10652. 
163. Lortet S, Samuel D, Had-Aissouni L, Masmejean F, Kerkerian-Le Goff 
L, Pisano P. Effects of PKA and PKC modulators on high affinity 
glutamate uptake in primary neuronal cell cultures from rat cerebral 
cortex. Neuropharmacology Mar 1999;38(3):395-402. 
164. Davis KE, Straff DJ, Weinstein EA, Bannerman PG, Correale DM, 
Rothstein JD, Robinson MB. Multiple signaling pathways regulate cell 
surface expression and activity of the excitatory amino acid carrier 1 
subtype of Glu transporter in C6 glioma. J Neurosci Apr 1 
1998;18(7):2475-2485. 
 140 
165. Dowd LA, Robinson MB. Rapid stimulation of EAAC1-mediated Na+-
dependent L-glutamate transport activity in C6 glioma cells by phorbol 
ester. J Neurochem Aug 1996;67(2):508-516. 
166. Dowd LA, Coyle AJ, Rothstein JD, Pritchett DB, Robinson MB. 
Comparison of Na+-dependent glutamate transport activity in 
synaptosomes, C6 glioma, and Xenopus oocytes expressing excitatory 
amino acid carrier 1 (EAAC1). Mol Pharmacol Mar 1996;49(3):465-
473. 
167. Sims KD, Straff DJ, Robinson MB. Platelet-derived growth factor 
rapidly increases activity and cell surface expression of the EAAC1 
subtype of glutamate transporter through activation of 
phosphatidylinositol 3-kinase. J Biol Chem Feb 18 2000;275(7):5228-
5237. 
168. Najimi M, Maloteaux JM, Hermans E. Cytoskeleton-related trafficking 
of the EAAC1 glutamate transporter after activation of the G(q/11)-
coupled neurotensin receptor NTS1. FEBS Lett Jul 17 2002;523(1-
3):224-228. 
169. Ma K, Zheng S, Zuo Z. The transcription factor regulatory factor X1 
increases the expression of neuronal glutamate transporter type 3. J 
Biol Chem Jul 28 2006;281(30):21250-21255. 
170. Yamada K, Watanabe M, Shibata T, Tanaka K, Wada K, Inoue Y. 
EAAT4 is a post-synaptic glutamate transporter at Purkinje cell 
synapses. Neuroreport 1996;7(12):2013-2017. 
171. Nagao S, Kwak S, Kanazawa I. EAAT4, a glutamate transporter with 
properties of a chloride channel, is predominantly localized in Purkinje 
cell dendrites, and forms parasagittal compartments in rat cerebellum. 
Neuroscience 1997;78(4):929-933. 
172. Hu WH, Walters WM, Xia XM, Karmally SA, Bethea JR. Neuronal 
glutamate transporter EAAT4 is expressed in astrocytes. Glia Oct 
2003;44(1):13-25. 
173. McCullumsmith RE, Meador-Woodruff JH. Striatal excitatory amino 
acid transporter transcript expression in schizophrenia, bipolar 
disorder, and major depressive disorder. Neuropsychopharmacology 
Mar 2002;26(3):368-375. 
174. Massie A, Vandesande F, Arckens L. Expression of the high-affinity 
glutamate transporter EAAT4 in mammalian cerebral cortex. 
Neuroreport Feb 12 2001;12(2):393-397. 
 141 
175. Dehnes Y, Chaudhry FA, Ullensvang K, Lehre KP, Storm-Mathisen J, 
Danbolt NC. The glutamate transporter EAAT4 in rat cerebellar 
Purkinje cells: a glutamate-gated chloride channel concentrated near 
the synapse in parts of the dendritic membrane facing astroglia. J 
Neurosci 1998;18(10):3606-3619. 
176. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants 
disrupt multiple genes in neurodevelopmental pathways in 
schizophrenia. Science Apr 25 2008;320(5875):539-543. 
177. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as 
a new approach to treat schizophrenia: a randomized Phase 2 clinical 
trial. Nat Med Sep 2007;13(9):1102-1107. 
178. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression 
of the human excitatory amino acid transporter 2 and metabotropic 
glutamate receptors 3 and 5 in the prefrontal cortex from normal 
individuals and patients with schizophrenia. Brain Res Mol Brain Res 
1998;56(1-2):207-217. 
179. Matute C, Melone M, Vallejo-Illarramendi A, Conti F. Increased 
expression of the astrocytic glutamate transporter GLT-1 in the 
prefrontal cortex of schizophrenics. Glia Feb 2005;49(3):451-455. 
180. Lauriat TL, Dracheva S, Chin B, Schmeidler J, McInnes LA, 
Haroutunian V. Quantitative analysis of glutamate transporter mRNA 
expression in prefrontal and primary visual cortex in normal and 
schizophrenic brain. Neuroscience Feb 2006;137(3):843-851. 
181. Chaudhry FA, Lehre KP, van Lookeren Campagne M, Ottersen OP, 
Danbolt NC, Storm-Mathisen J. Glutamate transporters in glial plasma 
membranes: highly differentiated localizations revealed by quantitative 
ultrastructural immunocytochemistry. Neuron Sep 1995;15(3):711-720. 
182. Kugler P, Schmitt A. Complementary neuronal and glial expression of 
two high-affinity glutamate transporter GLT1/EAAT2 forms in rat 
cerebral cortex. Histochem Cell Biol Jun 2003;119(6):425-435. 
183. Maragakis NJ, Dykes-Hoberg M, Rothstein JD. Altered expression of 
the glutamate transporter EAAT2b in neurological disease. Ann Neurol 
Apr 2004;55(4):469-477. 
184. Ohnuma T, Tessler S, Arai H, Faull RL, McKenna PJ, Emson PC. 
Gene expression of metabotropic glutamate receptor 5 and excitatory 
amino acid transporter 2 in the schizophrenic hippocampus. Brain Res 
Mol Brain Res Dec 28 2000;85(1-2):24-31. 
 142 
185. Eastwood SL, Harrison PJ. Decreased expression of vesicular 
glutamate transporter 1 and complexin II mRNAs in schizophrenia: 
further evidence for a synaptic pathology affecting glutamate neurons. 
Schizophr Res Mar 1 2005;73(2-3):159-172. 
186. Wilson NR, Kang J, Hueske EV, Leung T, Varoqui H, Murnick JG, 
Erickson JD, Liu G. Presynaptic regulation of quantal size by the 
vesicular glutamate transporter VGLUT1. J Neurosci Jun 29 
2005;25(26):6221-6234. 
187. Marie H, Attwell D. C-terminal interactions modulate the affinity of 
GLAST glutamate transporters in salamander retinal glial cells. J 
Physiol Oct 15 1999;520 Pt 2:393-397. 
188. Kinoshita N, Kimura K, Matsumoto N, Watanabe M, Fukaya M, Ide C. 
Mammalian septin Sept2 modulates the activity of GLAST, a glutamate 
transporter in astrocytes. Genes Cells Jan 2004;9(1):1-14. 
189. Sullivan SM, Lee A, Bjorkman ST, Miller SM, Sullivan RK, Poronnik P, 
Colditz PB, Pow DV. Cytoskeletal anchoring of GLAST determines 
susceptibility to brain damage: an identified role for GFAP. J Biol Chem 
Oct 5 2007;282(40):29414-29423. 
190. Lee A, Rayfield A, Hryciw DH, et al. Na+-H+ exchanger regulatory 
factor 1 is a PDZ scaffold for the astroglial glutamate transporter 
GLAST. Glia Jan 15 2007;55(2):119-129. 
191. Gonzalez MI, Susarla BT, Robinson MB. Evidence that protein kinase 
Calpha interacts with and regulates the glial glutamate transporter 
GLT-1. J Neurochem Sep 2005;94(5):1180-1188. 
192. Marie H, Pratt SJ, Betson M, et al. The LIM protein Ajuba is recruited 
to cadherin-dependent cell junctions through an association with alpha-
catenin. J Biol Chem Jan 10 2003;278(2):1220-1228. 
193. Boston-Howes W, Gibb SL, Williams EO, Pasinelli P, Brown RH, Jr., 
Trotti D. Caspase-3 cleaves and inactivates the glutamate transporter 
EAAT2. J Biol Chem May 19 2006;281(20):14076-14084. 
194. Gonzalez MI, Bannerman PG, Robinson MB. Phorbol myristate 
acetate-dependent interaction of protein kinase Calpha and the 
neuronal glutamate transporter EAAC1. J Neurosci Jul 2 
2003;23(13):5589-5593. 
195. Ruggiero A, Vidensky S, Rothstein JD. GTRAP3-18 protein is able to 
regulate the activity of excitatory amino acid transporters through 
alterations in ASN linked glycosyl processing. Abstract viewer, Society 
for Neuroscience 2003:Program No. 372.315. 
 143 
196. Butchbach ME, Lai L, Lin CL. Molecular cloning, gene structure, 
expression profile and functional characterization of the mouse 
glutamate transporter (EAAT3) interacting protein GTRAP3-18. Gene 
Jun 12 2002;292(1-2):81-90. 
197. Schweneker M, Bachmann AS, Moelling K. JM4 is a four-
transmembrane protein binding to the CCR5 receptor. FEBS Lett Mar 
14 2005;579(7):1751-1758. 
198. Xia P, Pei G, Schwarz W. Regulation of the glutamate transporter 
EAAC1 by expression and activation of delta-opioid receptor. Eur J 
Neurosci Jul 2006;24(1):87-93. 
199. Zhu Y, Fei J, Schwarz W. Expression and transport function of the 
glutamate transporter EAAC1 in Xenopus oocytes is regulated by 
syntaxin 1A. J Neurosci Res Feb 15 2005;79(4):503-508. 
200. Yu YX, Shen L, Xia P, Tang YW, Bao L, Pei G. Syntaxin 1A promotes 
the endocytic sorting of EAAC1 leading to inhibition of glutamate 
transport. J Cell Sci Sep 15 2006;119(Pt 18):3776-3787. 
201. Fournier KM, Robinson MB. A dominant-negative variant of SNAP-23 
decreases the cell surface expression of the neuronal glutamate 
transporter EAAC1 by slowing constitutive delivery. Neurochem Int 
May-Jun 2006;48(6-7):596-603. 
202. Kiryu-Seo S, Gamo K, Tachibana T, Tanaka K, Kiyama H. Unique anti-
apoptotic activity of EAAC1 in injured motor neurons. Embo J Jul 26 
2006;25(14):3411-3421. 
203. Kalandadze A, Wu Y, Robinson MB. Protein kinase C activation 
decreases cell surface expression of the GLT-1 subtype of glutamate 
transporter. Requirement of a carboxyl-terminal domain and partial 
dependence on serine 486. J Biol Chem Nov 29 2002;277(48):45741-
45750. 
204. Casado M, Bendahan A, Zafra F, Danbolt NC, Aragon C, Gimenez C, 
Kanner BI. Phosphorylation and modulation of brain glutamate 
transporters by protein kinase C. J Biol Chem Dec 25 
1993;268(36):27313-27317. 
205. Fang H, Huang Y, Zuo Z. The different responses of rat glutamate 
transporter type 2 and its mutant (tyrosine 403 to histidine) activity to 
volatile anesthetics and activation of protein kinase C. Brain Res Oct 
25 2002;953(1-2):255-264. 
 144 
206. Daniels KK, Vickroy TW. Reversible activation of glutamate transport in 
rat brain glia by protein kinase C and an okadaic acid-sensitive 
phosphoprotein phosphatase. Neurochem Res 1999;24(8):1017-1025. 
207. Sheldon AL, Gonzalez MI, Krizman-Genda EN, Susarla BT, Robinson 
MB. Ubiquitination-mediated internalization and degradation of the 
astroglial glutamate transporter, GLT-1. Neurochem Int Dec 2008;53(6-
8):296-308. 
208. Yang L, Wang S, Sung B, Lim G, Mao J. Morphine induces ubiquitin-
proteasome activity and glutamate transporter degradation. J Biol 
Chem Aug 1 2008;283(31):21703-21713. 
209. Conradt M, Storck T, Stoffel W. Localization of N-glycosylation sites 
and functional role of the carbohydrate units of GLAST-1, a cloned rat 
brain L-glutamate/L-aspartate transporter. Eur J Biochem May 1 
1995;229(3):682-687. 
210. Huggett J, Vaughan-Thomas A, Mason D. The open reading frame of 
the Na(+)-dependent glutamate transporter GLAST-1 is expressed in 
bone and a splice variant of this molecule is expressed in bone and 
brain. FEBS Lett Nov 17 2000;485(1):13-18. 
211. Raunser S, Haase W, Bostina M, Parcej DN, Kuhlbrandt W. High-yield 
expression, reconstitution and structure of the recombinant, fully 
functional glutamate transporter GLT-1 from Rattus norvegicus. J Mol 
Biol Aug 19 2005;351(3):598-613. 
212. Schulte S, Stoffel W. UDP galactose:ceramide galactosyltransferase 
and glutamate/aspartate transporter. Copurification, separation and 
characterization of the two glycoproteins. Eur J Biochem Nov 1 
1995;233(3):947-953. 
213. Yang W, Kilberg MS. Biosynthesis, intracellular targeting, and 
degradation of the EAAC1 glutamate/aspartate transporter in C6 
glioma cells. J Biol Chem Oct 11 2002;277(41):38350-38357. 
214. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health 
and disease. Cell Sep 8 2006;126(5):855-867. 
215. Narayan S, Head SR, Gilmartin TJ, Dean B, Thomas EA. Evidence for 
disruption of sphingolipid metabolism in schizophrenia. J Neurosci Res 
Aug 5 2008. 
216. Trotti D, Aoki M, Pasinelli P, Berger UV, Danbolt NC, Brown RH, Jr., 
Hediger MA. Amyotrophic lateral sclerosis-linked glutamate transporter 
mutant has impaired glutamate clearance capacity. J Biol Chem Jan 5 
2001;276(1):576-582. 
 145 
217. Meyer T, Fromm A, Munch C, et al. The RNA of the glutamate 
transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis 
and normal individuals. J Neurol Sci 1999;170(1):45-50. 
218. Munch C, Penndorf A, Schwalenstocker B, Troost D, Ludolph AC, Ince 
P, Meyer T. Impaired RNA splicing of 5'-regulatory sequences of the 
astroglial glutamate transporter EAAT2 in human astrocytoma. J 
Neurol Neurosurg Psychiatry Nov 2001;71(5):675-678. 
219. Honig LS, Chambliss DD, Bigio EH, Carroll SL, Elliott JL. Glutamate 
transporter EAAT2 splice variants occur not only in ALS, but also in AD 
and controls. Neurology Oct 24 2000;55(8):1082-1088. 
220. Lauriat TL, Schmeidler J, McInnes LA. Early rapid rise in EAAT2 
expression follows the period of maximal seizure susceptibility in 
human brain. Neurosci Lett Jan 22 2007;412(1):89-94. 
221. Lauriat TL, Richler E, McInnes LA. A quantitative regional expression 
profile of EAAT2 known and novel splice variants reopens the question 
of aberrant EAAT2 splicing in disease. Neurochem Int Jan 
2007;50(1):271-280. 
222. Hoogland G, van Oort RJ, Proper EA, et al. Alternative splicing of 
glutamate transporter EAAT2 RNA in neocortex and hippocampus of 
temporal lobe epilepsy patients. Epilepsy Res Apr-May 2004;59(2-
3):75-82. 
223. Macnab LT, Pow DV. Expression of the exon 9-skipping form of 
EAAT2 in astrocytes of rats. Neuroscience Dec 12 2007;150(3):705-
711. 
224. Pow DV, Cook DG. Neuronal Expression of Splice Variants of "Glial" 
Glutamate Transporters in Brains Afflicted by Alzheimer's Disease: 
Unmasking an Intrinsic Neuronal Property. Neurochem Res Mar 25 
2009. 
225. Lauriat TL, McInnes LA. EAAT2 regulation and splicing: relevance to 
psychiatric and neurological disorders. Mol Psychiatry Dec 
2007;12(12):1065-1078. 
226. Sullivan SM, Macnab LT, Bjorkman ST, Colditz PB, Pow DV. 
GLAST1b, the exon-9 skipping form of the glutamate-aspartate 
transporter EAAT1 is a sensitive marker of neuronal dysfunction in the 
hypoxic brain. Neuroscience Oct 26 2007;149(2):434-445. 
227. Macnab LT, Williams SM, Pow DV. Expression of the exon 3 skipping 
form of GLAST, GLAST1a, in brain and retina. Neuroreport Dec 18 
2006;17(18):1867-1870. 
 146 
228. Macnab LT, Pow DV. Central nervous system expression of the exon 9 
skipping form of the glutamate transporter GLAST. Neuroreport May 
28 2007;18(8):741-745. 
229. Vallejo-Illarramendi A, Domercq M, Matute C. A novel alternative 
splicing form of excitatory amino acid transporter 1 is a negative 
regulator of glutamate uptake. J Neurochem Oct 2005;95(2):341-348. 
230. Kalandadze A, Wu Y, Fournier K, Robinson MB. Identification of motifs 
involved in endoplasmic reticulum retention-forward trafficking of the 
GLT-1 subtype of glutamate transporter. J Neurosci Jun 2 
2004;24(22):5183-5192. 
231. Kindlundh-Hogberg AM, Blomqvist A, Malki R, Schioth HB. Extensive 
neuroadaptive changes in cortical gene-transcript expressions of the 
glutamate system in response to repeated intermittent MDMA 
administration in adolescent rats. BMC Neurosci 2008;9:39. 
232. Arriza JL, Eliasof S, Kavanaugh MP, Amara SG. Excitatory amino acid 
transporter 5, a retinal glutamate transporter coupled to a chloride 
conductance. Proc Natl Acad Sci U S A 1997;94(8):4155-4160. 
233. Williams SM, Sullivan RK, Scott HL, Finkelstein DI, Colditz PB, 
Lingwood BE, Dodd PR, Pow DV. Glial glutamate transporter 
expression patterns in brains from multiple mammalian species. Glia 
Mar 2005;49(4):520-541. 
234. Levenson J, Weeber E, Selcher JC, Kategaya LS, Sweatt JD, Eskin A. 
Long-term potentiation and contextual fear conditioning increase 
neuronal glutamate uptake. Nat Neurosci Feb 2002;5(2):155-161. 
235. Crino PB, Jin H, Shumate MD, Robinson MB, Coulter DA, Brooks-
Kayal AR. Increased expression of the neuronal glutamate transporter 
(EAAT3/EAAC1) in hippocampal and neocortical epilepsy. Epilepsia 
Mar 2002;43(3):211-218. 
236. Manoach DS. Prefrontal cortex dysfunction during working memory 
performance in schizophrenia: reconciling discrepant findings. 
Schizophr Res Apr 1 2003;60(2-3):285-298. 
237. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, 
Chase TN, Carpenter WT. Limbic system abnormalities identified in 
schizophrenia using positron emission tomography with 
fluorodeoxyglucose and neocortical alterations with deficit syndrome. 
Arch Gen Psychiatry Jul 1992;49(7):522-530. 
 147 
238. Liu YL, Shen-Jang Fann C, Liu CM, et al. Evaluation of RGS4 as a 
candidate gene for schizophrenia. Am J Med Genet B Neuropsychiatr 
Genet Jun 5 2006;141(4):418-420. 
239. Varoqui H, Schafer MK, Zhu H, Weihe E, Erickson JD. Identification of 
the differentiation-associated Na+/PI transporter as a novel vesicular 
glutamate transporter expressed in a distinct set of glutamatergic 
synapses. J Neurosci Jan 1 2002;22(1):142-155. 
240. Saransaari P, Lillrank SM, Oja SS. Phencyclidine treatment in mice: 
effects on phencyclidine binding sites and glutamate uptake in cerebral 
cortex preparations. J Neural Transm Gen Sect 1993;93(1):47-59. 
241. Goff DC, Wine L. Glutamate in schizophrenia: clinical and research 
implications. Schizophr Res Oct 30 1997;27(2-3):157-168. 
242. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. 
Harv Rev Psychiatry Jan-Feb 1996;3(5):241-253. 
243. Itil T, Keskiner A, Kiremitci N, Holden JM. Effect of phencyclidine in 
chronic schizophrenics. Can Psychiatr Assoc J 1967;12(2):209-212. 
244. Aanonsen LM, Wilcox GL. Phencyclidine selectively blocks a spinal 
action of N-methyl-D- aspartate in mice. Neurosci Lett 1986;67(2):191-
197. 
245. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the 
noncompetitive NMDA antagonist, ketamine, in humans. 
Psychotomimetic, perceptual, cognitive, and neuroendocrine 
responses. Arch Gen Psychiatry 1994;51(3):199-214. 
246. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA. Plasma 
amino acids in relation to cerebrospinal fluid monoamine metabolites in 
schizophrenic patients and healthy controls. Br J Psychiatry Sep 
1985;147:276-282. 
247. Macciardi F, Lucca A, Catalano M, Marino C, Zanardi R, Smeraldi E. 
Amino acid patterns in schizophrenia: some new findings. Psychiatry 
Res Apr 1990;32(1):63-70. 
248. Gattaz WF, Gasser T, Beckmann H. Multidimensional analysis of the 
concentrations of 17 substances in the CSF of schizophrenics and 
controls. Biol Psychiatry Apr 1985;20(4):360-366. 
249. Perry TL. Normal cerebrospinal fluid and brain glutamate levels in 
schizophrenia do not support the hypothesis of glutamatergic neuronal 
dysfunction. Neurosci Lett Jan 22 1982;28(1):81-85. 
 148 
250. Korpi ER, Kaufmann CA, Marnela KM, Weinberger DR. Cerebrospinal 
fluid amino acid concentrations in chronic schizophrenia. Psychiatry 
Res Apr 1987;20(4):337-345. 
251. Alfredsson G, Wiesel FA. Monoamine metabolites and amino acids in 
serum from schizophrenic patients before and during sulpiride 
treatment. Psychopharmacology (Berl) 1989;99(3):322-327. 
252. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A 
"glutamatergic hypothesis" of schizophrenia. Rationale for 
pharmacotherapy with glycine. Clin Neuropharmacol Feb 1989;12(1):1-
13. 
253. Omori M, Pearce J, Komoroski RA, Griffin WS, Mrak RE, Husain MM, 
Karson CN. In vitro 1H-magnetic resonance spectroscopy of 
postmortem brains with schizophrenia. Biol Psychiatry Sep 1 
1997;42(5):359-366. 
254. Kegeles LS, Humaran TJ, Mann JJ. In vivo neurochemistry of the brain 
in schizophrenia as revealed by magnetic resonance spectroscopy. 
Biol Psychiatry Sep 15 1998;44(6):382-398. 
255. Deicken RF, Zhou L, Schuff N, Weiner MW. Proton magnetic 
resonance spectroscopy of the anterior cingulate region in 
schizophrenia. Schizophr Res Oct 17 1997;27(1):65-71. 
256. Steel RM, Bastin ME, McConnell S, Marshall I, Cunningham-Owens 
DG, Lawrie SM, Johnstone EC, Best JJ. Diffusion tensor imaging (DTI) 
and proton magnetic resonance spectroscopy (1H MRS) in 
schizophrenic subjects and normal controls. Psychiatry Res May 30 
2001;106(3):161-170. 
257. Burbaeva G, Boksha IS, Turishcheva MS, Vorobyeva EA, Savushkina 
OK, Tereshkina EB. Glutamine synthetase and glutamate 
dehydrogenase in the prefrontal cortex of patients with schizophrenia. 
Prog Neuropsychopharmacol Biol Psychiatry Jun 2003;27(4):675-680. 
258. Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJ, 
Weinberger DR. Selective relationship between prefrontal N-
acetylaspartate measures and negative symptoms in schizophrenia. 
Am J Psychiatry Oct 2000;157(10):1646-1651. 
259. Cecil KM, Lenkinski RE, Gur RE, Gur RC. Proton magnetic resonance 
spectroscopy in the frontal and temporal lobes of neuroleptic naive 
patients with schizophrenia. Neuropsychopharmacology Feb 
1999;20(2):131-140. 
 149 
260. Bertolino A, Callicott JH, Nawroz S, Mattay VS, Duyn JH, Tedeschi G, 
Frank JA, Weinberger DR. Reproducibility of proton magnetic 
resonance spectroscopic imaging in patients with schizophrenia. 
Neuropsychopharmacology Jan 1998;18(1):1-9. 
261. Choe BY, Kim KT, Suh TS, Lee C, Paik IH, Bahk YW, Shinn KS, 
Lenkinski RE. 1H magnetic resonance spectroscopy characterization 
of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad 
Radiol Nov 1994;1(3):211-216. 
262. Egan MF, Straub RE, Goldberg TE, et al. Variation in GRM3 affects 
cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl 
Acad Sci U S A Aug 24 2004;101(34):12604-12609. 
263. Oni-Orisan A, Kristiansen LV, Haroutunian V, Meador-Woodruff JH, 
McCullumsmith RE. Altered Vesicular Glutamate Transporter 
Expression in the Anterior Cingulate Cortex in Schizophrenia. Biol 
Psychiatry Dec 21 2007. 
264. Rajkowska G, Goldman-Rakic PS. Cytoarchitectonic definition of 
prefrontal areas in the normal human cortex: I. Remapping of areas 9 
and 46 using quantitative criteria. Cereb Cortex Jul-Aug 1995;5(4):307-
322. 
265. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, 
Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-
1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's 
disease brain: the role of Abeta1-42. J Neurochem Jul 2001;78(2):413-
416. 
266. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, 
Hatanpaa KJ, Tamminga CA. Human postmortem tissue: what quality 
markers matter? Brain Res Dec 6 2006;1123(1):1-11. 
267. Robinson MB. The family of sodium-dependent glutamate transporters: 
a focus on the GLT-1/EAAT2 subtype. Neurochem Int 1998;33(6):479-
491. 
268. Watanabe M, Ueki T, Jackson M, Ruggiero AM, Sawa A, Kalandadze 
A, Robinson MB, Rothstein JD. CSN1 Downregulates GLT-1 activity. 
Paper presented at: SFN Abstract, 2004. 
269. Spain BH, Bowdish KS, Pacal AR, Staub SF, Koo D, Chang CY, Xie 
W, Colicelli J. Two human cDNAs, including a homolog of Arabidopsis 
FUS6 (COP11), suppress G-protein- and mitogen-activated protein 
kinase-mediated signal transduction in yeast and mammalian cells. 
Mol Cell Biol Dec 1996;16(12):6698-6706. 
 150 
270. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by 
metabotropic glutamate receptors. J Neurochem Sep 2000;75(3):889-
907. 
271. van Holde KE. Physical Biochemistry. 2nd ed. Englewood Cliffs, NJ: 
Prentice-Hall, Inc.; 1985. 
272. Diamond JS. Neuronal glutamate transporters limit activation of NMDA 
receptors by neurotransmitter spillover on CA1 pyramidal cells. J 
Neurosci Nov 1 2001;21(21):8328-8338. 
273. Huang YH, Bergles DE. Glutamate transporters bring competition to 
the synapse. Curr Opin Neurobiol Jun 2004;14(3):346-352. 
274. Lin CL, Tzingounis AV, Jin L, Furuta A, Kavanaugh MP, Rothstein JD. 
Molecular cloning and expression of the rat EAAT4 glutamate 
transporter subtype. Brain Res Mol Brain Res 1998;63(1):174-179. 
275. Holleran EA, Ligon LA, Tokito M, Stankewich MC, Morrow JS, 
Holzbaur EL. beta III spectrin binds to the Arp1 subunit of dynactin. J 
Biol Chem Sep 28 2001;276(39):36598-36605. 
276. Stankewich MC, Tse WT, Peters LL, et al. A widely expressed betaIII 
spectrin associated with Golgi and cytoplasmic vesicles. Proc Natl 
Acad Sci U S A Nov 24 1998;95(24):14158-14163. 
277. Katsel P, Davis KL, Gorman JM, Haroutunian V. Variations in 
differential gene expression patterns across multiple brain regions in 
schizophrenia. Schizophr Res Sep 15 2005;77(2-3):241-252. 
278. De Souza IE, McBean GJ, Meredith GE. Chronic haloperidol treatment 
impairs glutamate transport in the rat striatum. Eur J Pharmacol 
1999;382(2):139-142. 
279. Melone M, Vitellaro-Zuccarello L, Vallejo-Illarramendi A, et al. The 
expression of glutamate transporter GLT-1 in the rat cerebral cortex is 
down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 
2001;6(4):380-386. 
280. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the 
pathogenesis of diabetic vascular complications and Alzheimer's 
disease. J Alzheimers Dis Apr 2009;16(4):845-858. 
281. Hung WY, Mold DE, Tourian A. Huntington's-chorea fibroblasts. 
Cellular protein glycosylation. Biochem J Sep 15 1980;190(3):711-719. 
282. Gegelashvili G, Civenni G, Racagni G, Danbolt NC, Schousboe I, 
Schousboe A. Glutamate receptor agonists up-regulate glutamate 
 151 
transporter GLAST in astrocytes. Neuroreport Dec 20 1996;8(1):261-
265. 
283. Kondo K, Hashimoto H, Kitanaka J, Sawada M, Suzumura A, 
Marunouchi T, Baba A. Expression of glutamate transporters in 
cultured glial cells. Neurosci Lett Mar 24 1995;188(2):140-142. 
284. Escartin C, Brouillet E, Gubellini P, et al. Ciliary neurotrophic factor 
activates astrocytes, redistributes their glutamate transporters GLAST 
and GLT-1 to raft microdomains, and improves glutamate handling in 
vivo. J Neurosci May 31 2006;26(22):5978-5989. 
285. Shashidharan P, Huntley GW, Murray JM, Buku A, Moran T, Walsh 
MJ, Morrison JH, Plaitakis A. Immunohistochemical localization of the 
neuron-specific glutamate transporter EAAC1 (EAAT3) in rat brain and 
spinal cord revealed by a novel monoclonal antibody. Brain Res Oct 31 
1997;773(1-2):139-148. 
286. Bauer D, Gupta D, Harotunian V, Meador-Woodruff JH, 
McCullumsmith RE. Abnormal expression of glutamate transporter and 
transporter interacting molecules in prefrontal cortex in elderly patients 
with schizophrenia. Schizophr Res Sep 2008;104(1-3):108-120. 
287. Tsvetkov E, Shin RM, Bolshakov VY. Glutamate uptake determines 
pathway specificity of long-term potentiation in the neural circuitry of 
fear conditioning. Neuron Jan 8 2004;41(1):139-151. 
288. Overstreet LS, Kinney GA, Liu YB, Billups D, Slater NT. Glutamate 
transporters contribute to the time course of synaptic transmission in 
cerebellar granule cells. J Neurosci Nov 1 1999;19(21):9663-9673. 
289. Marcaggi P, Attwell D. Short- and long-term depression of rat 
cerebellar parallel fibre synaptic transmission mediated by synaptic 
crosstalk. J Physiol Jan 15 2007;578(Pt 2):545-550. 
290. Bradford MM. A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye 
binding. Anal Biochem May 7 1976;72:248-254. 
291. Jarvie KR, Niznik HB, Seeman P. Dopamine D2 receptor binding 
subunits of Mr congruent to 140,000 and 94,000 in brain: 
deglycosylation yields a common unit of Mr congruent to 44,000. Mol 
Pharmacol Aug 1988;34(2):91-97. 
292. Jimenez-Huete A, Lievens PM, Vidal R, Piccardo P, Ghetti B, 
Tagliavini F, Frangione B, Prelli F. Endogenous proteolytic cleavage of 
normal and disease-associated isoforms of the human prion protein in 
 152 
neural and non-neural tissues. Am J Pathol Nov 1998;153(5):1561-
1572. 
293. Nielsen D, Gyllberg H, Ostlund P, Bergman T, Bedecs K. Increased 
levels of insulin and insulin-like growth factor-1 hybrid receptors and 
decreased glycosylation of the insulin receptor alpha- and beta-
subunits in scrapie-infected neuroblastoma N2a cells. Biochem J Jun 1 
2004;380(Pt 2):571-579. 
294. Toledo JR, Sanchez O, Montesino Segui R, Fernandez Garcia Y, 
Rodriguez MP, Cremata JA. Differential in vitro and in vivo 
glycosylation of human erythropoietin expressed in adenovirally 
transduced mouse mammary epithelial cells. Biochim Biophys Acta 
Oct 30 2005;1726(1):48-56. 
295. Maguire TM, Thakore J, Dinan TG, Hopwood S, Breen KC. Plasma 
sialyltransferase levels in psychiatric disorders as a possible indicator 
of HPA axis function. Biol Psychiatry Jun 1 1997;41(11):1131-1136. 
296. Varma R, Hoshino AY. Serum glycoproteins in schizophrenia. 
Carbohydr Res Jul 1980;82(2):343-351. 
297. Barbeau D, Liang JJ, Robitalille Y, Quirion R, Srivastava LK. 
Decreased expression of the embryonic form of the neural cell 
adhesion molecule in schizophrenic brains. Proc Natl Acad Sci U S A 
Mar 28 1995;92(7):2785-2789. 
298. Holmseth S, Dehnes Y, Bjornsen LP, Boulland JL, Furness DN, 
Bergles D, Danbolt NC. Specificity of antibodies: unexpected cross-
reactivity of antibodies directed against the excitatory amino acid 
transporter 3 (EAAT3). Neuroscience 2005;136(3):649-660. 
299. Tzingounis AV, Wadiche JI. Glutamate transporters: confining runaway 
excitation by shaping synaptic transmission. Nat Rev Neurosci Dec 
2007;8(12):935-947. 
300. Tong G, Jahr CE. Block of glutamate transporters potentiates 
postsynaptic excitation. Neuron Nov 1994;13(5):1195-1203. 
301. Ruggiero AM, Liu Y, Vidensky S, et al. The endoplasmic reticulum exit 
of glutamate transporter is regulated by the inducible mammalian 
Yip6b/GTRAP3-18 protein. J Biol Chem Mar 7 2008;283(10):6175-
6183. 
302. Tucholski J, Patel S, Bauer D, Haroutunian V, Meador-Woodruff JH. 
Decreased Protein Expression and Alteration of N-Glycosylation of the 
Glur2 Ampa Receptor Subunit in Schizophrenia. Schizophrenia Bulletin 
2009;35:234-234. 
 153 
303. Wood SJ, Yucel M, Pantelis C, Berk M. Neurobiology of schizophrenia 
spectrum disorders: the role of oxidative stress. Ann Acad Med 
Singapore May 2009;38(5):396-396. 
304. Chakravarthi S, Jessop CE, Bulleid NJ. The role of glutathione in 
disulphide bond formation and endoplasmic-reticulum-generated 
oxidative stress. EMBO Rep Mar 2006;7(3):271-275. 
305. Olbrich HM, Valerius G, Rusch N, Buchert M, Thiel T, Hennig J, Ebert 
D, Van Elst LT. Frontolimbic glutamate alterations in first episode 
schizophrenia: evidence from a magnetic resonance spectroscopy 
study. World J Biol Psychiatry 2008;9(1):59-63. 
306. van Elst LT, Valerius G, Buchert M, et al. Increased prefrontal and 
hippocampal glutamate concentration in schizophrenia: evidence from 
a magnetic resonance spectroscopy study. Biol Psychiatry Nov 1 
2005;58(9):724-730. 
307. Fedorenko O, Tang C, Sopjani M, et al. PIP5K2A-dependent regulation 
of excitatory amino acid transporter EAAT3. Psychopharmacology 
(Berl) Jul 31 2009. 
308. Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. 
Cortical expression of glial fibrillary acidic protein and glutamine 
synthetase is decreased in schizophrenia. Schizophr Res Aug 
2008;103(1-3):71-82. 
309. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, 
Krystal JH. Attenuation of the neuropsychiatric effects of ketamine with 
lamotrigine: support for hyperglutamatergic effects of N-methyl-D-
aspartate receptor antagonists. Arch Gen Psychiatry Mar 
2000;57(3):270-276. 
310. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a 
group II metabotropic glutamate receptor agonist in rats. Science Aug 
28 1998;281(5381):1349-1352. 
311. Farber NB. The NMDA receptor hypofunction model of psychosis. Ann 
N Y Acad Sci Nov 2003;1003:119-130. 
312. Fattorini G, Melone M, Bragina L, et al. GLT-1 expression and Glu 
uptake in rat cerebral cortex are increased by phencyclidine. Glia Sep 
2008;56(12):1320-1327. 
313. Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia 
XD, Gage A. A randomized, placebo-controlled study of memantine as 
adjunctive treatment in patients with schizophrenia. 
Neuropsychopharmacology Apr 2009;34(5):1322-1329. 
 154 
314. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the 
glutamatergic system to develop novel, improved therapeutics for 
mood disorders. Nat Rev Drug Discov May 2008;7(5):426-437. 
315. Kline DD, Hendricks G, Hermann G, Rogers RC, Kunze DL. Dopamine 
inhibits N-type channels in visceral afferents to reduce synaptic 
transmitter release under normoxic and chronic intermittent hypoxic 
conditions. J Neurophysiol May 2009;101(5):2270-2278. 
316. Govindaiah G, Cox CL. Depression of retinogeniculate synaptic 
transmission by presynaptic D(2)-like dopamine receptors in rat lateral 
geniculate nucleus. Eur J Neurosci Jan 2006;23(2):423-434. 
317. Aoyama K, Watabe M, Nakaki T. Regulation of neuronal glutathione 
synthesis. J Pharmacol Sci Nov 2008;108(3):227-238. 
318. Schmitt A, Asan E, Puschel B, Jons T, Kugler P. Expression of the 
glutamate transporter GLT1 in neural cells of the rat central nervous 
system: non-radioactive in situ hybridization and comparative 
immunocytochemistry. Neuroscience 1996;71(4):989-1004. 
319. Selemon LD. Regionally diverse cortical pathology in schizophrenia: 
clues to the etiology of the disease. Schizophr Bull 2001;27(3):349-
377. 
320. Bennett MR. Synapse formation and regression in the cortex during 
adolescence and in schizophrenia. Med J Aust Feb 16 2009;190(4 
Suppl):S14-16. 
321. Roberts RC, Roche JK, Conley RR, Lahti AC. Dopaminergic synapses 
in the caudate of subjects with schizophrenia: relationship to treatment 
response. Synapse Jun 2009;63(6):520-530. 
322. Roberts RC, Roche JK, Conley RR. Differential synaptic changes in 
the striatum of subjects with undifferentiated versus paranoid 
schizophrenia. Synapse Aug 2008;62(8):616-627. 
323. Hutcherson L, Roberts RC. The immunocytochemical localization of 
substance P in the human striatum: a postmortem ultrastructural study. 
Synapse Sep 15 2005;57(4):191-201. 
324. Roberts RC, Xu L, Roche JK, Kirkpatrick B. Ultrastructural localization 
of reelin in the cortex in post-mortem human brain. J Comp Neurol Feb 
14 2005;482(3):294-308. 
325. Kung L, Force M, Chute DJ, Roberts RC. Immunocytochemical 
localization of tyrosine hydroxylase in the human striatum: a 
 155 
postmortem ultrastructural study. J Comp Neurol Jan 5 
1998;390(1):52-62. 
326. Dodd PR, Watson WE, Morrison MM, Johnston GA, Bird ED, Cowburn 
RF, Hardy JA. Uptake of gamma-aminobutyric acid and L-glutamic 
acid by synaptosomes from postmortem human cerebral cortex: 
multiple sites, sodium dependence and effect of tissue preparation. 
Brain Res Jun 26 1989;490(2):320-331. 
327. Hardy JA, Barton A, Lofdahl E, Cheetham SC, Johnston GA, Dodd PR. 
Uptake of gamma-aminobutyric acid and glycine by synaptosomes 
from postmortem human brain. J Neurochem Aug 1986;47(2):460-467. 
328. Westphalen RI, Scott HL, Dodd PR. Synaptic vesicle transport and 
synaptic membrane transporter sites in excitatory amino acid nerve 
terminals in Alzheimer disease. J Neural Transm Sep 
2003;110(9):1013-1027. 
329. Hassel B, Tessler S, Faull RL, Emson PC. Glutamate uptake is 
reduced in prefrontal cortex in Huntington's disease. Neurochem Res 
Feb 2008;33(2):232-237. 
330. Lewis DA, Cruz DA, Melchitzky DS, Pierri JN. Lamina-specific deficits 
in parvalbumin-immunoreactive varicosities in the prefrontal cortex of 
subjects with schizophrenia: evidence for fewer projections from the 
thalamus. Am J Psychiatry 2001;158(9):1411-1422. 
331. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, 
Sampson AR, Lewis DA. Gene expression deficits in a subclass of 
GABA neurons in the prefrontal cortex of subjects with schizophrenia. 
J Neurosci Jul 16 2003;23(15):6315-6326. 
332. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and 
schizophrenia. Nat Rev Neurosci Apr 2005;6(4):312-324. 
333. Lewis DA, Lund JS. Heterogeneity of chandelier neurons in monkey 
neocortex: corticotropin-releasing factor- and parvalbumin-
immunoreactive populations. J Comp Neurol Mar 22 1990;293(4):599-
615. 
334. Wang Q, Song C, Li CC. Molecular perspectives on p97-VCP: 
progress in understanding its structure and diverse biological functions. 
J Struct Biol Apr-May 2004;146(1-2):44-57. 
335. McNulty SE, Toscano WA, Jr. Transcriptional regulation of 
glyceraldehyde-3-phosphate dehydrogenase by 2,3,7,8-
tetrachlorodibenzo-p-dioxin. Biochem Biophys Res Commun Jul 6 
1995;212(1):165-171. 
 156 
336. Liu NK, Xu XM. beta-tubulin is a more suitable internal control than 
beta-actin in western blot analysis of spinal cord tissues after traumatic 
injury. J Neurotrauma Dec 2006;23(12):1794-1801. 
337. Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE. 
Housekeeping proteins: a preliminary study illustrating some limitations 
as useful references in protein expression studies. Proteomics Feb 
2005;5(2):566-571. 
338. Perrot-Sinal TS, Davis AM, McCarthy MM. Developmental sex 
differences in glutamic acid decarboxylase (GAD(65)) and the 
housekeeping gene, GAPDH. Brain Res Dec 20 2001;922(2):201-208. 
339. Eastwood SL, Harrison PJ. Synaptic pathology in the anterior cingulate 
cortex in schizophrenia and mood disorders. A review and a Western 
blot study of synaptophysin, GAP-43 and the complexins. Brain Res 
Bull Jul 15 2001;55(5):569-578. 
 
 
